Gene	Gene synonym	Ensembl	Gene description	Chromosome	Position	Protein class	Evidence	Antibody	Reliability (IH)	Reliability (Mouse Brain)	Reliability (IF)	Subcellular location	Prognostic p-value	RNA cancer category	RNA tissue category	RNA TS	RNA TS TPM	TPM max in non-specific	RNA cell line category	RNA CS	RNA CS TPM
ABCG1	ABC8	ENSG00000160179	ATP binding cassette subfamily G member 1	21	42199689-42297244	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA031470, HPA031471	Approved		Supported	Golgi apparatus<br>Vesicles	Renal cancer:7.16e-6 (favourable)	Expressed in all	Expressed in all			lung: 43.5	Cell line enhanced		MCF7: 25.3;MOLT-4: 25.1;SCLC-21H: 26.2
ABHD1	FLJ36128, LABH1	ENSG00000143994	Abhydrolase domain containing 1	2	27123789-27130812	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044390	Uncertain					Mixed	Tissue enriched	17	testis: 30.0	liver: 1.7	Cell line enhanced		RPMI-8226: 1.1;T-47d: 3.0;U-266/70: 2.4;U-266/84: 1.9
ABHD14A	DKFZP564O243, DORZ1	ENSG00000248487	Abhydrolase domain containing 14A	3	51971426-51981199	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038153, HPA056913			Enhanced	Vesicles	Lung cancer:4.72e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 51.0	Expressed in all		
AC114783.1		ENSG00000237524		2	126898882-126902097	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	183	testis: 57.8	kidney: 0.3	Not detected		
ACE	ACE1, CD143, DCP1	ENSG00000159640	Angiotensin I converting enzyme	17	63477061-63498380	Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002426, CAB002921, HPA029298, HPA069790	Enhanced		Approved	Vesicles		Expressed in all	Tissue enhanced		duodenum: 178.9;small intestine: 291.6	testis: 83.7	Cell line enhanced		ASC TERT1: 44.4;HUVEC TERT2: 28.2
ACHE	YT	ENSG00000087085	Acetylcholinesterase (Cartwright blood group)	7	100889994-100896974	Blood group antigen proteins, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019704, HPA027098			Approved	Golgi apparatus<br>Vesicles	Renal cancer:3.88e-5 (unfavourable), Glioma:7.16e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 58.5	cerebral cortex: 14.1	Cell line enhanced		BEWO: 11.7;CACO-2: 17.5;K-562: 20.7;Karpas-707: 25.8
ACP2	LAP	ENSG00000134575	Acid phosphatase 2, lysosomal	11	47239302-47248906	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 41.2	Expressed in all		
ACPP	ACP-3, ACP3, PAP	ENSG00000014257	Acid phosphatase, prostate	3	132317367-132368298	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000071, HPA004335, HPA063916	Enhanced					Tissue enriched	Tissue enriched	145	prostate: 6030.6	esophagus: 41.4	Cell line enhanced		BJ hTERT+: 14.1;RPMI-8226: 39.1;U-87 MG: 14.6
ACSF2	ACSMW, FLJ20920	ENSG00000167107	Acyl-CoA synthetase family member 2	17	50426158-50474845	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA024693	Enhanced		Approved	Nucleoplasm<br>Microtubules<br>Cytosol	Renal cancer:2.17e-4 (unfavourable), Urothelial cancer:2.41e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 136.9	thyroid gland: 68.6	Expressed in all		
ACVR1	ACVR1A, ACVRLK2, ALK2, SKR1	ENSG00000115170	Activin A receptor type 1	2	157736444-157875862	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007505, HPA046514	Approved		Approved	Nucleoli<br>Cytosol	Urothelial cancer:5.17e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 74.2	Mixed		
ACVR1C	ACVRLK7, ALK7	ENSG00000123612	Activin A receptor type 1C	2	157526767-157629005	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007982, HPA011933	Approved					Mixed	Tissue enriched	8	adipose tissue: 34.1	ovary: 4.3	Cell line enhanced		ASC diff: 7.5;HDLM-2: 4.8
ACVRL1	ACVRLK1, ALK1, HHT, HHT2, ORW2	ENSG00000139567	Activin A receptor like type 1	12	51906908-51923361	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007041	Approved					Expressed in all	Tissue enhanced		placenta: 126.4	lung: 76.4	Cell line enhanced		ASC diff: 42.2;EFO-21: 52.0;HUVEC TERT2: 171.4;TIME: 130.8
ADAM10	CD156c, HsT18717, kuz, MADM	ENSG00000137845	ADAM metallopeptidase domain 10	15	58588807-58749978	Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB001709, HPA050670	Approved		Supported	Vesicles<br>Plasma membrane	Lung cancer:8.46e-5 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 47.9	Expressed in all		
ADAM12	MCMPMltna, MLTN	ENSG00000148848	ADAM metallopeptidase domain 12	10	126012381-126388455	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA030866, HPA030867, HPA030868	Enhanced		Supported	Plasma membrane	Renal cancer:2.39e-14 (unfavourable)	Mixed	Tissue enriched	8	placenta: 237.2	cervix, uterine: 29.7	Cell line enhanced		fHDF/TERT166: 119.5;hTEC/SVTERT24-B: 94.3;U-2197: 86.6;U-251 MG: 71.0
ADAM15	MDC15	ENSG00000143537	ADAM metallopeptidase domain 15	1	155050566-155062775	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011633, HPA072878	Uncertain		Uncertain	Vesicles	Renal cancer:5.64e-9 (unfavourable), Glioma:3.49e-5 (unfavourable), Liver cancer:3.49e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 72.6	Cell line enhanced		PC-3: 305.3
ADAM17	CD156B, cSVP, TACE	ENSG00000151694	ADAM metallopeptidase domain 17	2	9488486-9555792	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA010738, CAB025906, HPA051575	Approved		Supported	Cytosol	Urothelial cancer:4.23e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 33.8	Expressed in all		
ADAM18	ADAM27, tMDCIII	ENSG00000168619	ADAM metallopeptidase domain 18	8	39584489-39730064	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	85	testis: 8.4	all non-specific tissues: 0.0	Not detected		
ADAM22	MDC2	ENSG00000008277	ADAM metallopeptidase domain 22	7	87934143-88202889	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050325			Approved	Cell Junctions		Mixed	Tissue enhanced		cerebral cortex: 47.6	prostate: 18.2	Cell line enhanced		Karpas-707: 58.7;SH-SY5Y: 81.7
ADAM28	ADAM23, eMDCII, MDC-Lm, MDC-Ls	ENSG00000042980	ADAM metallopeptidase domain 28	8	24294040-24359018	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA074034	Enhanced		Approved	Plasma membrane<br>Mitochondria	Endometrial cancer:3.17e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 435.5	stomach: 104.6	Cell line enriched	10	CAPAN-2: 24.6
ADAM29	CT73, svph1	ENSG00000168594	ADAM metallopeptidase domain 29	4	174829668-174978180	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	145	testis: 73.3	endometrium: 0.5	Not detected		
ADAM32		ENSG00000197140	ADAM metallopeptidase domain 32	8	39106990-39284911	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044156, HPA062151	Enhanced		Approved	Nucleus<br>Vesicles		Not detected	Tissue enriched	35	testis: 28.7	skin: 0.8	Cell line enhanced		U-2 OS: 1.1
ADAM33	C20orf153, dJ964F7.1, DKFZp434K0521	ENSG00000149451	ADAM metallopeptidase domain 33	20	3667965-3682246	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA067152, HPA071758	Approved		Uncertain	Nuclear speckles<br>Plasma membrane		Mixed	Mixed			endometrium: 103.3	Cell line enhanced		ASC diff: 55.2;ASC TERT1: 72.4;BJ: 31.3;BJ hTERT+: 51.1;fHDF/TERT166: 29.6;U-2197: 46.1
ADAM7	EAPI, GP-83	ENSG00000069206	ADAM metallopeptidase domain 7	8	24440930-24526970	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008879	Enhanced					Group enriched	Tissue enriched	199	epididymis: 4534.6	seminal vesicle: 22.7	Group enriched	23	BEWO: 2.3;NB-4: 3.9;RPMI-8226: 1.1;SH-SY5Y: 1.9
ADAM8	CD156, CD156a, MS2	ENSG00000151651	ADAM metallopeptidase domain 8	10	133262403-133276868	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064637	Approved				Renal cancer:3.99e-10 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 43.8;spleen: 32.9	appendix: 30.1	Cell line enhanced		A-431: 51.7;BEWO: 78.4;CAPAN-2: 61.7;HaCaT: 61.1;HDLM-2: 42.3;U-87 MG: 33.6
ADAM9	CORD9, KIAA0021, MCMP, MDC9, Mltng	ENSG00000168615	ADAM metallopeptidase domain 9	8	38996869-39105144	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004000			Approved	Endoplasmic reticulum<br>Vesicles	Liver cancer:7.21e-6 (unfavourable), Pancreatic cancer:2.52e-5 (unfavourable), Breast cancer:1.14e-4 (unfavourable), Cervical cancer:2.25e-4 (unfavourable), Renal cancer:3.99e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 118.7	Expressed in all		
ADAMTS1	C3-C5, KIAA1346, METH1	ENSG00000154734	ADAM metallopeptidase with thrombospondin type 1 motif 1	21	26835747-26845409	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016394	Uncertain				Head and neck cancer:5.13e-4 (unfavourable)	Expressed in all	Tissue enhanced		ovary: 412.9	adipose tissue: 279.9	Cell line enhanced		BJ: 346.6;hTEC/SVTERT24-B: 277.6
ADCYAP1R1	PAC1, PAC1R, PACAPR	ENSG00000078549	ADCYAP receptor type I	7	31052461-31111479	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA030739, HPA049877	Enhanced		Supported	Vesicles	Endometrial cancer:5.78e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 137.1;fallopian tube: 46.8	cervix, uterine: 20.7	Group enriched	6	AF22: 3.6;NTERA-2: 4.9;SCLC-21H: 4.8;SH-SY5Y: 7.8
ADGRA3	FLJ38547, GPR125, PGR21	ENSG00000152990	Adhesion G protein-coupled receptor A3	4	22345071-22516054	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008904	Uncertain					Expressed in all	Expressed in all			thyroid gland: 42.5	Mixed		
ADGRB2	BAI2	ENSG00000121753	Adhesion G protein-coupled receptor B2	1	31727117-31764893	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052612, HPA054617			Supported	Centrosome	Lung cancer:4.02e-5 (unfavourable), Breast cancer:6.46e-4 (favourable)	Tissue enhanced	Tissue enriched	14	cerebral cortex: 72.3	adrenal gland: 5.1	Cell line enhanced		SH-SY5Y: 26.4;T-47d: 27.3;U-2 OS: 28.9
ADGRD1	DKFZp434B1272, GPR133, PGR25	ENSG00000111452	Adhesion G protein-coupled receptor D1	12	130953907-131141469	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042395	Uncertain		Approved	Nucleus<br>Cytosol	Liver cancer:9.27e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 44.7	lung: 32.4	Cell line enhanced		BJ: 4.0;fHDF/TERT166: 4.1;HeLa: 6.4;HHSteC: 5.0;HMC-1: 11.4;U-2 OS: 6.6
ADGRE3	EMR3	ENSG00000131355	Adhesion G protein-coupled receptor E3	19	14619117-14690027	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA015638	Uncertain					Not detected	Tissue enhanced		appendix: 8.7;spleen: 8.6	lung: 3.9	Cell line enriched	50	HMC-1: 39.7
ADGRE5	CD97, TM7LN1	ENSG00000123146	Adhesion G protein-coupled receptor E5	19	14380501-14408725	CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA013707	Enhanced		Approved	Cytosol	Renal cancer:1.87e-6 (unfavourable), Liver cancer:3.73e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 140.3	Mixed		
ADGRF1	GPR110, hGPCR36, PGR19	ENSG00000153292	Adhesion G protein-coupled receptor F1	6	46997703-47042363	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038438	Approved				Renal cancer:1.35e-5 (favourable)	Mixed	Tissue enhanced		esophagus: 14.6;kidney: 17.6;urinary bladder: 18.9	gallbladder: 9.4	Group enriched	9	A-431: 27.0;CAPAN-2: 99.3;HaCaT: 22.4;PC-3: 33.9;RPTEC TERT1: 38.6;RT4: 104.1
ADGRG1	GPR56, TM7LN4, TM7XN1	ENSG00000205336	Adhesion G protein-coupled receptor G1	16	57610652-57665580	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046065	Uncertain				Renal cancer:5.52e-7 (favourable), Head and neck cancer:2.53e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 349.0	Cell line enhanced		SK-MEL-30: 229.9
ADGRG5	GPR114, PGR27	ENSG00000159618	Adhesion G protein-coupled receptor G5	16	57542421-57591681	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007133	Enhanced		Approved	Nucleoplasm<br>Nuclear membrane<br>Vesicles	Cervical cancer:4.25e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 11.2;tonsil: 8.8	appendix,spleen: 5.9	Cell line enriched	8	HMC-1: 31.8
ADGRG6	FLJ14937, GPR126	ENSG00000112414	Adhesion G protein-coupled receptor G6	6	142301854-142446266	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017346	Approved				Pancreatic cancer:2.78e-5 (unfavourable), Lung cancer:8.78e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 67.2	liver: 36.9	Cell line enhanced		HUVEC TERT2: 133.3;MCF7: 118.0
ADGRV1	DKFZp761P0710, FEB4, GPR98, KIAA0686, MASS1, USH2C, VLGR1	ENSG00000164199	Adhesion G protein-coupled receptor V1	5	90529344-91164437	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA067503	Approved		Approved	Lipid droplets		Mixed	Tissue enriched	11	adrenal gland: 261.4	kidney: 22.9	Cell line enhanced		AF22: 15.3;HAP1: 23.8;NTERA-2: 11.7;SCLC-21H: 13.1
ADIG	MGC39724, RP5-1100H13.2, SMAF1	ENSG00000182035	Adipogenin	20	38581195-38588463	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA041124	Uncertain					Tissue enhanced	Group enriched	10	epididymis: 5.1;testis: 16.1;thyroid gland: 3.4	seminal vesicle: 0.8	Not detected		
AGER	RAGE, SCARJ1	ENSG00000204305	Advanced glycosylation end-product specific receptor	6	32180968-32184324	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB011682, HPA064436	Enhanced		Approved	Nucleoli fibrillar center<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.01e-7 (unfavourable), Urothelial cancer:2.74e-6 (favourable), Pancreatic cancer:3.41e-4 (favourable)	Expressed in all	Tissue enriched	181	lung: 889.2	thyroid gland: 4.9	Cell line enhanced		HEK93: 2.5;U-266/70: 2.6
AGRN	AGRIN	ENSG00000188157	Agrin	1	1020123-1056118	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040090	Approved		Supported	Plasma membrane<br>Cytosol	Liver cancer:4.62e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 33.2	Cell line enhanced		EFO-21: 223.9
AGTRAP	ATRAP	ENSG00000177674	Angiotensin II receptor associated protein	1	11736084-11754802	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044120	Approved		Supported	Vesicles	Liver cancer:6.57e-7 (unfavourable)	Expressed in all	Expressed in all			prostate: 92.6	Expressed in all		
AIG1	AIG-1, dJ95L4.1, FLJ10485	ENSG00000146416	Androgen induced 1	6	143060496-143340304	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA060766	Approved		Approved	Golgi apparatus	Head and neck cancer:3.25e-7 (unfavourable), Cervical cancer:3.26e-6 (unfavourable), Endometrial cancer:3.06e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 153.1	Expressed in all		
ALDOA		ENSG00000149925	Aldolase, fructose-bisphosphate A	16	30053090-30070457	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004177, CAB006252	Enhanced		Supported	Cytosol	Liver cancer:5.79e-5 (unfavourable), Lung cancer:7.32e-5 (unfavourable)	Expressed in all	Tissue enriched	7	skeletal muscle: 9377.0	esophagus: 1428.8	Expressed in all		
ALG1	CDG1K, HMAT1, HMT-1, Mat-1	ENSG00000033011	ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase	16	5033960-5087379	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA060392	Approved		Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum	Colorectal cancer:5.79e-4 (favourable), Testis cancer:6.93e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.4	Expressed in all		
ALG9	DIBD1	ENSG00000086848	ALG9, alpha-1,2-mannosyltransferase	11	111782195-111871581	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038575	Approved		Approved	Endoplasmic reticulum	Renal cancer:7.29e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 25.8	Expressed in all		
ALPL	HOPS, TNSALP	ENSG00000162551	Alkaline phosphatase, liver/bone/kidney	1	21509372-21578412	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007105, HPA008765, CAB020829	Enhanced		Approved	Cytosol	Melanoma:7.08e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 78.8	kidney: 47.2	Group enriched	8	HAP1: 31.9;HSkMC: 126.3;hTEC/SVTERT24-B: 139.0;LHCN-M2: 85.3;NTERA-2: 40.7;SCLC-21H: 103.8
ANO7	IPCA-5, NGEP, PCANAP5, PCANAP5L, TMEM16G	ENSG00000146205	Anoctamin 7	2	241188509-241225377	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035730	Uncertain					Tissue enriched	Tissue enhanced		prostate: 100.6;stomach: 26.0	small intestine: 15.4	Cell line enhanced		BEWO: 2.1;Hep G2: 1.5
ANTXR1	ATR, FLJ10601, FLJ21776, TEM8	ENSG00000169604	Anthrax toxin receptor 1	2	69013178-69249327	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054785			Uncertain	Vesicles	Thyroid cancer:1.22e-5 (unfavourable), Cervical cancer:5.76e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 180.5	Cell line enhanced		LHCN-M2: 286.7
APCDD1	B7323	ENSG00000154856	APC down-regulated 1	18	10454628-10489948	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:6.39e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 153.1	cerebral cortex: 60.6	Cell line enhanced		AF22: 31.6;BJ hTERT+: 56.8;HaCaT: 37.9;HSkMC: 28.6
APLP2	APPH, APPL2	ENSG00000084234	Amyloid beta precursor like protein 2	11	130069837-130144811	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039319	Approved		Approved	Vesicles	Renal cancer:1.33e-9 (favourable), Thyroid cancer:2.90e-4 (favourable), Liver cancer:3.37e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 1056.8	Expressed in all		
APOL1	APOL	ENSG00000100342	Apolipoprotein L1	22	36253010-36267530	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018885, CAB056156	Supported				Renal cancer:7.43e-6 (unfavourable), Urothelial cancer:2.01e-5 (favourable), Lung cancer:5.35e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 116.1	Cell line enhanced		EFO-21: 233.1;HDLM-2: 156.1;RT4: 120.9
ARSE	CDPX, CDPX1	ENSG00000157399	Arylsulfatase E (chondrodysplasia punctata 1)	X	2934632-2968310	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA060518, HPA070651	Approved		Supported	Golgi apparatus	Colorectal cancer:8.95e-4 (favourable)	Mixed	Tissue enhanced		kidney: 41.3;liver: 49.3	pancreas: 23.9	Cell line enhanced		A549: 65.1;CACO-2: 37.1;Hep G2: 46.2;NTERA-2: 32.8
ART3		ENSG00000156219	ADP-ribosyltransferase 3	4	76011184-76112802	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011268	Enhanced					Tissue enhanced	Tissue enhanced		skeletal muscle: 77.0;testis: 174.4	heart muscle: 29.1	Group enriched	7	NB-4: 3.4;NTERA-2: 14.0;SK-MEL-30: 4.9
ART4	CD297, DO, DOK1	ENSG00000111339	ADP-ribosyltransferase 4 (Dombrock blood group)	12	14825569-14843495	Blood group antigen proteins, CD markers, Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA075664			Approved	Rods & Rings		Tissue enhanced	Tissue enhanced		liver: 27.2;spleen: 26.9	gallbladder: 15.1	Cell line enhanced		AN3-CA: 5.6;HEL: 10.9;Hep G2: 4.9;HUVEC TERT2: 22.5
ATP13A1	ATP13A, CGI-152, FLJ31858, KIAA1825	ENSG00000105726	ATPase 13A1	19	19645198-19663693	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA031798, HPA049717	Approved		Approved	Vesicles	Renal cancer:6.51e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 52.5	Expressed in all		
ATP5F1		ENSG00000116459	ATP synthase, H+ transporting, mitochondrial Fo complex subunit B1	1	111448864-111462773	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046067, HPA057347	Enhanced		Supported	Mitochondria	Renal cancer:3.26e-9 (favourable), Stomach cancer:8.07e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 50.4	Expressed in all		
ATP6AP1	16A, Ac45, ATP6IP1, ATP6S1, CF2, ORF, VATPS1, XAP-3, XAP3	ENSG00000071553	ATPase H+ transporting accessory protein 1	X	154428632-154436516	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB015218	Uncertain		Approved	Plasma membrane<br>Microtubules<br>Cytosol	Renal cancer:5.26e-8 (favourable), Breast cancer:2.40e-4 (unfavourable), Glioma:7.82e-4 (unfavourable), Pancreatic cancer:7.83e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 209.7	Expressed in all		
ATP6AP2	APT6M8-9, ATP6IP2, ATP6M8-9, M8-9, PRR, RENR	ENSG00000182220	ATPase H+ transporting accessory protein 2	X	40579372-40606848	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA003156	Approved				Renal cancer:2.01e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 893.4	Expressed in all		
BACE2	AEPLC, ALP56, CEAP1, DRAP	ENSG00000182240	Beta-site APP-cleaving enzyme 2	21	41167801-41282518	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035416	Approved				Cervical cancer:1.11e-4 (unfavourable), Glioma:8.13e-4 (unfavourable)	Expressed in all	Mixed			stomach: 30.5	Cell line enhanced		SK-BR-3: 43.8;WM-115: 41.2
BCAM	CD239, LU	ENSG00000187244	Basal cell adhesion molecule (Lutheran blood group)	19	44809059-44821420	Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005654	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:5.94e-6 (favourable), Endometrial cancer:1.24e-5 (unfavourable), Colorectal cancer:2.31e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 174.7	Cell line enhanced		HaCaT: 278.4;SK-BR-3: 217.2;T-47d: 152.4
BCAP29	BAP29, DKFZp686M2086	ENSG00000075790	B-cell receptor associated protein 29	7	107579977-107629170	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA029215, HPA049694	Enhanced		Approved	Cytosol	Liver cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 93.0	Expressed in all		
BDNF		ENSG00000176697	Brain derived neurotrophic factor	11	27654893-27722058	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009564, HPA031440, HPA056104	Enhanced		Supported	Nuclear speckles<br>Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 11.9	epididymis: 4.9	Cell line enhanced		BJ: 37.3;BJ hTERT+ SV40 Large T+: 30.7;HBF TERT88: 30.4;U-138 MG: 45.3
BOC	CDON2	ENSG00000144857	BOC cell adhesion associated, oncogene regulated	3	113211003-113287459	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025806, HPA060778, HPA061787	Uncertain		Supported	Nucleoplasm<br>Plasma membrane	Urothelial cancer:1.18e-5 (unfavourable), Head and neck cancer:4.89e-4 (favourable)	Mixed	Mixed			fallopian tube: 51.7	Cell line enhanced		AN3-CA: 73.4;ASC diff: 77.9;BJ hTERT+: 34.1
BPI	BPIFD1	ENSG00000101425	Bactericidal/permeability-increasing protein	20	38260149-38337505	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA061284	Enhanced					Not detected	Tissue enriched	37	bone marrow: 961.6	testis: 25.9	Group enriched	5	AF22: 2.3;ASC diff: 1.1;ASC TERT1: 3.1;BJ: 2.1;BJ hTERT+: 2.1;HL-60: 1.1
BSG	CD147, EMMPRIN, OK	ENSG00000172270	Basigin (Ok blood group)	19	571277-583493	Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB002427, HPA036048, HPA074870	Enhanced		Approved	Vesicles	Renal cancer:1.95e-6 (favourable), Liver cancer:5.48e-6 (unfavourable), Endometrial cancer:2.59e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 593.5	Expressed in all		
BTN2A2	BT2.2, BTF2, BTN2.2	ENSG00000124508	Butyrophilin subfamily 2 member A2	6	26383096-26394874	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051504	Uncertain		Supported	Mitochondria	Breast cancer:1.01e-4 (favourable)	Expressed in all	Mixed			lymph node: 37.6	Mixed		
BTN3A1	BT3.1, BTF5, BTN3.1, CD277	ENSG00000026950	Butyrophilin subfamily 3 member A1	6	26402237-26415216	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012565	Approved		Uncertain	Vesicles	Renal cancer:4.15e-5 (unfavourable), Urothelial cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			spleen: 112.6	Mixed		
BTN3A2	BTN3.2	ENSG00000186470	Butyrophilin subfamily 3 member A2	6	26365159-26378320	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB019392	Uncertain				Renal cancer:4.24e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 129.4	Mixed		
BTN3A3	BTF3, BTN3.3	ENSG00000111801	Butyrophilin subfamily 3 member A3	6	26440472-26453415	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007904, HPA011871	Enhanced				Renal cancer:2.42e-5 (unfavourable), Ovarian cancer:1.80e-4 (favourable)	Expressed in all	Mixed			spleen: 64.0	Cell line enhanced		ASC TERT1: 43.5;BJ hTERT+ SV40 Large T+ RasG12V: 41.9
C11orf24	DM4E3	ENSG00000171067	Chromosome 11 open reading frame 24	11	68261335-68272001	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012748	Uncertain		Uncertain	Nucleoplasm<br>Vesicles	Renal cancer:1.60e-9 (unfavourable), Lung cancer:6.05e-4 (unfavourable), Glioma:9.83e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 65.9	Expressed in all		
C12orf76	FLJ40142	ENSG00000174456	Chromosome 12 open reading frame 76	12	110027028-110073686	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA039713, HPA042013	Uncertain		Approved	Plasma membrane<br>Actin filaments	Renal cancer:5.74e-5 (unfavourable), Lung cancer:6.44e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 105.7	Expressed in all		
C1orf159	FLJ20584	ENSG00000131591	Chromosome 1 open reading frame 159	1	1081818-1116361	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010019	Approved		Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:1.77e-6 (unfavourable), Liver cancer:9.58e-6 (unfavourable), Urothelial cancer:1.62e-4 (favourable)	Expressed in all	Mixed			skin: 15.3	Expressed in all		
CA9	CAIX, MN	ENSG00000107159	Carbonic anhydrase 9	9	35673856-35681159	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005100, CAB017107, HPA055207	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:2.22e-7 (unfavourable), Liver cancer:1.71e-5 (unfavourable), Testis cancer:9.50e-4 (favourable)	Mixed	Tissue enhanced		gallbladder: 36.0;stomach: 93.6	small intestine: 14.5	Group enriched	11	A-431: 152.1;HDLM-2: 84.3;U-87 MG: 337.9
CACNA2D1	CACNA2, CACNL2A, LINC01112, lncRNA-N3, MHS3	ENSG00000153956	Calcium voltage-gated channel auxiliary subunit alpha2delta 1	7	81946444-82443798	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA008213, HPA008621	Enhanced				Renal cancer:1.16e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 35.4	Cell line enhanced		HUVEC TERT2: 45.6;SH-SY5Y: 66.1
CACNA2D4		ENSG00000151062	Calcium voltage-gated channel auxiliary subunit alpha2delta 4	12	1791957-1918836	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031952	Uncertain					Mixed	Not detected			placenta,testis: 0.8	Cell line enhanced		Hep G2: 6.4;HL-60: 4.5;HMC-1: 24.8;NB-4: 8.3
CADM3	BIgR, FLJ10698, IGSF4B, Necl-1, NECL1, SynCAM3, TSLL1	ENSG00000162706	Cell adhesion molecule 3	1	159171609-159203313	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002981, CAB025746	Enhanced				Renal cancer:1.03e-5 (unfavourable), Urothelial cancer:5.75e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 278.5;placenta: 113.9	cervix, uterine: 44.7	Group enriched	7	HHSteC: 54.6;HSkMC: 158.9;hTERT-HME1: 91.2;U-2 OS: 34.5;WM-115: 59.5
CALCR	CTR	ENSG00000004948	Calcitonin receptor	7	93424487-93574730	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA028962, HPA061428	Enhanced					Tissue enriched	Tissue enhanced		kidney: 2.1;testis: 1.4	placenta: 1.0	Cell line enhanced		RPTEC TERT1: 1.5;T-47d: 3.6
CALCRL	CGRPR, CRLR	ENSG00000064989	Calcitonin receptor like receptor	2	187343129-187448460	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA008070, HPA046515	Uncertain		Supported	Plasma membrane		Expressed in all	Tissue enhanced		lung: 114.3	adipose tissue: 76.8	Cell line enhanced		HUVEC TERT2: 145.5;RPTEC TERT1: 30.7;TIME: 20.7
CAMK2D	CAMKD	ENSG00000145349	Calcium/calmodulin dependent protein kinase II delta	4	113451032-113761927	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026281, HPA051783, HPA051785, HPA053973	Approved		Supported	Plasma membrane<br>Cell Junctions<br>Cytosol		Expressed in all	Expressed in all			heart muscle: 110.3	Mixed		
CANX	CNX, IP90, P90	ENSG00000127022	Calnexin	5	179678628-179730925	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004738, HPA009433, HPA009696	Enhanced		Enhanced	Endoplasmic reticulum	Colorectal cancer:1.38e-4 (favourable), Thyroid cancer:3.17e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 294.4	Expressed in all		
CATSPERG	C19orf15, DKFZp434A1022, FLJ46353	ENSG00000099338	Cation channel sperm associated auxiliary subunit gamma	19	38335775-38370943	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052777			Approved	Nucleus<br>Nucleoli<br>Cytosol		Mixed	Tissue enriched	41	testis: 48.6	skin: 1.1	Cell line enhanced		BEWO: 1.4;HMC-1: 1.6;MCF7: 1.2
CCL5	D17S136E, MGC17164, RANTES, SCYA5, SISd, TCP228	ENSG00000271503	C-C motif chemokine ligand 5	17	35871491-35880793	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:3.61e-7 (unfavourable), Endometrial cancer:1.34e-5 (favourable), Melanoma:2.42e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 80.5	lymph node: 68.5	Group enriched	7	HL-60: 31.8;NB-4: 158.3;THP-1: 39.1;U-937: 41.8
CCL7	FIC, MARC, MCP-3, MCP3, NC28, SCYA6, SCYA7	ENSG00000108688	C-C motif chemokine ligand 7	17	34270221-34272242	Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Group enriched	8	appendix: 3.6;bone marrow: 15.2	gallbladder,rectum: 1.1	Cell line enhanced		BJ hTERT+: 9.3;BJ hTERT+ SV40 Large T+: 2.2;BJ hTERT+ SV40 Large T+ RasG12V: 2.8;HSkMC: 2.4
CD164	DFNA66, MGC-24, MUC-24	ENSG00000135535	CD164 molecule	6	109366514-109382457	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010636	Uncertain					Expressed in all	Expressed in all			thyroid gland: 613.1	Expressed in all		
CD1E		ENSG00000158488	CD1e molecule	1	158353696-158357553	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057769	Uncertain					Mixed	Tissue enhanced		skin: 18.3	tonsil: 10.4	Cell line enriched	980	MOLT-4: 1075.1
CD2	SRBC	ENSG00000116824	CD2 molecule	1	116754385-116769228	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002430, HPA003883	Enhanced				Renal cancer:4.82e-6 (unfavourable), Endometrial cancer:1.69e-5 (favourable), Melanoma:3.97e-5 (favourable), Head and neck cancer:7.46e-5 (favourable), Cervical cancer:1.47e-4 (favourable), Breast cancer:4.36e-4 (favourable), Ovarian cancer:7.72e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 131.1	tonsil: 70.8	Group enriched	27	HDLM-2: 201.2;MOLT-4: 129.2
CD200	MOX1, MOX2, MRC, OX-2	ENSG00000091972	CD200 molecule	3	112332347-112362812	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031149	Approved					Expressed in all	Mixed			cerebral cortex: 78.6	Cell line enhanced		AF22: 74.9;NTERA-2: 47.6;REH: 38.6;WM-115: 82.4
CD200R1	CD200R, HCRTR2, MOX2R, OX2R	ENSG00000163606	CD200 receptor 1	3	112921209-112975122	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA068512			Supported	Plasma membrane		Mixed	Tissue enhanced		spleen: 14.5	placenta: 10.2	Cell line enriched	8	HEL: 26.4
CD22	SIGLEC-2, SIGLEC2	ENSG00000012124	CD22 molecule	19	35319261-35347355	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002418, HPA024353	Enhanced					Mixed	Tissue enhanced		lymph node: 264.4;ovary: 162.2;spleen: 151.7;tonsil: 210.1	appendix: 98.1	Group enriched	11	Daudi: 201.6;REH: 76.6;U-698: 153.7;WM-115: 49.6
CD226	DNAM-1, DNAM1, PTA1, TLiSA1	ENSG00000150637	CD226 molecule	18	69831158-69961803	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015715, HPA050348	Supported		Approved	Midbody		Not detected	Tissue enriched	11	parathyroid gland: 318.5	spleen: 28.4	Group enriched	7	HEL: 89.9;HMC-1: 37.6
CD276	B7-H3, B7H3, B7RP-2	ENSG00000103855	CD276 molecule	15	73683966-73714518	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009285, HPA017139, CAB017826	Enhanced		Approved	Vesicles	Renal cancer:6.31e-5 (unfavourable), Liver cancer:9.81e-4 (unfavourable)	Expressed in all	Mixed			placenta: 30.2	Cell line enhanced		U-2197: 176.1
CD300A	CMRF-35-H9, CMRF35H, IGSF12, IRC1, IRC2, Irp60	ENSG00000167851	CD300a molecule	17	74466416-74484796	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011645	Approved				Renal cancer:1.91e-5 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 85.8	appendix: 40.0	Cell line enhanced		HMC-1: 88.9;NB-4: 27.4;RPMI-8226: 57.9
CD300LB	CLM7, TREM5	ENSG00000178789	CD300 molecule like family member b	17	74521174-74531474	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 11.4	spleen: 5.2	Cell line enhanced		HL-60: 1.5;NB-4: 1.5;THP-1: 1.3
CD300LF	CD300f, CLM1, IGSF13, IREM1, NKIR	ENSG00000186074	CD300 molecule like family member f	17	74694311-74712978	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013712	Supported					Expressed in all	Tissue enhanced		lung: 25.6;spleen: 28.0	appendix: 18.2	Group enriched	7	THP-1: 16.6;U-937: 37.2
CD300LG	CLM9, Trem4	ENSG00000161649	CD300 molecule like family member g	17	43847148-43863629	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Group enriched	5	adipose tissue: 143.0;placenta: 86.4;testis: 33.9	lung: 17.3	Not detected		
CD3D	T3D	ENSG00000167286	CD3d molecule	11	118338954-118342744	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013055	Enhanced				Endometrial cancer:1.73e-7 (favourable), Renal cancer:3.07e-5 (unfavourable), Cervical cancer:8.46e-5 (favourable), Head and neck cancer:1.70e-4 (favourable), Breast cancer:3.00e-4 (favourable), Urothelial cancer:6.16e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 199.3;tonsil: 119.1	appendix: 86.9	Cell line enriched	7	MOLT-4: 903.0
CD4		ENSG00000010610	CD4 molecule	12	6786858-6820808	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000011, HPA004252, HPA004472, CAB068180	Enhanced		Supported	Plasma membrane	Endometrial cancer:2.16e-4 (favourable), Renal cancer:7.45e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 549.0	spleen: 220.5	Group enriched	5	HEL: 90.7;HL-60: 32.7;NB-4: 37.0;THP-1: 77.1;U-937: 84.2
CD40	Bp50, p50, TNFRSF5	ENSG00000101017	CD40 molecule	20	46118272-46129863	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002495, HPA031567, HPA031568, CAB072868	Enhanced				Renal cancer:4.48e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 64.7	Cell line enhanced		CAPAN-2: 63.4;EFO-21: 116.6
CD44	CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1	ENSG00000026508	CD44 molecule (Indian blood group)	11	35138870-35232402	Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000112, CAB000316, HPA005785	Enhanced		Enhanced	Golgi apparatus<br>Plasma membrane	Renal cancer:1.78e-8 (unfavourable)	Expressed in all	Expressed in all			skin: 530.1	Mixed		
CD48	BCM1, BLAST, hCD48, mCD48, SLAMF2	ENSG00000117091	CD48 molecule	1	160678746-160711851	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002497, HPA055146	Enhanced		Supported	Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Renal cancer:3.36e-4 (unfavourable), Breast cancer:3.91e-4 (favourable), Colorectal cancer:4.17e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 311.4;spleen: 213.1;tonsil: 226.0	appendix: 148.5	Cell line enhanced		Daudi: 153.4;HMC-1: 202.6;U-266/70: 372.1;U-266/84: 244.7
CD5	LEU1, T1	ENSG00000110448	CD5 molecule	11	61102395-61127852	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB015392, CAB020308, HPA043416, HPA060839	Enhanced				Head and neck cancer:7.41e-6 (favourable), Renal cancer:8.94e-5 (unfavourable), Endometrial cancer:9.00e-5 (favourable), Cervical cancer:9.16e-5 (favourable), Melanoma:3.93e-4 (favourable), Breast cancer:4.05e-4 (favourable)	Mixed	Tissue enhanced		appendix: 29.8;lymph node: 43.0	tonsil: 20.2	Cell line enriched	71	MOLT-4: 56.4
CD55	CR, CROM, DAF, TC	ENSG00000196352	CD55 molecule (Cromer blood group)	1	207321508-207386804	Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002190, CAB010454, HPA024386	Enhanced		Uncertain	Vesicles<br>Midbody ring	Renal cancer:9.36e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 324.4	Cell line enhanced		HMC-1: 495.0;U-2197: 364.6
CD59	16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20	ENSG00000085063	CD59 molecule	11	33698261-33736445	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB001448, HPA026494	Supported		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.39e-10 (favourable), Pancreatic cancer:2.92e-5 (unfavourable), Head and neck cancer:3.10e-5 (unfavourable), Cervical cancer:3.81e-5 (unfavourable), Stomach cancer:9.03e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 923.3	Cell line enhanced		TIME: 2367.1;U-2197: 2401.2
CD6	Tp120	ENSG00000013725	CD6 molecule	11	60971680-61020377	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002489, CAB016252	Enhanced				Head and neck cancer:5.10e-6 (favourable), Cervical cancer:1.57e-5 (favourable), Renal cancer:1.82e-4 (unfavourable), Breast cancer:1.95e-4 (favourable), Endometrial cancer:2.41e-4 (favourable)	Mixed	Tissue enhanced		appendix: 28.5;lymph node: 49.2	tonsil: 26.8	Cell line enriched	17	MOLT-4: 31.3
CD68	DKFZp686M18236, GP110, LAMP4, macrosialin, SCARD1	ENSG00000129226	CD68 molecule	17	7579467-7582113	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000051, CAB000066, HPA048982, CAB072861, CAB072862	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.14e-5 (unfavourable)	Mixed	Expressed in all			lung: 532.4	Expressed in all		
CD7	GP40, LEU-9, Tp40, TP41	ENSG00000173762	CD7 molecule	17	82314868-82317602	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002594, HPA039079	Enhanced				Renal cancer:7.75e-11 (unfavourable), Endometrial cancer:2.03e-5 (favourable), Melanoma:2.69e-4 (favourable), Cervical cancer:5.51e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 43.1;lymph node: 41.5;spleen: 43.1	small intestine: 17.0	Group enriched	5	Hep G2: 35.2;MOLT-4: 95.7
CD79A	IGA, MB-1	ENSG00000105369	CD79a molecule	19	41877120-41881372	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000019	Enhanced				Head and neck cancer:1.18e-5 (favourable), Renal cancer:2.15e-5 (unfavourable), Breast cancer:8.45e-5 (favourable)	Mixed	Group enriched	6	appendix: 263.8;lymph node: 515.1;spleen: 317.9;tonsil: 423.1	stomach: 63.3	Group enriched	23	Daudi: 1084.6;REH: 432.6;U-698: 905.8
CD80	B7-1, B7.1, CD28LG, CD28LG1	ENSG00000121594	CD80 molecule	3	119524293-119559602	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025368, HPA050092	Enhanced					Mixed	Tissue enhanced		appendix: 7.2;lymph node: 6.7;tonsil: 6.3	spleen: 4.7	Cell line enhanced		Daudi: 8.5;HDLM-2: 39.3;Karpas-707: 12.2;U-266/70: 5.5
CD86	B7-2, B7.2, CD28LG2	ENSG00000114013	CD86 molecule	3	122055366-122121139	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004319	Uncertain				Renal cancer:9.83e-5 (unfavourable)	Expressed in all	Mixed			appendix: 47.8	Cell line enriched	10	HDLM-2: 275.8
CD8A	CD8	ENSG00000153563	CD8a molecule	2	86784610-86808396	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000012, HPA037756, CAB075722	Enhanced				Endometrial cancer:6.15e-6 (favourable), Renal cancer:1.91e-5 (unfavourable), Cervical cancer:4.54e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 161.9	lymph node: 46.9	Cell line enriched	5	MOLT-4: 11.7
CD8B	CD8B1	ENSG00000172116	CD8b molecule	2	86815339-86861924	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004353, HPA029164	Enhanced		Supported	Plasma membrane	Endometrial cancer:7.88e-7 (favourable), Renal cancer:7.11e-6 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 60.8;lymph node: 39.6	parathyroid gland: 22.7	Cell line enriched	50	RPMI-8226: 837.8
CD99	MIC2	ENSG00000002586	CD99 molecule	X	2691179-2741309	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000020, HPA035304	Supported		Approved	Golgi apparatus	Renal cancer:5.87e-7 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 375.1	Mixed		
CDCP1	CD318, SIMA135	ENSG00000163814	CUB domain containing protein 1	3	45082278-45146422	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010978, HPA010979, CAB025637	Enhanced				Lung cancer:1.41e-5 (unfavourable), Pancreatic cancer:1.48e-4 (unfavourable)	Expressed in all	Mixed			skin: 27.7	Cell line enhanced		hTEC/SVTERT24-B: 263.4;hTERT-HME1: 135.9
CDCP2		ENSG00000157211	CUB domain containing protein 2	1	54132968-54153770	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA031143	Uncertain					Not detected	Not detected			breast,cervix, uterine,spleen: 0.1	Not detected		
CDH1	CD324, UVO, uvomorulin	ENSG00000039068	Cadherin 1	16	68737225-68835548	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857	Enhanced		Supported	Golgi apparatus<br>Plasma membrane<br>Cell Junctions	Renal cancer:2.06e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 475.1	thyroid gland: 266.2	Cell line enhanced		BEWO: 645.6;CAPAN-2: 281.0;HaCaT: 273.9
CDH11	CAD11, OB	ENSG00000140937	Cadherin 11	16	64943753-65126112	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013072	Enhanced				Renal cancer:2.48e-9 (unfavourable)	Expressed in all	Tissue enhanced		ovary: 223.4	placenta: 173.7	Cell line enhanced		BJ: 205.7;fHDF/TERT166: 259.6;HSkMC: 159.5;PC-3: 262.9;U-2197: 178.5
CDH17	cadherin, HPT-1	ENSG00000079112	Cadherin 17	8	94127171-94217303	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA023614, HPA023616, CAB025143, HPA026556	Enhanced		Supported	Cell Junctions		Group enriched	Group enriched	8	colon: 256.9;duodenum: 314.3;rectum: 267.3;small intestine: 294.3	appendix: 37.5	Group enriched	6	CACO-2: 81.5;U-266/70: 121.0
CDH18	CDH14, EY-CADHERIN	ENSG00000145526	Cadherin 18	5	19472951-20575873	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014416	Uncertain					Mixed	Tissue enhanced		adrenal gland: 5.9;cerebral cortex: 19.0	testis: 3.2	Cell line enhanced		EFO-21: 4.1;U-2 OS: 7.1;U-2197: 5.6
CDH19	CDH7	ENSG00000071991	Cadherin 19	18	66501083-66604138	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056332	Uncertain					Tissue enriched	Mixed			heart muscle: 8.4	Group enriched	15	SK-MEL-30: 28.3;WM-115: 63.0
CDH23	CDHR23, DFNB12, USH1D	ENSG00000107736	Cadherin related 23	10	71396934-71815947	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017232	Approved				Urothelial cancer:3.40e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 30.2	ovary: 19.4	Cell line enhanced		RT4: 11.9;SCLC-21H: 6.6
CDH5	7B4, CD144	ENSG00000179776	Cadherin 5	16	66366622-66404786	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB028366	Approved				Renal cancer:5.14e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 335.1	lung: 120.5	Group enriched	5	HUVEC TERT2: 616.7;TIME: 522.0
CDHR1	CORD15, KIAA1775, PCDH21, RP65	ENSG00000148600	Cadherin related family member 1	10	84194635-84219621	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036819	Supported					Tissue enhanced	Group enriched	5	rectum: 57.9;skin: 252.1	colon: 29.2	Cell line enhanced		HAP1: 10.5;HEK93: 4.8;HEL: 5.7;RPTEC TERT1: 12.5
CDHR4	CDH29, VLLR9392	ENSG00000187492	Cadherin related family member 4	3	49790732-49799835	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA076277	Enhanced					Tissue enriched	Tissue enriched	9	fallopian tube: 105.0	lung: 11.4	Cell line enhanced		ASC TERT1: 1.0
CDHR5	FLJ20219, MU-PCDH, MUCDHL, MUPCDH	ENSG00000099834	Cadherin related family member 5	11	616565-626078	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009081, HPA009173, CAB025004	Enhanced					Group enriched	Group enriched	9	colon: 41.7;duodenum: 82.7;kidney: 23.6;liver: 21.0;rectum: 54.3;small intestine: 64.3	gallbladder: 5.3	Cell line enhanced		CACO-2: 2.1
CDON	CDO, CDON1, ORCAM	ENSG00000064309	Cell adhesion associated, oncogene regulated	11	125955796-126063335	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB012422, HPA017377	Uncertain				Renal cancer:1.78e-7 (unfavourable), Breast cancer:1.35e-4 (favourable)	Mixed	Tissue enhanced		thyroid gland: 75.5	ovary: 53.5	Cell line enhanced		AF22: 55.0;ASC diff: 47.4;RH-30: 93.1
CEACAM19	CEAL1	ENSG00000186567	Carcinoembryonic antigen related cell adhesion molecule 19	19	44662278-44684359	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA014462, HPA052865	Uncertain		Approved	Nucleus<br>Nucleoli<br>Mitochondria		Expressed in all	Mixed			skin: 12.7	Cell line enhanced		RPTEC TERT1: 11.9;TIME: 16.9
CEACAM7	CEA, CGM2	ENSG00000007306	Carcinoembryonic antigen related cell adhesion molecule 7	19	41673307-41706976	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069621	Supported					Tissue enhanced	Group enriched	7	colon: 583.2;rectum: 691.9	appendix: 91.6	Not detected		
CERS1	LAG1, LASS1, UOG1	ENSG00000223802	Ceramide synthase 1	19	18868545-18896727	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045724	Approved		Approved	Endoplasmic reticulum		Tissue enhanced	Group enriched	13	cerebral cortex: 136.3;testis: 28.0	skeletal muscle: 6.5	Cell line enhanced		AN3-CA: 28.0;HEK93: 28.4
CHEK2	bA444G7, CDS1, CHK2, HuCds1, PP1425, RAD53	ENSG00000183765	Checkpoint kinase 2	22	28687743-28742422	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001878, CAB002030	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:7.80e-9 (unfavourable)	Expressed in all	Mixed			testis: 13.4	Expressed in all		
CHL1	CALL, FLJ44930, L1CAM2, MGC132578	ENSG00000134121	Cell adhesion molecule L1 like	3	196596-409417	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003345, CAB026120	Enhanced				Renal cancer:1.21e-6 (favourable)	Tissue enhanced	Tissue enriched	5	cerebral cortex: 111.8	ovary: 20.9	Group enriched	6	SK-MEL-30: 73.7;WM-115: 29.2
CHRNA2		ENSG00000120903	Cholinergic receptor nicotinic alpha 2 subunit	8	27459761-27479883	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	24	prostate: 46.8	breast: 1.9	Not detected		
CHRNA5		ENSG00000169684	Cholinergic receptor nicotinic alpha 5 subunit	15	78565520-78595269	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054381	Approved		Approved	Plasma membrane<br>Focal adhesion sites	Lung cancer:3.64e-5 (unfavourable)	Mixed	Mixed			gallbladder: 6.9	Mixed		
CHRNB1	CHRNB	ENSG00000170175	Cholinergic receptor nicotinic beta 1 subunit	17	7445061-7457707	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA005822, CAB011200	Approved					Expressed in all	Expressed in all			skeletal muscle: 21.9	Cell line enhanced		LHCN-M2: 28.7;RH-30: 68.7
CHRND	ACHRD	ENSG00000135902	Cholinergic receptor nicotinic delta subunit	2	232525993-232536667	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA056404, HPA065404			Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	12	skeletal muscle: 9.6	prostate: 0.8	Cell line enriched	76	RH-30: 79.9
CHST10	HNK-1ST	ENSG00000115526	Carbohydrate sulfotransferase 10	2	100391860-100417656	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012884, HPA051545	Approved		Approved	Cytosol	Pancreatic cancer:4.05e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 46.4	endometrium: 19.4	Mixed		
CHST5	FLJ22167, I-GLCNAC-6-ST	ENSG00000135702	Carbohydrate sulfotransferase 5	16	75528535-75535247	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043804	Enhanced					Group enriched	Group enriched	14	colon: 45.6;duodenum: 85.9;rectum: 59.7;small intestine: 83.5	stomach: 4.8	Mixed		
CKLF	C32, CKLF1, CKLF3, CKLF4, HSPC224, UCK-1	ENSG00000217555	Chemokine like factor	16	66552563-66566251	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA062779			Approved	Vesicles	Renal cancer:1.06e-9 (unfavourable), Liver cancer:5.67e-5 (unfavourable), Thyroid cancer:2.22e-4 (favourable)	Expressed in all	Expressed in all			testis: 90.9	Expressed in all		
CLDN15		ENSG00000106404	Claudin 15	7	101232092-101238820	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level						Renal cancer:5.31e-5 (unfavourable), Pancreatic cancer:2.56e-4 (favourable), Urothelial cancer:3.30e-4 (favourable)	Expressed in all	Group enriched	16	duodenum: 241.3;small intestine: 183.5	spleen: 13.3	Expressed in all		
CLDN7	CEPTRL2, CPETRL2, Hs.84359	ENSG00000181885	Claudin 7	17	7259903-7263983	Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB013063, HPA014703, HPA073662	Enhanced		Approved	Vesicles<br>Cell Junctions	Renal cancer:8.96e-11 (favourable), Thyroid cancer:1.85e-4 (favourable), Stomach cancer:4.09e-4 (favourable)	Expressed in all	Mixed			small intestine: 350.1	Cell line enhanced		BEWO: 162.4;CAPAN-2: 304.6;HaCaT: 644.4;MCF7: 198.9;SK-BR-3: 225.1
CLDND1	C3orf4	ENSG00000080822	Claudin domain containing 1	3	98497912-98523066	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA029841	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:5.84e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 399.9	Expressed in all		
CLGN		ENSG00000153132	Calmegin	4	140388455-140427968	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB020709, HPA048761, HPA058627	Enhanced		Enhanced	Endoplasmic reticulum		Tissue enhanced	Tissue enriched	5	testis: 186.4	heart muscle: 35.6	Cell line enhanced		U-251 MG: 54.9
CLN5		ENSG00000102805	Ceroid-lipofuscinosis, neuronal 5	13	76990660-77019143	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041788	Approved				Renal cancer:1.52e-9 (favourable)	Expressed in all	Expressed in all			thyroid gland: 127.1	Expressed in all		
CLSTN3	CDHR14, CSTN3, KIAA0726	ENSG00000139182	Calsyntenin 3	12	7129698-7158945	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.19e-5 (favourable), Renal cancer:4.49e-5 (unfavourable), Breast cancer:5.08e-4 (favourable), Urothelial cancer:8.07e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 126.6	parathyroid gland: 40.3	Mixed		
CNTFR		ENSG00000122756	Ciliary neurotrophic factor receptor	9	34551432-34590140	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025310	Approved					Tissue enhanced	Tissue enhanced		adipose tissue: 62.6;cerebral cortex: 53.4	spleen: 27.5	Group enriched	9	AF22: 107.8;SH-SY5Y: 55.3
CNTNAP2	Caspr2, KIAA0868, NRXN4	ENSG00000174469	Contactin associated protein-like 2	7	146116002-148420998	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002739	Enhanced					Tissue enhanced	Group enriched	11	cerebral cortex: 17.9;prostate: 6.0	fallopian tube: 1.0	Cell line enhanced		AF22: 7.9;CACO-2: 5.7;NTERA-2: 11.9;SCLC-21H: 28.5
CNTNAP3	CASPR3, CNTNAP3A, FLJ14195, KIAA1714	ENSG00000106714	Contactin associated protein-like 3	9	39072767-39288315	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA047731	Uncertain					Mixed	Mixed			esophagus: 8.2	Cell line enhanced		A549: 17.0;AF22: 22.2;WM-115: 37.4
CNTNAP3B		ENSG00000154529	Contactin associated protein-like 3B	9	41890314-42129510	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA047731	Uncertain					Not detected	Mixed			esophagus,skin: 10.4	Cell line enhanced		A549: 27.0;AF22: 41.2;WM-115: 28.0
CPM		ENSG00000135678	Carboxypeptidase M	12	68842197-68971570	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002657, HPA077243	Uncertain		Uncertain	Vesicles	Endometrial cancer:1.00e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 164.0	placenta: 101.2	Cell line enhanced		ASC diff: 48.8;ASC TERT1: 35.1;HSkMC: 66.3;SiHa: 73.7
CRB1	LCA8, RP12	ENSG00000134376	Crumbs 1, cell polarity complex component	1	197268204-197478455	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA061250, HPA063127	Approved		Uncertain	Vesicles		Tissue enriched	Group enriched	10	cerebral cortex: 12.2;testis: 5.0	ovary: 0.8	Cell line enriched	5	HeLa: 9.0
CRB2	FLJ16786, FLJ38464	ENSG00000148204	Crumbs 2, cell polarity complex component	9	123356170-123380324	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043674	Supported					Group enriched	Tissue enhanced		cerebral cortex: 9.4	kidney: 2.0	Cell line enriched	7	AF22: 32.2
CRELD1	AVSD2	ENSG00000163703	Cysteine rich with EGF like domains 1	3	9933822-9945413	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026964	Uncertain		Approved	Nucleoli<br>Cytosol	Glioma:6.05e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 65.6	Expressed in all		
CRHR1	CRF-R, CRF1, CRHR	ENSG00000120088	Corticotropin releasing hormone receptor 1	17	45784280-45835828	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB025251	Approved					Mixed	Tissue enhanced		cerebral cortex: 4.0	endometrium: 0.8	Cell line enhanced		RT4: 2.7;SH-SY5Y: 2.2
CRHR2	CRF-RB, CRF2, HM-CRF	ENSG00000106113	Corticotropin releasing hormone receptor 2	7	30651943-30700129	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046683	Uncertain					Not detected	Tissue enhanced		seminal vesicle: 1.7	cerebral cortex: 1.2	Not detected		
CSF1	M-CSF, MCSF, MGC31930	ENSG00000184371	Colony stimulating factor 1	1	109910242-109930992	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level						Renal cancer:1.00e-11 (unfavourable), Liver cancer:4.25e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 66.6	Cell line enhanced		ASC diff: 146.1;HHSteC: 271.2;HSkMC: 150.5
CSF1R	C-FMS, CD115, CSFR, FMS	ENSG00000182578	Colony stimulating factor 1 receptor	5	150053291-150113372	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB008970, HPA012323	Uncertain		Supported	Vesicles<br>Plasma membrane	Renal cancer:1.08e-4 (unfavourable), Testis cancer:4.92e-4 (unfavourable)	Expressed in all	Mixed			spleen: 147.7	Group enriched	6	BEWO: 118.6;SK-BR-3: 35.4
CSF2RA	CD116, CSF2R	ENSG00000198223	Colony stimulating factor 2 receptor alpha subunit	X	1268800-1310381	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016148	Uncertain				Cervical cancer:2.38e-5 (favourable), Head and neck cancer:2.81e-4 (favourable), Testis cancer:5.53e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 93.3	appendix: 34.6	Group enriched	8	BEWO: 187.1;HMC-1: 51.2;SK-MEL-30: 109.5
CTD-2370N5.3		ENSG00000265118		17	31305213-31318831	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA045033	Uncertain					Not detected	Tissue enhanced		appendix: 5.1	tonsil: 3.0	Cell line enhanced		MOLT-4: 5.4;RPMI-8226: 3.7
CTLA4	CD, CD152, CELIAC3, GSE, IDDM12	ENSG00000163599	Cytotoxic T-lymphocyte associated protein 4	2	203867786-203873960	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Head and neck cancer:4.48e-5 (favourable)	Mixed	Tissue enhanced		appendix: 23.5;lymph node: 31.9	tonsil: 15.3	Group enriched	5	SK-MEL-30: 2.4;U-266/70: 3.5;U-266/84: 9.7
CTNS	CTNS-LSB, PQLC4	ENSG00000040531	Cystinosin, lysosomal cystine transporter	17	3636468-3661542	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA046947			Supported	Vesicles<br>Intermediate filaments	Pancreatic cancer:6.39e-5 (favourable), Head and neck cancer:7.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 42.6	Expressed in all		
CTSK	CTSO, CTSO2, PKND, PYCD	ENSG00000143387	Cathepsin K	1	150796208-150808323	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050346			Supported	Vesicles	Renal cancer:7.12e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 575.0	Group enriched	6	ASC diff: 1592.3;ASC TERT1: 590.6;BJ hTERT+: 1576.7
CX3CL1	ABCD-3, C3Xkine, CXC3, CXC3C, fractalkine, neurotactin, NTN, SCYD1	ENSG00000006210	C-X3-C motif chemokine ligand 1	16	57372458-57385048	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026192, HPA040361	Approved		Supported	Plasma membrane	Renal cancer:8.52e-7 (favourable), Cervical cancer:9.46e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 100.1	lung: 69.3	Cell line enhanced		EFO-21: 28.0;HDLM-2: 78.9;Hep G2: 42.9;RPTEC TERT1: 27.3
CXADR	CAR	ENSG00000154639	Coxsackie virus and adenovirus receptor	21	17512382-17593579	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003342, CAB005103, HPA030411, HPA030412	Enhanced		Enhanced	Plasma membrane<br>Cell Junctions	Head and neck cancer:3.50e-4 (favourable)	Expressed in all	Mixed			skin: 59.1	Cell line enhanced		CACO-2: 77.2;NTERA-2: 105.2;RT4: 82.7
CYHR1	CHRP, KIAA0496, MGC13010	ENSG00000187954	Cysteine and histidine rich 1	8	144449582-144465677	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053653, HPA059543	Approved		Enhanced	Nucleoplasm	Colorectal cancer:1.05e-4 (unfavourable), Liver cancer:3.90e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 51.4	Expressed in all		
CYP20A1	CYP-M	ENSG00000119004	Cytochrome P450 family 20 subfamily A member 1	2	203238940-203305611	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055872, HPA058461	Uncertain		Approved	Plasma membrane<br>Cell Junctions<br>Actin filaments		Expressed in all	Mixed			thyroid gland: 16.4	Mixed		
CYP2S1		ENSG00000167600	Cytochrome P450 family 2 subfamily S member 1	19	41193049-41207539	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049227, HPA069248	Approved		Approved	Endoplasmic reticulum	Renal cancer:1.60e-6 (unfavourable)	Expressed in all	Tissue enhanced		duodenum: 96.7;small intestine: 68.6;stomach: 111.7	colon: 25.9	Cell line enhanced		A549: 83.4;CACO-2: 39.6;HaCaT: 43.5;NTERA-2: 68.5
CYP4F2		ENSG00000186115	Cytochrome P450 family 4 subfamily F member 2	19	15878023-15898120	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014048, HPA017265, HPA058960	Supported					Tissue enriched	Group enriched	6	duodenum: 78.2;epididymis: 28.0;kidney: 39.3;liver: 84.6;small intestine: 84.3	prostate: 10.4	Cell line enhanced		Hep G2: 2.5
DAG1	156DAG, A3a, AGRNR, DAG	ENSG00000173402	Dystroglycan 1	3	49468703-49535618	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB001960, CAB016353	Enhanced		Supported	Vesicles	Renal cancer:2.59e-4 (favourable)	Expressed in all	Expressed in all			placenta: 109.3	Expressed in all		
DDOST	KIAA0115, OST, OST48, WBP1	ENSG00000244038	Dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit	1	20651767-20661544	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009746, HPA046841, HPA052867	Supported		Supported	Endoplasmic reticulum	Renal cancer:9.05e-7 (unfavourable), Liver cancer:2.64e-5 (unfavourable), Head and neck cancer:4.88e-4 (unfavourable), Endometrial cancer:5.99e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 308.3	Expressed in all		
DDR1	CAK, CD167, EDDR1, NEP, NTRK4, PTK3A, RTK6	ENSG00000204580	Discoidin domain receptor tyrosine kinase 1	6	30876421-30900156	CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010162, CAB025656, HPA057194	Approved		Approved	Nucleoplasm<br>Cell Junctions	Renal cancer:3.31e-10 (favourable)	Expressed in all	Mixed			cerebral cortex: 51.6	Cell line enhanced		HaCaT: 80.3;RT4: 74.6;T-47d: 96.8
DDR2	NTRKR3, TKT, TYRO10	ENSG00000162733	Discoidin domain receptor tyrosine kinase 2	1	162631373-162787400	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA070112			Supported	Plasma membrane<br>Actin filaments	Renal cancer:1.73e-7 (unfavourable)	Expressed in all	Mixed			adrenal gland: 93.5	Cell line enhanced		ASC diff: 203.0;ASC TERT1: 203.2;BJ hTERT+: 181.9
DHRS9	3alpha-HSD, RDH15, RDHL, RETSDR8, SDR9C4	ENSG00000073737	Dehydrogenase/reductase 9	2	169064789-169096167	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036491, HPA036667	Approved				Pancreatic cancer:2.73e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 66.5;rectum: 48.1	esophagus: 30.1	Cell line enhanced		NB-4: 21.6;THP-1: 66.4;TIME: 35.4;U-2197: 29.3
DIO2	SelY, TXDI2	ENSG00000211448	Iodothyronine deiodinase 2	14	80197527-80387757	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029544, HPA048002			Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:4.62e-6 (favourable), Colorectal cancer:1.67e-4 (favourable)	Tissue enhanced	Group enriched	6	cervix, uterine: 269.4;thyroid gland: 601.2	esophagus: 70.3	Cell line enhanced		BJ: 70.1;HeLa: 63.5;SiHa: 184.0
DLK1	Delta1, FA1, pG2, Pref-1, ZOG	ENSG00000185559	Delta like non-canonical Notch ligand 1	14	100725705-100738224	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005872, HPA053879, HPA062262	Supported		Approved	Golgi apparatus	Endometrial cancer:2.31e-4 (unfavourable)	Tissue enhanced	Group enriched	20	adrenal gland: 1591.0;placenta: 2331.6	ovary: 100.3	Group enriched	6	AF22: 118.4;Hep G2: 282.9;SH-SY5Y: 501.8
DLL1		ENSG00000198719	Delta like canonical Notch ligand 1	6	170282206-170306565	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA078298			Uncertain	Nucleoplasm		Expressed in all	Mixed			spleen: 20.0	Cell line enhanced		HaCaT: 7.0;HBEC3-KT: 8.8;NB-4: 13.1;THP-1: 11.4
DLL3	SCDO1	ENSG00000090932	Delta like canonical Notch ligand 3	19	39498895-39508481	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056533			Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:2.94e-4 (unfavourable)	Group enriched	Tissue enriched	49	cerebral cortex: 51.3	testis: 1.0	Group enriched	6	SCLC-21H: 16.1;SH-SY5Y: 14.9;SK-MEL-30: 62.1
DPEP2		ENSG00000167261	Dipeptidase 2	16	67987394-68000586	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035644	Approved				Testis cancer:8.47e-4 (unfavourable)	Mixed	Tissue enhanced		spleen: 38.7	lung: 27.9	Cell line enhanced		HEL: 3.7;HMC-1: 16.1;U-937: 4.9
DSE	DSEPI, SART2	ENSG00000111817	Dermatan sulfate epimerase	6	116254173-116444860	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014764, HPA052151	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.50e-4 (unfavourable), Cervical cancer:3.36e-4 (unfavourable), Ovarian cancer:6.34e-4 (unfavourable)	Mixed	Mixed			appendix: 36.2	Mixed		
DSG2	CDHF5	ENSG00000046604	Desmoglein 2	18	31498043-31549008	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004896, CAB025122	Enhanced		Enhanced	Plasma membrane<br>Cell Junctions	Renal cancer:3.14e-10 (favourable), Pancreatic cancer:4.94e-5 (unfavourable), Lung cancer:2.43e-4 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable), Colorectal cancer:7.81e-4 (favourable), Cervical cancer:8.22e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 251.3	rectum: 106.9	Cell line enhanced		HaCaT: 233.0;hTERT-HME1: 159.3
DUOX1	LNOX1, NOXEF1, THOX1	ENSG00000137857	Dual oxidase 1	15	45129933-45165576	Enzymes, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA023544	Approved				Cervical cancer:4.31e-6 (favourable)	Tissue enhanced	Tissue enhanced		skin: 96.9;thyroid gland: 92.6	esophagus: 73.2	Cell line enhanced		HaCaT: 56.9;hTCEpi: 22.1;RT4: 29.0
E2F5		ENSG00000133740	E2F transcription factor 5	8	85177225-85217158	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA055723			Supported	Nucleus<br>Nucleoli	Renal cancer:1.89e-6 (unfavourable)	Expressed in all	Mixed			lymph node: 30.9	Cell line enhanced		AF22: 76.4;Daudi: 112.8
EDNRB	ETB, HSCR, HSCR2	ENSG00000136160	Endothelin receptor type B	13	77895481-77919768	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB017842, HPA027546	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:7.20e-5 (favourable)	Group enriched	Tissue enhanced		placenta: 180.2	cerebral cortex: 88.8	Cell line enhanced		AF22: 59.4;ASC diff: 35.4;SK-MEL-30: 42.0;U-266/70: 29.1;WM-115: 122.9
EFNA4	EPLG4, LERK4	ENSG00000243364	Ephrin A4	1	155063731-155069553	Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB021350, HPA064952	Approved		Uncertain	Nucleus<br>Vesicles	Liver cancer:1.00e-5 (unfavourable), Stomach cancer:3.60e-5 (favourable), Renal cancer:3.14e-4 (unfavourable)	Expressed in all	Mixed			skin: 24.5	Expressed in all		
EGFR	ERBB, ERBB1	ENSG00000146648	Epidermal growth factor receptor	7	55019021-55211628	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB000035, HPA001200, HPA018530, CAB068186, CAB073534	Enhanced		Enhanced	Plasma membrane	Urothelial cancer:2.04e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 100.0	skin: 58.7	Cell line enriched	15	A-431: 4682.9
EMC1	KIAA0090	ENSG00000127463	ER membrane protein complex subunit 1	1	19215664-19251552	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048904	Approved		Approved	Microtubules<br>Cytokinetic bridge	Liver cancer:8.56e-6 (unfavourable), Urothelial cancer:1.43e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 34.4	Expressed in all		
EMC10	C19orf63, HSM1, HSS1, INM02	ENSG00000161671	ER membrane protein complex subunit 10	19	50476400-50490870	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053905	Uncertain				Renal cancer:6.64e-6 (favourable), Pancreatic cancer:4.39e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 63.8	Cell line enhanced		HEK93: 176.7
EMCN	MUC14	ENSG00000164035	Endomucin	4	100395341-100880126	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005928	Approved				Liver cancer:1.03e-4 (favourable), Renal cancer:2.25e-4 (favourable)	Expressed in all	Mixed			kidney: 83.7	Cell line enriched	6	HUVEC TERT2: 25.7
ENTPD8	NTPDase-8, UNQ2492	ENSG00000188833	Ectonucleoside triphosphate diphosphohydrolase 8	9	137434364-137441816	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA021509	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Stomach cancer:7.17e-4 (favourable)	Mixed	Tissue enhanced		colon: 21.7;duodenum: 28.7;small intestine: 31.6	rectum: 12.5	Cell line enhanced		CAPAN-2: 4.8;RPMI-8226: 3.7;T-47d: 2.7
EOGT	AER61, C3orf64, FLJ33770	ENSG00000163378	EGF domain specific O-linked N-acetylglucosamine transferase	3	68975214-69013961	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019460	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Renal cancer:8.97e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 50.3	Mixed		
EPCAM	17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1	ENSG00000119888	Epithelial cell adhesion molecule	2	47345158-47387601	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB003809, HPA026761, CAB030012, CAB055098, HPA067463	Enhanced		Supported	Plasma membrane	Renal cancer:1.04e-6 (favourable), Ovarian cancer:3.30e-4 (favourable)	Mixed	Tissue enhanced		rectum: 680.5;small intestine: 714.7	colon: 659.9	Cell line enhanced		A-431: 382.2;CACO-2: 461.4;CAPAN-2: 680.1;SCLC-21H: 345.3
EPGN	ALGV3072, EPG, epigen, PRO9904	ENSG00000182585	Epithelial mitogen	4	74308473-74315307	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014369			Approved	Nucleus<br>Nuclear membrane<br>Cytosol	Urothelial cancer:2.40e-4 (unfavourable)	Tissue enhanced	Tissue enriched	12	esophagus: 63.6	seminal vesicle: 5.4	Group enriched	7	hTCEpi: 132.6;U-2197: 76.6
EPHA10	FLJ16103, FLJ33655	ENSG00000183317	EPH receptor A10	1	37713880-37765133	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027497	Uncertain					Mixed	Tissue enhanced		testis: 20.4	colon: 7.9	Cell line enhanced		BEWO: 4.7;HDLM-2: 18.1;SCLC-21H: 10.2
EPHA3	ETK, ETK1, HEK, HEK4, TYRO4	ENSG00000044524	EPH receptor A3	3	89107524-89482134	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010462	Approved		Uncertain	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:3.28e-7 (unfavourable)	Mixed	Tissue enhanced		prostate: 51.9	gallbladder: 29.8	Cell line enriched	7	AF22: 192.5
EPHA4	Hek8, TYRO1	ENSG00000116106	EPH receptor A4	2	221418027-221574202	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB028368	Enhanced				Renal cancer:5.67e-4 (favourable), Ovarian cancer:9.56e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 41.6	testis: 22.2	Cell line enhanced		AF22: 77.5;CACO-2: 49.0;U-2197: 35.7
EPHA7	Hek11	ENSG00000135333	EPH receptor A7	6	93240020-93419547	Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010496	Approved					Tissue enhanced	Tissue enriched	13	parathyroid gland: 253.5	prostate: 20.2	Cell line enhanced		AF22: 15.6;HEK93: 41.9;RH-30: 41.8;THP-1: 25.7
EPHA8	EEK, Hek3	ENSG00000070886	EPH receptor A8	1	22563564-22603594	Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009660, HPA031433	Uncertain					Mixed	Tissue enhanced		adrenal gland: 4.7;spleen: 2.6;testis: 1.9	cerebral cortex: 1.3	Cell line enriched	14	SCLC-21H: 70.4
EPHB2	DRT, EPHT3, ERK, Hek5, Tyro5	ENSG00000133216	EPH receptor B2	1	22710839-22921500	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013647, HPA071200	Approved		Supported	Nucleus<br>Plasma membrane	Endometrial cancer:1.05e-5 (unfavourable), Colorectal cancer:4.98e-4 (favourable)	Tissue enhanced	Mixed			rectum: 27.3	Cell line enhanced		HUVEC TERT2: 71.2;TIME: 69.5
EPHB4	HTK, Tyro11	ENSG00000196411	EPH receptor B4	7	100802565-100827521	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013537	Uncertain				Colorectal cancer:4.33e-4 (unfavourable), Breast cancer:8.56e-4 (unfavourable), Urothelial cancer:8.84e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 50.6	Mixed		
EQTN	AFAF, C9orf11, equatorin, SPACA8	ENSG00000120160	Equatorin	9	27284659-27297139	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015089, HPA015504	Enhanced					Not detected	Tissue enriched	94	testis: 67.7	ovary: 0.7	Not detected		
ERBB3	HER3, LCCS2	ENSG00000065361	Erb-b2 receptor tyrosine kinase 3	12	56079857-56103505	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025331, HPA045396	Uncertain		Approved	Plasma membrane<br>Actin filaments		Expressed in all	Mixed			small intestine: 86.8	Cell line enhanced		Hep G2: 79.5;SK-BR-3: 77.6;SK-MEL-30: 109.7;T-47d: 108.2;WM-115: 145.7
ERN1	IRE1, IRE1P	ENSG00000178607	Endoplasmic reticulum to nucleus signaling 1	17	64039142-64130819	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009495, HPA027730	Supported				Renal cancer:1.68e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 53.4	Cell line enhanced		Karpas-707: 74.5;U-266/70: 74.0
ERN2	IRE1b	ENSG00000134398	Endoplasmic reticulum to nucleus signaling 2	16	23690326-23713500	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016558	Uncertain					Mixed	Group enriched	7	cervix, uterine: 27.6;colon: 27.5;duodenum: 12.3;gallbladder: 25.1;rectum: 23.2;small intestine: 9.9;stomach: 49.1	appendix: 3.8	Cell line enriched	8	CAPAN-2: 5.9
F2R	CF2R, PAR-1, PAR1, TR	ENSG00000181104	Coagulation factor II thrombin receptor	5	76716043-76735781	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB008973, CAB012962	Approved				Renal cancer:2.21e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 94.1	Cell line enhanced		HUVEC TERT2: 297.4;WM-115: 331.7
F2RL3	PAR4	ENSG00000127533	F2R like thrombin/trypsin receptor 3	19	16888860-16892606	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:6.25e-4 (favourable)	Mixed	Mixed			thyroid gland: 7.7	Group enriched	8	HEL: 26.3;HMC-1: 10.0
FAM171A1	C10orf38, FLJ12884	ENSG00000148468	Family with sequence similarity 171 member A1	10	15211643-15371062	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051345	Approved		Approved	Nucleoplasm<br>Plasma membrane	Thyroid cancer:4.90e-6 (unfavourable), Renal cancer:2.71e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 73.2	Cell line enhanced		TIME: 95.9
FAM171B	FLJ34104, KIAA1946	ENSG00000144369	Family with sequence similarity 171 member B	2	186693971-186765965	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010639, HPA013434	Approved		Approved	Nucleus<br>Mitochondria	Renal cancer:9.51e-7 (unfavourable), Urothelial cancer:5.03e-4 (unfavourable)	Tissue enriched	Tissue enriched	6	cerebral cortex: 114.5	parathyroid gland: 19.3	Mixed		
FAM189A1	KIAA0574, TMEM228	ENSG00000104059	Family with sequence similarity 189 member A1	15	29120254-29570723	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA009410, HPA010637	Uncertain		Supported	Nucleus		Mixed	Tissue enhanced		cerebral cortex: 2.2;parathyroid gland: 2.0	colon,testis: 0.8	Cell line enhanced		EFO-21: 4.4;HDLM-2: 11.1;REH: 2.6
FAM26D	C6orf78, FLJ32239	ENSG00000164451	Family with sequence similarity 26 member D	6	116529013-116558868	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	46	placenta: 33.8	testis: 0.7	Not detected		
FAM57A	CT120, FLJ22282	ENSG00000167695	Family with sequence similarity 57 member A	17	732412-742972	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:3.53e-6 (favourable), Renal cancer:1.44e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 82.7	esophagus: 25.9	Expressed in all		
FAS	APO-1, APT1, CD95, FAS1, TNFRSF6	ENSG00000026103	Fas cell surface death receptor	10	88990582-89015785	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027444	Enhanced		Approved	Plasma membrane<br>Cytosol		Expressed in all	Mixed			rectum: 32.9	Cell line enhanced		Karpas-707: 104.1
FAT1	CDHF7, CDHR8, FAT	ENSG00000083857	FAT atypical cadherin 1	4	186587783-186726722	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001869, HPA023882	Approved				Lung cancer:4.22e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 37.6	Cell line enhanced		fHDF/TERT166: 221.3
FCAR	CD89	ENSG00000186431	Fc fragment of IgA receptor	19	54874248-54890472	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014050	Approved		Supported	Plasma membrane		Not detected	Tissue enriched	15	bone marrow: 12.3	appendix: 0.8	Not detected		
FCGR1B	CD64b	ENSG00000198019	Fc fragment of IgG receptor Ib	1	121087345-121096310	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		appendix: 27.5;epididymis: 61.7	placenta: 17.0	Cell line enhanced		HMC-1: 6.6;NB-4: 12.8;THP-1: 51.9
FCGR3A	CD16, CD16a, FCG3, FCGR3	ENSG00000203747	Fc fragment of IgG receptor IIIa	1	161541759-161550737	CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB032435, HPA055431	Supported				Renal cancer:3.22e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 419.4	Not detected		
FCGRT	alpha-chain, FCRN	ENSG00000104870	Fc fragment of IgG receptor and transporter	19	49506816-49526333	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012122, HPA015130	Approved					Expressed in all	Expressed in all			small intestine: 312.0	Mixed		
FCMR	FAIM3, TOSO	ENSG00000162894	Fc fragment of IgM receptor	1	206904386-206923247	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003910	Approved		Approved	Nucleus<br>Focal adhesion sites<br>Cytosol	Breast cancer:4.23e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 175.8;spleen: 148.0;tonsil: 146.7	appendix: 88.1	Group enriched	5	RPMI-8226: 97.7;U-266/70: 51.8
FCN1	FCNM	ENSG00000085265	Ficolin 1	9	134905890-134917963	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA000685, HPA001295, CAB016760	Enhanced				Renal cancer:3.98e-4 (unfavourable)	Mixed	Group enriched	5	appendix: 323.4;bone marrow: 634.5	spleen: 94.6	Group enriched	7	NB-4: 12.4;U-937: 22.6
FCRL1	CD307a, FCRH1, IFGP1, IRTA5	ENSG00000163534	Fc receptor like 1	1	157794403-157820105	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013323	Enhanced					Mixed	Tissue enhanced		lymph node: 30.3;spleen: 23.5;tonsil: 20.0	appendix: 12.5	Group enriched	31	Daudi: 3.7;U-698: 11.9
FCRL3	CD307c, FCRH3, IFGP3, IRTA3, SPAP2, SPAP2a, SPAP2b, SPAP2c, SPAP2d, SPAP2e	ENSG00000160856	Fc receptor like 3	1	157674321-157700857	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048022	Enhanced					Mixed	Group enriched	13	appendix: 18.1;lymph node: 55.9;spleen: 36.7;tonsil: 32.3	urinary bladder: 2.8	Cell line enriched	7	Daudi: 6.9
FCRL5	BXMAS1, CD307e, FCRH5, IRTA2	ENSG00000143297	Fc receptor like 5	1	157513377-157552520	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 28.7;spleen: 20.5;tonsil: 32.8	appendix: 17.9	Cell line enhanced		U-266/70: 2.5;U-698: 5.1
FCRLA	FCRL, FCRLa, FCRLb, FCRLc1, FCRLc2, FCRLd, FCRLe, FCRLM1, FCRLX, FREB, MGC4595	ENSG00000132185	Fc receptor like A	1	161706972-161714352	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016545	Enhanced					Tissue enriched	Group enriched	10	appendix: 31.2;lymph node: 80.5;spleen: 56.4;tonsil: 86.7	urinary bladder: 6.2	Cell line enhanced		Daudi: 338.0;SK-MEL-30: 150.5;U-698: 179.6
FGFR1	BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM	ENSG00000077782	Fibroblast growth factor receptor 1	8	38411138-38468834	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB033614, HPA056402, HPA076274	Approved		Supported	Nucleoli		Expressed in all	Expressed in all			cervix, uterine: 109.5	Cell line enhanced		AN3-CA: 602.2
FGFR2	BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25	ENSG00000066468	Fibroblast growth factor receptor 2	10	121478334-121598458	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010886, HPA035305, HPA056562	Uncertain		Approved	Vesicles	Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable)	Expressed in all	Mixed			skin: 129.4	Cell line enhanced		AN3-CA: 169.6;BEWO: 58.8;HAP1: 61.4;NTERA-2: 58.4
FGFR3	ACH, CD333, CEK2, JTK4	ENSG00000068078	Fibroblast growth factor receptor 3	4	1793307-1808872	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB004231, HPA067204	Enhanced		Supported	Endoplasmic reticulum	Endometrial cancer:3.77e-4 (unfavourable)	Expressed in all	Tissue enriched	7	skin: 333.1	cerebral cortex: 49.4	Cell line enhanced		CACO-2: 41.4;Hep G2: 56.1;NTERA-2: 37.4;RT4: 81.0
FGFR4	CD334, JTK2	ENSG00000160867	Fibroblast growth factor receptor 4	5	177086886-177098144	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005196, HPA027273, HPA027369, HPA028251	Approved					Mixed	Tissue enhanced		lung: 38.9	duodenum: 21.4	Cell line enhanced		CACO-2: 142.3;Hep G2: 118.3;RH-30: 260.0
FGFRL1		ENSG00000127418	Fibroblast growth factor receptor-like 1	4	1009936-1026897	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB026019, HPA068828	Approved		Supported	Vesicles		Expressed in all	Expressed in all			thyroid gland: 67.6	Mixed		
FKBP11	FKBP19	ENSG00000134285	FK506 binding protein 11	12	48921518-48926474	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041709	Enhanced		Approved	Centrosome	Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:7.09e-4 (favourable)	Expressed in all	Mixed			pancreas: 60.7	Mixed		
FLT1	FLT, VEGFR1	ENSG00000102755	Fms related tyrosine kinase 1	13	28300344-28495145	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA011740, HPA014290, CAB068189, CAB068190	Enhanced		Supported	Plasma membrane<br>Actin filaments	Renal cancer:2.19e-4 (unfavourable)	Expressed in all	Tissue enriched	8	placenta: 622.5	thyroid gland: 81.9	Cell line enhanced		BJ: 61.1;HMC-1: 308.1;WM-115: 126.2
FLT4	PCL, VEGFR3	ENSG00000037280	Fms related tyrosine kinase 4	5	180601506-180649624	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB000099, HPA046519, HPA067906	Approved		Enhanced	Nuclear speckles<br>Plasma membrane<br>Cell Junctions		Expressed in all	Mixed			spleen: 18.3	Cell line enhanced		BEWO: 11.8;HEK93: 14.1;T-47d: 13.7;TIME: 12.7
FMO2		ENSG00000094963	Flavin containing monooxygenase 2	1	171185208-171211230	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA028261	Approved					Mixed	Tissue enhanced		adipose tissue: 98.3;esophagus: 102.9;lung: 158.2	breast: 55.8	Group enriched	48	ASC diff: 27.9;ASC TERT1: 12.9;HSkMC: 35.2
FMO3		ENSG00000007933	Flavin containing monooxygenase 3	1	171090877-171117819	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013750	Enhanced				Lung cancer:5.60e-5 (favourable), Renal cancer:1.13e-4 (unfavourable), Liver cancer:3.46e-4 (favourable)	Tissue enriched	Tissue enriched	24	liver: 556.7	fallopian tube: 22.8	Group enriched	13	ASC diff: 23.4;ASC TERT1: 17.9;HSkMC: 5.1
FMO5		ENSG00000131781	Flavin containing monooxygenase 5	1	147175351-147243050	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012373	Enhanced		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:1.34e-6 (favourable)	Tissue enriched	Tissue enhanced		liver: 324.7	small intestine: 75.4	Cell line enhanced		Hep G2: 26.6;HMC-1: 7.7;THP-1: 6.7
FOCAD	FLJ20375, KIAA1797	ENSG00000188352	Focadhesin	9	20658309-20995955	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055015	Uncertain		Uncertain	Mitochondria	Renal cancer:3.09e-8 (favourable), Liver cancer:4.41e-5 (unfavourable), Colorectal cancer:3.25e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 34.2	Mixed		
FOLR2		ENSG00000165457	Folate receptor beta	11	72216601-72221950	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Thyroid cancer:8.41e-4 (favourable), Colorectal cancer:8.42e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 235.4	Group enriched	6	Daudi: 2.6;U-698: 12.5
FRAS1	FLJ14927, FLJ22031, KIAA1500	ENSG00000138759	Fraser extracellular matrix complex subunit 1	4	78057570-78544269	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011281, HPA051601	Approved		Approved	Nucleoli fibrillar center	Renal cancer:4.69e-4 (favourable)	Mixed	Tissue enhanced		thyroid gland: 20.2	kidney,placenta: 8.2	Cell line enhanced		fHDF/TERT166: 28.1;RH-30: 19.7;SiHa: 23.0
FSHR	FSHRO, LGR1, ODG1	ENSG00000170820	Follicle stimulating hormone receptor	2	48962157-49154537	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Group enriched	9	ovary: 2.5;testis: 4.3	gallbladder: 0.3	Not detected		
FURIN	FUR, PACE, PCSK3, SPC1	ENSG00000140564	Furin, paired basic amino acid cleaving enzyme	15	90868592-90883458	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009499	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Lung cancer:1.58e-4 (unfavourable)	Expressed in all	Expressed in all			salivary gland: 92.8	Expressed in all		
FXYD1	PLM	ENSG00000266964	FXYD domain containing ion transport regulator 1	19	35138808-35143109	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026873			Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:7.59e-8 (unfavourable), Glioma:9.67e-4 (unfavourable)	Tissue enhanced	Expressed in all			skeletal muscle: 469.1	Cell line enhanced		ASC diff: 30.9;ASC TERT1: 9.1;HSkMC: 13.6
FXYD3	MAT-8, PLML	ENSG00000089356	FXYD domain containing ion transport regulator 3	19	35115879-35124324	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010856	Enhanced				Renal cancer:1.15e-6 (unfavourable)	Expressed in all	Tissue enhanced		colon: 1455.6;rectum: 1952.1	stomach: 557.3	Cell line enhanced		HaCaT: 792.6;hTCEpi: 1156.1;RT4: 686.4;SK-BR-3: 621.3;WM-115: 590.3
GABBR1	GPRC3A, hGB1a	ENSG00000204681	Gamma-aminobutyric acid type B receptor subunit 1	6	29555629-29633976	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050483, HPA058459	Uncertain		Approved	Centrosome	Renal cancer:3.77e-10 (unfavourable), Pancreatic cancer:2.54e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 20.8	spleen: 13.1	Cell line enhanced		U-2 OS: 6.7
GABRA1	EJM5	ENSG00000022355	Gamma-aminobutyric acid type A receptor alpha1 subunit	5	161847063-161899981	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB022502, HPA055746	Enhanced					Tissue enriched	Tissue enriched	46	cerebral cortex: 85.0	adrenal gland: 1.8	Not detected		
GABRA2		ENSG00000151834	Gamma-aminobutyric acid type A receptor alpha2 subunit	4	46248427-46475230	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB079061		Supported				Tissue enhanced	Tissue enriched	7	cerebral cortex: 74.3	epididymis: 11.3	Cell line enhanced		U-2 OS: 4.9;U-87 MG: 2.2;WM-115: 2.5
GABRA5		ENSG00000186297	Gamma-aminobutyric acid type A receptor alpha5 subunit	15	26866363-26949207	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA077031, CAB079022		Supported	Supported	Plasma membrane		Mixed	Tissue enriched	43	cerebral cortex: 81.6	esophagus: 1.8	Group enriched	10	A549: 32.7;HAP1: 12.7;NTERA-2: 14.6;U-2 OS: 13.1
GABRD		ENSG00000187730	Gamma-aminobutyric acid type A receptor delta subunit	1	2019298-2030758	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044371	Enhanced		Uncertain	Golgi apparatus<br>Vesicles	Renal cancer:4.12e-8 (unfavourable)	Expressed in all	Tissue enriched	12	cerebral cortex: 34.0	testis: 2.7	Cell line enhanced		EFO-21: 1.3;MCF7: 3.1;NB-4: 1.6;SH-SY5Y: 1.6
GABRG3		ENSG00000182256	Gamma-aminobutyric acid type A receptor gamma3 subunit	15	26971282-27541991	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054010	Supported					Tissue enhanced	Tissue enhanced		prostate: 10.6;testis: 16.5	cerebral cortex: 4.2	Cell line enhanced		K-562: 4.0;PC-3: 5.1;U-87 MG: 14.0
GABRP		ENSG00000094755	Gamma-aminobutyric acid type A receptor pi subunit	5	170763350-170814047	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB014883	Uncertain				Cervical cancer:3.37e-4 (favourable)	Mixed	Expressed in all			breast: 177.0	Cell line enhanced		A-431: 184.7;EFO-21: 182.4;PC-3: 293.8
GALC		ENSG00000054983	Galactosylceramidase	14	87837820-87993665	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB022196	Approved					Expressed in all	Expressed in all			testis: 44.0	Cell line enhanced		CAPAN-2: 72.3;HMC-1: 67.2
GALNT8	GALNAC-T8	ENSG00000130035	Polypeptide N-acetylgalactosaminyltransferase 8	12	4720341-4851927	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012638, HPA014418, HPA073461	Approved		Approved	Vesicles		Tissue enhanced	Group enriched	7	cerebral cortex: 19.4;colon: 17.6;duodenum: 8.1;rectum: 40.6;small intestine: 18.9;testis: 26.5	appendix: 3.2	Cell line enhanced		Karpas-707: 24.5;NTERA-2: 12.1;U-2 OS: 4.6;U-266/84: 7.3
GCGR	GGR	ENSG00000215644	Glucagon receptor	17	81804132-81814013	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071228			Approved	Golgi apparatus		Tissue enhanced	Group enriched	7	adrenal gland: 6.6;kidney: 8.4;liver: 20.8;parathyroid gland: 8.0	skin: 1.6	Cell line enhanced		HeLa: 1.2;MCF7: 2.2;SK-BR-3: 1.8;U-87 MG: 2.7
GFPT2	GFAT2	ENSG00000131459	Glutamine-fructose-6-phosphate transaminase 2	5	180300690-180353387	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056892, HPA059910	Uncertain		Supported	Vesicles	Renal cancer:2.58e-14 (unfavourable), Lung cancer:2.95e-4 (unfavourable), Thyroid cancer:3.47e-4 (unfavourable), Cervical cancer:9.09e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 90.9	appendix: 25.7	Cell line enhanced		ASC TERT1: 138.7;hTEC/SVTERT24-B: 242.9;U-87 MG: 409.1
GGT1	CD224, D22S672, D22S732, GGT	ENSG00000100031	Gamma-glutamyltransferase 1	22	24583750-24629005	Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045635, HPA047534, HPA065444	Supported		Approved	Vesicles	Renal cancer:4.83e-4 (favourable), Ovarian cancer:7.44e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 161.2	small intestine: 95.9	Cell line enhanced		HDLM-2: 148.2;Karpas-707: 162.6;RPMI-8226: 159.9;RPTEC TERT1: 155.8
GHRHR		ENSG00000106128	Growth hormone releasing hormone receptor	7	30938669-30993254	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Tissue enhanced	Not detected			adrenal gland: 0.5	Not detected		
GLG1	CFR-1, ESL-1, MG-160	ENSG00000090863	Golgi glycoprotein 1	16	74447427-74607144	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010815	Supported		Enhanced	Golgi apparatus	Renal cancer:1.56e-7 (favourable), Cervical cancer:1.99e-4 (unfavourable), Urothelial cancer:7.97e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 167.1	Expressed in all		
GLIPR1	GliPR, RTVP1	ENSG00000139278	GLI pathogenesis related 1	12	75480680-75503853	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011014	Approved				Renal cancer:8.69e-9 (unfavourable)	Expressed in all	Mixed			appendix: 64.9	Cell line enhanced		hTEC/SVTERT24-B: 189.5;U-138 MG: 359.6
GLMP	C1orf85, MGC31963, NCU-G1	ENSG00000198715	Glycosylated lysosomal membrane protein	1	156290089-156295689	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029121	Uncertain				Liver cancer:6.35e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 96.6	Mixed		
GLRB		ENSG00000109738	Glycine receptor beta	4	157076057-157172090	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052363	Approved				Renal cancer:4.89e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 62.0;parathyroid gland: 63.1	cervix, uterine: 14.1	Mixed		
GP2	ZAP75	ENSG00000169347	Glycoprotein 2	16	20309572-20327808	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015739, HPA016668	Enhanced					Tissue enriched	Tissue enriched	206	pancreas: 7530.3	duodenum: 36.5	Not detected		
GP6	GPVI	ENSG00000088053	Glycoprotein VI platelet	19	55013705-55038264	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA066482	Approved		Approved	Nucleoplasm		Not detected	Tissue enhanced		testis: 1.2	skin: 0.7	Group enriched	12	HEL: 8.5;K-562: 3.7;U-2 OS: 2.7
GPER1	CEPR, CMKRL2, DRY12, FEG-1, GPCR-Br, GPER, GPR30, LERGU, LERGU2, LyGPR	ENSG00000164850	G protein-coupled estrogen receptor 1	7	1082208-1093815	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA027052	Approved				Endometrial cancer:1.17e-4 (favourable)	Expressed in all	Mixed			placenta: 9.1	Cell line enhanced		AN3-CA: 10.6;Hep G2: 15.3
GPNMB	HGFIN, NMB	ENSG00000136235	Glycoprotein nmb	7	23235967-23275108	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Expressed in all			skin: 654.6	Cell line enriched	5	ASC diff: 3230.9
GPR162	A-2, GRCA	ENSG00000250510	G protein-coupled receptor 162	12	6821545-6829972	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055135	Enhanced		Approved	Microtubule organizing center	Renal cancer:1.37e-6 (unfavourable), Pancreatic cancer:4.29e-5 (favourable)	Tissue enriched	Group enriched	6	cerebral cortex: 84.3;fallopian tube: 29.4	lung: 9.5	Cell line enhanced		AF22: 17.4;AN3-CA: 19.5;NTERA-2: 19.7;SH-SY5Y: 14.2;U-2 OS: 17.2
GRIA2	GluA2, GLUR2, GLURB	ENSG00000120251	Glutamate ionotropic receptor AMPA type subunit 2	4	157204182-157366075	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB007812, HPA008441	Enhanced					Group enriched	Tissue enriched	7	cerebral cortex: 206.6	endometrium: 27.5	Cell line enriched	8	SCLC-21H: 19.9
GRIA3	GluA3, GLUR3, GLURC, MRX94	ENSG00000125675	Glutamate ionotropic receptor AMPA type subunit 3	X	123184153-123490915	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA058659	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 56.6	adrenal gland: 11.3	Cell line enhanced		BJ: 20.3;BJ hTERT+: 28.1;fHDF/TERT166: 35.8;U-2197: 14.1
GRIA4	GluA4, GLUR4, GLURD	ENSG00000152578	Glutamate ionotropic receptor AMPA type subunit 4	11	105609994-105982092	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	10	cerebral cortex: 73.2	adrenal gland: 7.3	Cell line enhanced		AF22: 11.9;NTERA-2: 4.0;SCLC-21H: 5.1
GRIK2	GluK2, GLUR6, MRT6	ENSG00000164418	Glutamate ionotropic receptor kainate type subunit 2	6	101398788-102070083	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014395, HPA014623, CAB022463	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 22.5	thyroid gland: 6.3	Cell line enhanced		BJ: 14.3;BJ hTERT+: 22.6;fHDF/TERT166: 16.5;WM-115: 25.2
GRIN2B	GluN2B, NMDAR2B	ENSG00000273079	Glutamate ionotropic receptor NMDA type subunit 2B	12	13437942-13981957	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA069762	Approved					Not detected	Tissue enriched	23	cerebral cortex: 13.1	adipose tissue,testis: 0.5	Cell line enhanced		AF22: 1.2;CACO-2: 1.2;NTERA-2: 1.8;RPTEC TERT1: 1.3
GRM2	GPRC1B, mGlu2, MGLUR2	ENSG00000164082	Glutamate metabotropic receptor 2	3	51707070-51718613	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027868, HPA065166	Approved	Supported				Tissue enhanced	Tissue enriched	10	cerebral cortex: 4.4	testis: 0.4	Cell line enriched	7	SCLC-21H: 7.3
GRM3	GPRC1C, mGlu3, MGLUR3	ENSG00000198822	Glutamate metabotropic receptor 3	7	86643914-86864884	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	43	cerebral cortex: 62.3	testis: 1.4	Cell line enriched	8	AF22: 35.5
GRM5	GPRC1E, mGlu5, MGLUR5, PPP1R86	ENSG00000168959	Glutamate metabotropic receptor 5	11	88504576-89065945	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	8	cerebral cortex: 27.2	testis: 3.2	Not detected		
GSG1	MGC3146	ENSG00000111305	Germ cell associated 1	12	13083560-13103683	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	377	testis: 574.9	duodenum: 1.5	Cell line enhanced		fHDF/TERT166: 6.7;LHCN-M2: 8.2;RPTEC TERT1: 9.2;U-2 OS: 6.4
GYPB	CD235b, GPB, MNS, SS	ENSG00000250361	Glycophorin B (MNS blood group)	4	143996104-144019345	Blood group antigen proteins, CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	5	bone marrow: 37.2	placenta: 7.3	Cell line enriched	5	HEL: 225.3
HAPLN3	EXLD1, HsT19883	ENSG00000140511	Hyaluronan and proteoglycan link protein 3	15	88877288-88895626	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039237	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.18e-13 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 13.8;lymph node: 10.8	spleen: 4.0	Cell line enhanced		HDLM-2: 29.8;U-2 OS: 31.7
HAVCR1	CD365, HAVCR, HAVCR-1, KIM1, TIM-1, TIM1, TIMD1	ENSG00000113249	Hepatitis A virus cellular receptor 1	5	157029413-157059119	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007173, CAB075697	Approved		Approved	Vesicles	Urothelial cancer:1.32e-4 (favourable), Stomach cancer:7.81e-4 (unfavourable)	Tissue enriched	Group enriched	6	colon: 4.8;kidney: 8.3;rectum: 4.1;testis: 1.7	gallbladder: 0.8	Group enriched	5	A549: 86.4;CACO-2: 95.7;RPTEC TERT1: 33.8
HEATR5A	C14orf125, DKFZP434I1735	ENSG00000129493	HEAT repeat containing 5A	14	31291791-31420582	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049539	Uncertain				Renal cancer:1.11e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 18.2	Expressed in all		
HEPH	CPL, KIAA0698	ENSG00000089472	Hephaestin	X	66162549-66268867	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005824	Approved				Renal cancer:7.00e-6 (unfavourable), Glioma:6.23e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 119.0	Cell line enhanced		AF22: 28.1;HEL: 22.8;HSkMC: 26.1;K-562: 64.5;LHCN-M2: 23.8
HFE2	haemojuvelin, hemojuvelin, HFE2A, HJV, JH, RGMC	ENSG00000168509	Hemochromatosis type 2 (juvenile)	1	146017468-146036746	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	15	heart muscle: 45.4;liver: 123.4;skeletal muscle: 212.6	esophagus: 8.6	Cell line enhanced		HSkMC: 1.1;K-562: 1.4
HHIP	FLJ20992, HIP	ENSG00000164161	Hedgehog interacting protein	4	144646021-144745271	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012616	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		lung: 24.2	cerebral cortex: 10.8	Group enriched	6	HUVEC TERT2: 269.0;RH-30: 62.9;TIME: 306.5
HHLA2	B7-H5, B7H7, B7y	ENSG00000114455	HERV-H LTR-associating 2	3	108296490-108378285	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055478	Enhanced					Group enriched	Group enriched	10	colon: 87.7;duodenum: 87.1;gallbladder: 46.0;rectum: 90.5;small intestine: 143.9	stomach: 9.2	Cell line enhanced		HDLM-2: 3.7;Karpas-707: 2.0
HIPK1	KIAA0630, MGC26642, MGC33446, MGC33548, Myak, Nbak2	ENSG00000163349	Homeodomain interacting protein kinase 1	1	113929192-113977869	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016664	Approved		Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 89.7	Expressed in all		
HLA-A		ENSG00000206503	Major histocompatibility complex, class I, A	6	29941260-29945884	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB078470			Supported	Golgi apparatus<br>Plasma membrane	Ovarian cancer:6.47e-4 (favourable), Endometrial cancer:9.59e-4 (favourable)	Expressed in all	Mixed			gallbladder: 340.9	Cell line enhanced		A-431: 1127.9
HLA-C	D6S204, HLA-JY3, PSORS1	ENSG00000204525	Major histocompatibility complex, class I, C	6	31268749-31272130	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		lung: 744.7	small intestine: 396.9	Cell line enhanced		A-431: 660.6;EFO-21: 748.1;RPTEC TERT1: 346.0;U-266/70: 367.3;U-266/84: 281.2
HLA-DOA	HLA-D0-alpha, HLA-DNA, HLA-DZA	ENSG00000204252	Major histocompatibility complex, class II, DO alpha	6	33004178-33009612	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045038	Enhanced					Expressed in all	Tissue enhanced		spleen: 14.4	tonsil: 8.9	Cell line enhanced		Daudi: 4.6;HDLM-2: 4.3;REH: 19.0;U-698: 3.4
HLA-DPA1	HLA-DP1A	ENSG00000231389	Major histocompatibility complex, class II, DP alpha 1	6	33064569-33080775	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017967	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			lung: 120.6	Cell line enhanced		Daudi: 26.7;HDLM-2: 107.3;REH: 26.8
HLA-DQA1	CELIAC1, HLA-DQA	ENSG00000196735	Major histocompatibility complex, class II, DQ alpha 1	6	32628179-32647062	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012315	Enhanced					Expressed in all	Tissue enhanced		lung: 504.8	lymph node: 338.6	Cell line enriched	9	HDLM-2: 1315.9
HLA-DQB1	CELIAC1, HLA-DQB, IDDM1	ENSG00000179344	Major histocompatibility complex, class II, DQ beta 1	6	32659467-32668383	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013667	Uncertain		Supported	Golgi apparatus<br>Rods & Rings		Expressed in all	Tissue enhanced		lymph node: 287.3	lung: 268.5	Cell line enriched	8	HDLM-2: 555.8
HLA-DQB2	HLA-DXB	ENSG00000232629	Major histocompatibility complex, class II, DQ beta 2	6	32756098-32763534	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Breast cancer:5.55e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 8.1;skin: 13.3	tonsil: 5.9	Not detected		
HS6ST2		ENSG00000171004	Heparan sulfate 6-O-sulfotransferase 2	X	132626016-132961395	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA034625, HPA034626	Uncertain		Supported	Nucleoplasm	Urothelial cancer:6.03e-4 (favourable)	Mixed	Tissue enhanced		kidney: 15.0;ovary: 17.6	placenta: 11.9	Cell line enhanced		HEK93: 42.3;RH-30: 63.9;SH-SY5Y: 87.0
HSD11B1L	SCDR10, SDR26C2	ENSG00000167733	Hydroxysteroid 11-beta dehydrogenase 1 like	19	5680604-5688523	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA049078			Approved	Vesicles	Head and neck cancer:4.38e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 25.6	fallopian tube: 7.9	Cell line enhanced		SH-SY5Y: 20.1
HSD17B7	PRAP, SDR37C1	ENSG00000132196	Hydroxysteroid 17-beta dehydrogenase 7	1	162790702-162812817	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047496	Approved				Renal cancer:8.47e-5 (unfavourable)	Expressed in all	Mixed			liver: 16.9	Expressed in all		
HTATIP2	CC3, FLJ26963, SDR44U1, TIP30	ENSG00000109854	HIV-1 Tat interactive protein 2	11	20363685-20383783	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006417, HPA024321	Approved		Supported	Cytosol	Liver cancer:2.86e-4 (unfavourable), Pancreatic cancer:6.18e-4 (unfavourable), Renal cancer:8.01e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 135.2	Mixed		
HYAL2	LuCa-2, LUCA2	ENSG00000068001	Hyaluronoglucosaminidase 2	3	50317790-50322906	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036436	Uncertain					Expressed in all	Expressed in all			spleen: 214.2	Expressed in all		
ICAM1	BB2, CD54	ENSG00000090339	Intercellular adhesion molecule 1	19	10270835-10286615	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002126, CAB002142, HPA004877	Enhanced		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable)	Expressed in all	Expressed in all			lung: 255.9	Cell line enhanced		Karpas-707: 302.5
ICAM2	CD102	ENSG00000108622	Intercellular adhesion molecule 2	17	64002594-64020634	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071155			Uncertain	Cytosol		Expressed in all	Expressed in all			spleen: 200.5	Group enriched	7	HUVEC TERT2: 1043.9;TIME: 259.9
ICAM4	CD242, LW	ENSG00000105371	Intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)	19	10286967-10288522	Blood group antigen proteins, CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		bone marrow: 8.7;lung: 14.5	epididymis: 2.9	Cell line enhanced		HEL: 67.4;K-562: 35.3;NB-4: 20.5
IER3IP1		ENSG00000134049	Immediate early response 3 interacting protein 1	18	47152834-47176374	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010027	Supported		Supported	Endoplasmic reticulum	Liver cancer:6.47e-6 (unfavourable), Ovarian cancer:8.59e-4 (favourable)	Expressed in all	Expressed in all			kidney: 32.8	Expressed in all		
IFI30	GILT, IFI-30, IP-30, IP30, MGC32056	ENSG00000216490	IFI30, lysosomal thiol reductase	19	18173162-18178117	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026650	Approved		Supported	Vesicles<br>Cytosol		Mixed	Expressed in all			appendix: 828.7	Cell line enhanced		Daudi: 385.9;RPMI-8226: 408.1;U-266/84: 467.0
IFNAR1	IFNAR, IFRC	ENSG00000142166	Interferon alpha and beta receptor subunit 1	21	33324477-33359862	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018015, HPA029226	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 61.3	Expressed in all		
IFNGR1	CD119, IFNGR	ENSG00000027697	Interferon gamma receptor 1	6	137197484-137219449	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025889, HPA063871	Approved				Renal cancer:5.48e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 221.9	Expressed in all		
IFNLR1	CRF2/12, IFNLR, IL-28R1, IL28RA	ENSG00000185436	Interferon lambda receptor 1	1	24154157-24187959	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017319	Uncertain		Approved	Cytosol	Breast cancer:5.12e-4 (favourable)	Expressed in all	Mixed			small intestine: 10.1	Cell line enhanced		U-266/70: 39.6;U-698: 28.0
IGF2	C11orf43, FLJ44734, IGF-II	ENSG00000167244	Insulin like growth factor 2	11	2129112-2141238	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007556, HPA007993	Enhanced		Approved	Nucleoplasm<br>Vesicles	Liver cancer:7.12e-4 (favourable)	Group enriched	Tissue enriched	18	placenta: 3962.9	fallopian tube: 217.6	Cell line enhanced		CACO-2: 711.5;Hep G2: 406.1;LHCN-M2: 277.7;RH-30: 396.9;SH-SY5Y: 525.9
IGFALS	ALS	ENSG00000099769	Insulin like growth factor binding protein acid labile subunit	16	1790413-1794971	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040692, HPA040948	Approved		Supported	Nucleoplasm	Liver cancer:5.97e-4 (favourable), Endometrial cancer:6.06e-4 (unfavourable)	Tissue enhanced	Group enriched	6	liver: 25.0;stomach: 6.6	gallbladder: 2.5	Cell line enhanced		Hep G2: 1.2;U-266/70: 1.3
IGFLR1	FLJ22573, TMEM149, U2AF1L4	ENSG00000126246	IGF like family receptor 1	19	35738801-35742453	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012369	Uncertain		Approved	Focal adhesion sites	Ovarian cancer:1.59e-5 (favourable), Cervical cancer:6.55e-4 (favourable)	Expressed in all	Mixed			lymph node: 37.8	Cell line enhanced		HMC-1: 29.7;U-266/70: 26.0
IGSF1	IGCD1, IGDC1, INHBP, KIAA0364, MGC75490, PGSF2	ENSG00000147255	Immunoglobulin superfamily member 1	X	131273506-131578899	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012732, HPA035582	Enhanced		Approved	Cytosol	Endometrial cancer:4.25e-8 (unfavourable)	Tissue enriched	Tissue enhanced		testis: 20.0	adrenal gland: 13.1	Cell line enhanced		Hep G2: 22.7;SH-SY5Y: 30.6
IGSF11	BT-IgSF, CT119, Igsf13, MGC35227, VSIG3	ENSG00000144847	Immunoglobulin superfamily member 11	3	118900557-119146068	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046377	Uncertain		Approved	Nucleus<br>Cell Junctions<br>Cytosol		Group enriched	Tissue enhanced		cerebral cortex: 31.0;testis: 64.9	ovary: 20.1	Cell line enhanced		A549: 7.2;SK-MEL-30: 26.9;U-266/70: 8.9;U-266/84: 10.2
IGSF8	CD316, CD81P3, EWI2, PGRL	ENSG00000162729	Immunoglobulin superfamily member 8	1	160091340-160098943	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011917	Uncertain				Cervical cancer:7.32e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 107.8	Expressed in all		
IGSF9	IGSF9A, KIAA1355, Nrt1	ENSG00000085552	Immunoglobulin superfamily member 9	1	159927039-159945604	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA037753	Uncertain				Endometrial cancer:5.16e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 28.1	stomach: 13.2	Cell line enhanced		BEWO: 25.2;HaCaT: 34.4;SCLC-21H: 40.2
IL11RA		ENSG00000137070	Interleukin 11 receptor subunit alpha	9	34650702-34661892	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013162, CAB032830, HPA036652	Supported				Renal cancer:6.56e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 72.6	Mixed		
IL12RB1	CD212, IL12RB	ENSG00000096996	Interleukin 12 receptor subunit beta 1	19	18058995-18098944	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074414			Approved	Plasma membrane	Renal cancer:5.90e-5 (unfavourable), Cervical cancer:3.41e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 25.9	spleen: 20.6	Cell line enhanced		Daudi: 13.1;HDLM-2: 28.9;Karpas-707: 36.8
IL12RB2		ENSG00000081985	Interleukin 12 receptor subunit beta 2	1	67307364-67396900	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA024168	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		placenta: 11.8	cerebral cortex: 4.4	Cell line enhanced		HMC-1: 4.6;SCLC-21H: 12.2;SK-MEL-30: 21.0;THP-1: 10.6
IL13RA1	CD213a1, IL-13Ra, NR4	ENSG00000131724	Interleukin 13 receptor subunit alpha 1	X	118727572-118794539	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA000293			Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.19e-8 (unfavourable)	Expressed in all	Expressed in all			lung: 72.0	Mixed		
IL15RA	CD215, IL-15RA	ENSG00000134470	Interleukin 15 receptor subunit alpha	10	5943639-5978187	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026215	Approved		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.27e-12 (unfavourable), Liver cancer:2.67e-6 (unfavourable), Pancreatic cancer:5.35e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 33.5	Cell line enhanced		CAPAN-2: 59.4;HDLM-2: 70.4
IL17RA	CD217, CDw217, hIL-17R, IL-17RA, IL17R	ENSG00000177663	Interleukin 17 receptor A	22	17084954-17115694	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB024996	Enhanced		Approved	Nucleoplasm<br>Cytosol	Stomach cancer:8.35e-4 (favourable)	Expressed in all	Mixed			bone marrow: 20.6	Cell line enhanced		HL-60: 47.4;THP-1: 50.1
IL17RC	IL17-RL	ENSG00000163702	Interleukin 17 receptor C	3	9917074-9933630	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019885, CAB026255	Approved				Endometrial cancer:1.38e-4 (favourable)	Expressed in all	Expressed in all			prostate: 24.2	Mixed		
IL17RE	FLJ23658	ENSG00000163701	Interleukin 17 receptor E	3	9902612-9916402	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019011	Uncertain					Expressed in all	Mixed			small intestine: 22.6	Cell line enhanced		ASC TERT1: 27.7;BEWO: 14.7;T-47d: 18.4
IL18R1	CD218a, IL-1Rrp, IL1RRP	ENSG00000115604	Interleukin 18 receptor 1	2	102311529-102398775	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007615	Approved		Approved	Mitochondria	Renal cancer:4.52e-4 (unfavourable)	Mixed	Mixed			placenta: 14.4	Cell line enhanced		HDLM-2: 28.1;HHSteC: 51.3;HMC-1: 36.8;U-937: 54.3
IL18RAP	AcPL, CD218b	ENSG00000115607	Interleukin 18 receptor accessory protein	2	102418689-102452565	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025270	Enhanced					Mixed	Tissue enhanced		bone marrow: 70.9	appendix: 16.9	Cell line enriched	10	U-937: 42.2
IL19	IL-10C, IL-19, MDA1, NG.1, ZMDA1	ENSG00000142224	Interleukin 19	1	206798870-206842981	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	9	cervix, uterine: 21.0	salivary gland: 2.3	Cell line enriched	11	BJ hTERT+: 4.9
IL1R1	CD121A, D2S1473, IL1R, IL1RA	ENSG00000115594	Interleukin 1 receptor type 1	2	102064544-102179874	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005823, CAB007779, HPA029560	Approved				Renal cancer:6.92e-6 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 246.0	Cell line enhanced		ASC diff: 431.3;ASC TERT1: 195.1;HHSteC: 165.4;HSkMC: 562.6
IL1R2	CD121b, IL1RB	ENSG00000115590	Interleukin 1 receptor type 2	2	101991844-102028544	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027597, HPA027598	Uncertain				Renal cancer:5.58e-12 (unfavourable)	Mixed	Mixed			appendix: 50.3	Cell line enriched	24	HDLM-2: 436.8
IL1RAP	C3orf13, IL-1RAcP, IL1R3	ENSG00000196083	Interleukin 1 receptor accessory protein	3	190514051-190659750	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035293	Uncertain		Approved	Vesicles<br>Cytosol	Renal cancer:2.16e-7 (unfavourable), Pancreatic cancer:1.31e-4 (unfavourable), Urothelial cancer:6.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 113.0;placenta: 53.7	gallbladder: 19.8	Cell line enhanced		SK-MEL-30: 193.6
IL1RL1	DER4, FIT-1, IL33R, ST2, ST2L, ST2V, T1	ENSG00000115602	Interleukin 1 receptor like 1	2	102311502-102352037	Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007406, HPA007917	Uncertain		Approved	Vesicles		Tissue enhanced	Tissue enriched	12	placenta: 289.6	gallbladder: 23.7	Group enriched	6	HHSteC: 206.0;HMC-1: 327.3;HUVEC TERT2: 154.2
IL1RL2	IL1R-rp2, IL1RRP2	ENSG00000115598	Interleukin 1 receptor like 2	2	102186973-102240002	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015485	Uncertain					Mixed	Tissue enhanced		skin: 15.5	parathyroid gland: 8.5	Cell line enhanced		A-431: 7.2;ASC TERT1: 3.6;HaCaT: 3.3;HSkMC: 3.1
IL20RA	IL-20R1, ZCYTOR7	ENSG00000016402	Interleukin 20 receptor subunit alpha	6	136999971-137045180	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB024990, HPA042281	Approved		Approved	Cytosol	Endometrial cancer:1.43e-6 (favourable), Head and neck cancer:2.29e-5 (favourable)	Mixed	Tissue enhanced		skin: 45.0	breast: 33.5	Group enriched	7	CAPAN-2: 8.4;HaCaT: 6.1;RT4: 9.2;SH-SY5Y: 11.4;T-47d: 10.0
IL2RB	CD122, IL15RB	ENSG00000100385	Interleukin 2 receptor subunit beta	22	37125838-37175054	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062657	Enhanced				Renal cancer:3.50e-7 (unfavourable), Endometrial cancer:3.18e-5 (favourable), Colorectal cancer:6.76e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 52.7;spleen: 67.1	lymph node: 39.8	Cell line enriched	10	HDLM-2: 476.9
IL31RA	CRL, CRL3, GLM-R, Glmr, IL-31RA	ENSG00000164509	Interleukin 31 receptor A	5	55851379-55922853	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051532, HPA068114	Approved		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enhanced		testis: 3.6	bone marrow: 1.2	Cell line enhanced		hTERT-HME1: 10.7;U-2 OS: 21.6;U-87 MG: 23.4
IL3RA	CD123	ENSG00000185291	Interleukin 3 receptor subunit alpha	X	1336616-1382689	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003539, CAB018374	Approved				Cervical cancer:4.27e-4 (favourable), Breast cancer:9.78e-4 (favourable)	Expressed in all	Mixed			lung: 33.2	Cell line enhanced		HDLM-2: 109.2;RPMI-8226: 33.2
IL4R	CD124	ENSG00000077238	Interleukin 4 receptor	16	27313668-27364778	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004451, HPA050124	Enhanced				Renal cancer:1.23e-5 (unfavourable), Endometrial cancer:6.43e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 137.6	Mixed		
IL5RA	CD125, CDw125, IL5R	ENSG00000091181	Interleukin 5 receptor subunit alpha	3	3066326-3126613	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		fallopian tube: 22.7	lung: 4.9	Cell line enriched	28	HMC-1: 66.2
IL6R	CD126	ENSG00000160712	Interleukin 6 receptor	1	154405193-154469450	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.65e-4 (favourable)	Expressed in all	Mixed			appendix: 33.4	Cell line enhanced		THP-1: 147.4;U-266/84: 186.8
IL6ST	CD130, GP130	ENSG00000134352	Interleukin 6 signal transducer	5	55935095-55994993	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010558, CAB025784	Uncertain		Supported	Golgi apparatus<br>Plasma membrane	Renal cancer:5.05e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 329.8	Expressed in all		
IL7R	CD127	ENSG00000168685	Interleukin 7 receptor	5	35852695-35879603	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010215	Approved		Approved	Plasma membrane<br>Microtubule organizing center		Expressed in all	Tissue enhanced		appendix: 182.9;lymph node: 158.5	tonsil: 112.9	Cell line enhanced		fHDF/TERT166: 149.9;HBF TERT88: 165.6;REH: 372.0
ILDR1	DFNB42, MGC50831	ENSG00000145103	Immunoglobulin like domain containing receptor 1	3	121987323-122022204	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018207	Approved				Renal cancer:5.79e-9 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 35.1	cervix, uterine: 20.0	Cell line enhanced		CAPAN-2: 6.5;HDLM-2: 10.3;MCF7: 5.7;RT4: 7.7;T-47d: 6.4;U-266/70: 5.6
ILDR2	C1orf32	ENSG00000143195	Immunoglobulin like domain containing receptor 2	1	166895711-166975482	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012545	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 11.3;testis: 17.4	kidney: 3.1	Cell line enhanced		AF22: 7.8;U-2 OS: 10.6;U-251 MG: 4.6
ILVBL	209L8, AHAS, FLJ39061, HACL1L, ILV2H, MGC1269, MGC19535	ENSG00000105135	IlvB acetolactate synthase like	19	15114984-15125785	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA067682	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.91e-8 (favourable), Endometrial cancer:1.52e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 80.2	Expressed in all		
ISLR2	KIAA1465	ENSG00000167178	Immunoglobulin superfamily containing leucine rich repeat 2	15	74100311-74138540	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012930, HPA067333	Uncertain					Mixed	Group enriched	5	cerebral cortex: 31.1;testis: 14.8	endometrium: 4.5	Group enriched	13	SCLC-21H: 68.2;SH-SY5Y: 91.6
ITGA4	CD49D	ENSG00000115232	Integrin subunit alpha 4	2	181457202-181536187	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074961			Approved	Plasma membrane	Renal cancer:3.08e-5 (unfavourable), Head and neck cancer:8.29e-4 (favourable)	Mixed	Tissue enhanced		spleen: 67.6	appendix: 49.6	Cell line enhanced		fHDF/TERT166: 148.2;HEL: 275.3;MOLT-4: 291.8
ITGA9	ALPHA-RLC, ITGA4L, RLC	ENSG00000144668	Integrin subunit alpha 9	3	37452115-37823514	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030609	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cell Junctions		Expressed in all	Mixed			thyroid gland: 34.7	Cell line enhanced		CACO-2: 8.3;HEL: 7.3;SH-SY5Y: 12.3;WM-115: 6.1
ITGAL	CD11A, LFA-1	ENSG00000005844	Integrin subunit alpha L	16	30472658-30523185	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025011	Enhanced				Renal cancer:2.69e-5 (unfavourable), Endometrial cancer:5.63e-5 (favourable), Head and neck cancer:3.34e-4 (favourable), Melanoma:5.57e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 79.0;spleen: 80.9	appendix: 52.5	Cell line enriched	5	HMC-1: 570.1
ITGAX	CD11C	ENSG00000140678	Integrin subunit alpha X	16	31355134-31382997	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004458, HPA004723, CAB072871	Enhanced				Renal cancer:1.37e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 58.3;spleen: 59.0	bone marrow: 30.4	Cell line enriched	5	HMC-1: 92.2
ITGB1	CD29, FNRB, GPIIA, MDF2, MSK12	ENSG00000150093	Integrin subunit beta 1	10	32900319-33005792	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB003434, HPA059297, HPA069003	Enhanced		Supported	Endoplasmic reticulum<br>Plasma membrane<br>Focal adhesion sites	Lung cancer:3.36e-6 (unfavourable), Cervical cancer:5.01e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 1069.5	Expressed in all		
ITGB2	CD18, LFA-1, MAC-1, MFI7	ENSG00000160255	Integrin subunit beta 2	21	44885953-44931989	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008877, HPA016894	Enhanced		Approved	Plasma membrane		Expressed in all	Expressed in all			appendix: 239.2	Cell line enhanced		EFO-21: 120.5;THP-1: 518.6;U-937: 447.2
ITGB3	CD61, GP3A, GPIIIa	ENSG00000259207	Integrin subunit beta 3	17	47253846-47311816	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027852	Supported					Group enriched	Tissue enhanced		thyroid gland: 95.6	smooth muscle: 36.8	Cell line enhanced		EFO-21: 179.0;HEL: 158.0;WM-115: 275.8
ITGB7		ENSG00000139626	Integrin subunit beta 7	12	53191318-53207307	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042277			Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			spleen: 32.5	Group enriched	97	Karpas-707: 3399.5;RPMI-8226: 2658.1
JAML	AMICA, AMICA1, Gm638	ENSG00000160593	Junction adhesion molecule like	11	118193740-118225094	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047919	Approved				Head and neck cancer:3.11e-4 (favourable), Lung cancer:3.92e-4 (favourable)	Mixed	Tissue enhanced		appendix: 82.3	spleen: 67.0	Cell line enhanced		CACO-2: 4.8;HMC-1: 24.2
KCNK7	K2p7.1	ENSG00000173338	Potassium two pore domain channel subfamily K member 7	11	65592855-65595996	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Voltage-gated ion channels	Evidence at transcript level	HPA077577			Approved	Plasma membrane		Tissue enhanced	Tissue enriched	7	skin: 53.2	esophagus: 7.9	Cell line enhanced		SCLC-21H: 8.4
KCNN4	hIKCa1, hKCa4, hSK4, IK, KCa3.1	ENSG00000104783	Potassium calcium-activated channel subfamily N member 4	19	43766533-43781257	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA053841, HPA059622	Approved				Renal cancer:1.05e-14 (unfavourable), Urothelial cancer:1.75e-4 (favourable), Glioma:3.77e-4 (unfavourable), Pancreatic cancer:4.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		salivary gland: 73.7	stomach: 36.6	Cell line enhanced		CAPAN-2: 93.3;WM-115: 264.9
KCNU1	KCa5.1, Kcnma3, KCNMC1, Slo3	ENSG00000215262	Potassium calcium-activated channel subfamily U member 1	8	36784324-36936128	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA063317			Uncertain	Plasma membrane		Tissue enhanced	Tissue enriched	28	testis: 13.5	adipose tissue,epididymis: 0.4	Cell line enriched	6	HDLM-2: 7.3
KDSR	DHSR, FVT1, SDR35C1	ENSG00000119537	3-ketodihydrosphingosine reductase	18	63327726-63367510	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB003673, HPA044884	Approved				Renal cancer:9.53e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 45.5	Expressed in all		
KIAA0319	NMIG	ENSG00000137261	KIAA0319	6	24544104-24646155	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015607, HPA076313	Enhanced		Uncertain	Vesicles		Mixed	Tissue enriched	6	cerebral cortex: 15.8	fallopian tube: 2.8	Cell line enhanced		HDLM-2: 2.6;SCLC-21H: 5.1;U-266/84: 2.6
KIAA1324	EIG121, maba1	ENSG00000116299	KIAA1324	1	109113679-109206781	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029869, HPA070749	Enhanced		Supported	Plasma membrane	Endometrial cancer:2.14e-7 (favourable), Lung cancer:5.69e-5 (favourable), Ovarian cancer:2.16e-4 (favourable)	Mixed	Mixed			cervix, uterine: 129.0	Cell line enhanced		MCF7: 21.5;SCLC-21H: 20.3;SK-BR-3: 15.8;T-47d: 68.2;U-87 MG: 13.3
KIR2DL4	103AS, 15.212, CD158D	ENSG00000189013	Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4	19	54803535-54814517	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Not detected			all non-specific tissues: 0.0	Not detected		
KIRREL2	DKFZp564A1164, FILTRIN, MGC15718, NEPH3, NLG1	ENSG00000126259	Kin of IRRE like 2 (Drosophila)	19	35855861-35867109	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071587, HPA074326			Supported	Microtubule organizing center		Mixed	Tissue enriched	8	pancreas: 11.6	cerebral cortex: 1.4	Cell line enhanced		HDLM-2: 20.2;HMC-1: 29.3
KREMEN2	KRM2, MGC10791	ENSG00000131650	Kringle containing transmembrane protein 2	16	2963944-2968383	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA003223	Uncertain		Approved	Nucleoli	Lung cancer:8.98e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 6.9	cerebral cortex: 2.1	Cell line enhanced		HMC-1: 24.6;RPMI-8226: 19.1
L1CAM	CD171, HSAS, HSAS1, MASA, MIC5, S10, SPG1	ENSG00000198910	L1 cell adhesion molecule	X	153861514-153909223	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010896	Enhanced		Approved	Nucleoplasm<br>Plasma membrane	Endometrial cancer:8.51e-10 (unfavourable), Lung cancer:2.36e-6 (unfavourable), Renal cancer:1.17e-4 (unfavourable), Head and neck cancer:3.81e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 36.0;cerebral cortex: 66.9	seminal vesicle: 12.8	Cell line enhanced		BJ hTERT+: 303.8;BJ hTERT+ SV40 Large T+ RasG12V: 195.5;HeLa: 182.1
LAG3	CD223	ENSG00000089692	Lymphocyte activating 3	12	6772512-6778455	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002301, HPA013967	Enhanced				Renal cancer:4.62e-11 (unfavourable), Cervical cancer:3.89e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 32.0	lymph node: 17.6	Cell line enriched	140	HDLM-2: 136.0
LAMP3	CD208, DC-LAMP, DCLAMP, LAMP, TSC403	ENSG00000078081	Lysosomal associated membrane protein 3	3	183122213-183163839	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025133, HPA051467	Enhanced		Enhanced	Vesicles	Renal cancer:1.89e-7 (unfavourable), Ovarian cancer:9.90e-4 (favourable)	Mixed	Tissue enriched	7	lung: 319.3	appendix: 44.9	Group enriched	8	EFO-21: 154.0;HDLM-2: 40.5;HHSteC: 50.0;hTCEpi: 40.3
LAT	LAT1	ENSG00000213658	Linker for activation of T-cells	16	28984826-28990783	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB002223, HPA011157, CAB012978	Enhanced		Supported	Golgi apparatus<br>Plasma membrane		Not detected	Tissue enhanced		lymph node: 75.3	appendix: 31.8	Group enriched	8	HEL: 173.8;HMC-1: 690.0;MOLT-4: 227.5
LDLR	LDLCQ2	ENSG00000130164	Low density lipoprotein receptor	19	11089362-11133816	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009647, HPA013159	Approved				Pancreatic cancer:6.60e-5 (unfavourable), Urothelial cancer:3.43e-4 (unfavourable), Renal cancer:5.92e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 87.6	Expressed in all		
LGR4	GPR48	ENSG00000205213	Leucine rich repeat containing G protein-coupled receptor 4	11	27365961-27472775	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030267, HPA054350	Uncertain		Approved	Microtubule organizing center	Renal cancer:2.00e-7 (favourable)	Expressed in all	Expressed in all			kidney: 56.2	Cell line enhanced		HAP1: 86.6
LHCGR	HHG, LCGR, LGR2, LHR, ULG5	ENSG00000138039	Luteinizing hormone/choriogonadotropin receptor	2	48686775-48755730	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009814	Uncertain					Not detected	Tissue enhanced		ovary: 1.6;testis: 4.3	adipose tissue: 1.3	Not detected		
LIFR	CD118	ENSG00000113594	Leukemia inhibitory factor receptor alpha	5	38474963-38608354	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004478, CAB010252	Approved		Approved	Nuclear speckles<br>Golgi apparatus	Renal cancer:1.40e-7 (favourable), Lung cancer:1.92e-4 (favourable)	Mixed	Mixed			thyroid gland: 68.0	Cell line enhanced		AF22: 93.6;SCLC-21H: 72.8
LILRA2	CD85h, ILT1, LIR-7, LIR7	ENSG00000239998	Leukocyte immunoglobulin like receptor A2	19	54572920-54590287	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		bone marrow: 9.9;spleen: 7.0	appendix: 4.0	Cell line enhanced		REH: 1.8;THP-1: 2.7;U-937: 7.1
LILRB3	CD85a, HL9, ILT5, LIR-3, LIR3, PIR-B, PIRB	ENSG00000204577	Leukocyte immunoglobulin like receptor B3	19	54216278-54223506	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Group enriched	5	adipose tissue: 5.4;appendix: 11.3;bone marrow: 9.9;lung: 9.2;spleen: 11.1;urinary bladder: 6.8	placenta: 1.7	Not detected		
LINC01125		ENSG00000228486	Long intergenic non-protein coding RNA 1125	2	97664217-97703064	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		testis: 11.7	skin: 2.4	Cell line enhanced		AF22: 1.7;HDLM-2: 1.8
LINGO1	FLJ14594, LERN1, LRRN6A	ENSG00000169783	Leucine rich repeat and Ig domain containing 1	15	77613027-77820900	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074653	Enhanced		Approved	Plasma membrane	Renal cancer:3.23e-7 (unfavourable)	Expressed in all	Tissue enriched	13	cerebral cortex: 130.8	placenta: 9.8	Cell line enhanced		AF22: 23.6;AN3-CA: 18.6;HAP1: 31.4;HEK93: 19.6;NTERA-2: 56.8
LMAN2	C5orf8, GP36B, VIP36	ENSG00000169223	Lectin, mannose binding 2	5	177331562-177351852	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003927	Approved				Renal cancer:8.53e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 164.8	Expressed in all		
LRAT	LCA14	ENSG00000121207	Lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase)	4	154626945-154753118	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA070726			Uncertain	Endoplasmic reticulum<br>Golgi apparatus		Mixed	Tissue enhanced		thyroid gland: 2.3	testis: 1.6	Cell line enriched	11	NTERA-2: 11.7
LRCH3	MGC4126	ENSG00000186001	Leucine rich repeats and calponin homology domain containing 3	3	197791226-197888436	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012380, HPA017299	Uncertain		Enhanced	Cytosol	Liver cancer:2.95e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 26.2	Expressed in all		
LRFN4	FIGLER6, MGC3103, SALM3.	ENSG00000173621	Leucine rich repeat and fibronectin type III domain containing 4	11	66856647-66860475	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Mixed			cerebral cortex: 13.3	Mixed		
LRFN5	C14orf146, FIGLER8, SALM5	ENSG00000165379	Leucine rich repeat and fibronectin type III domain containing 5	14	41607570-41904549	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001177	Uncertain					Mixed	Tissue enhanced		parathyroid gland: 52.3	cervix, uterine: 16.8	Cell line enhanced		AN3-CA: 16.8;RPTEC TERT1: 4.6;SCLC-21H: 11.1;U-138 MG: 11.4
LRP1	A2MR, APOER, APR, CD91, LRP, LRP1A	ENSG00000123384	LDL receptor related protein 1	12	57128493-57213351	Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004182, CAB018621, HPA022903	Supported		Supported	Nucleoplasm<br>Vesicles	Urothelial cancer:1.29e-5 (unfavourable), Renal cancer:1.52e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 123.8	Cell line enhanced		ASC diff: 333.3;ASC TERT1: 342.9;HSkMC: 232.4
LRP11	bA350J20.3, MANSC3	ENSG00000120256	LDL receptor related protein 11	6	149818798-149864026	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064002			Approved	Mitochondria	Breast cancer:2.31e-8 (unfavourable), Liver cancer:2.01e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 89.2	Mixed		
LRP1B	LRP-DIT, LRPDIT	ENSG00000168702	LDL receptor related protein 1B	2	140231423-142131701	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069094, HPA074788	Approved		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 16.4;thyroid gland: 9.6	epididymis: 2.7	Cell line enhanced		ASC diff: 1.0;HEK93: 1.5;U-138 MG: 1.8
LRP2	DBS, gp330	ENSG00000081479	LDL receptor related protein 2	2	169127109-169362685	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005980, HPA064792	Enhanced		Approved	Vesicles<br>Mitochondria	Renal cancer:3.43e-5 (favourable)	Group enriched	Group enriched	6	kidney: 49.8;parathyroid gland: 155.8;thyroid gland: 37.0	breast: 14.2	Group enriched	11	AF22: 39.4;CACO-2: 56.2
LRP4	CLSS, LRP-4, MEGF7, SOST2	ENSG00000134569	LDL receptor related protein 4	11	46856868-46918642	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011934, HPA012300	Approved		Uncertain	Nucleus<br>Nucleoli<br>Mitochondria		Expressed in all	Tissue enhanced		cerebral cortex: 35.4;skin: 37.9	parathyroid gland: 13.1	Cell line enhanced		AF22: 21.2
LRRC32	D11S833E, GARP	ENSG00000137507	Leucine rich repeat containing 32	11	76657524-76670747	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055775, HPA058434			Supported	Nucleoplasm	Renal cancer:3.93e-5 (unfavourable), Urothelial cancer:2.64e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 76.4	Group enriched	5	ASC diff: 78.8;ASC TERT1: 49.2;HSkMC: 32.0;HUVEC TERT2: 43.0;U-2197: 100.6
LRRC3B	LRP15	ENSG00000179796	Leucine rich repeat containing 3B	3	26622806-26710776	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015568	Approved					Group enriched	Group enriched	7	cerebral cortex: 19.2;skeletal muscle: 3.9;testis: 13.0	endometrium,ovary: 1.6	Cell line enhanced		NTERA-2: 1.6
LRRC4B	DKFZp761A179, HSM, LRIG4	ENSG00000131409	Leucine rich repeat containing 4B	19	50516892-50568045	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA058986	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 61.4	cervix, uterine: 12.9	Cell line enhanced		HMC-1: 29.7;SH-SY5Y: 31.3;U-2 OS: 28.7
LRRC70	LOC100130733, SLRN	ENSG00000186105	Leucine rich repeat containing 70	5	62578735-62581448	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013409	Uncertain					Mixed	Mixed			thyroid gland: 6.4	Group enriched	16	HUVEC TERT2: 13.7;TIME: 7.3
LRRN3	FIGLER5, FLJ11129, NLRR3	ENSG00000173114	Leucine rich repeat neuronal 3	7	111091006-111125454	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA043820, HPA046792	Uncertain		Approved	Nucleus<br>Cytosol		Group enriched	Tissue enhanced		adrenal gland: 30.8;cerebral cortex: 31.2;testis: 29.1;thyroid gland: 33.6	lung: 11.6	Cell line enhanced		AF22: 24.9;BJ hTERT+: 25.6;SH-SY5Y: 47.7;T-47d: 23.4
LRRTM1	FLJ32082	ENSG00000162951	Leucine rich repeat transmembrane neuronal 1	2	80288351-80304749	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA062660	Approved					Group enriched	Tissue enhanced		cerebral cortex: 13.3;salivary gland: 4.9	thyroid gland: 2.2	Cell line enhanced		SH-SY5Y: 1.4
LRRTM2	KIAA0416	ENSG00000146006	Leucine rich repeat transmembrane neuronal 2	5	138868923-138875368	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	10	cerebral cortex: 29.0	placenta: 3.0	Group enriched	7	HDLM-2: 14.6;SCLC-21H: 5.8
LRRTM4	FLJ12568	ENSG00000176204	Leucine rich repeat transmembrane neuronal 4	2	76747719-77593319	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	9	cerebral cortex: 21.3	epididymis: 2.4	Cell line enriched	7	Karpas-707: 91.1
LRTM2		ENSG00000166159	Leucine rich repeats and transmembrane domains 2	12	1820267-1836752	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055094	Uncertain					Not detected	Tissue enriched	47	cerebral cortex: 8.3	testis: 0.1	Group enriched	12	HEL: 7.7;SCLC-21H: 5.2
LSR	ILDR3, LISCH7	ENSG00000105699	Lipolysis stimulated lipoprotein receptor	19	35248330-35267964	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007270	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.09e-4 (favourable)	Expressed in all	Expressed in all			stomach: 128.7	Cell line enhanced		A-431: 435.7
LST1	B144, D6S49E, LST-1	ENSG00000204482	Leukocyte specific transcript 1	6	31586124-31588909	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.97e-5 (unfavourable), Testis cancer:7.62e-4 (unfavourable), Cervical cancer:7.89e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 68.7;spleen: 48.9	appendix: 32.1	Cell line enhanced		HMC-1: 64.7;NB-4: 50.8;THP-1: 128.8;U-937: 79.6
LTBR	D12S370, TNF-R-III, TNFCR, TNFR-RP, TNFR2-RP, TNFRSF3	ENSG00000111321	Lymphotoxin beta receptor	12	6375045-6391571	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026202, HPA061617	Uncertain		Supported	Golgi apparatus	Liver cancer:5.13e-4 (unfavourable), Renal cancer:5.92e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 89.5	Cell line enhanced		HHSteC: 330.0
LTK	TYK1	ENSG00000062524	Leukocyte receptor tyrosine kinase	15	41503638-41513887	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059545	Uncertain		Approved	Vesicles		Mixed	Mixed			placenta: 15.2	Cell line enhanced		HEL: 4.4;NB-4: 6.1;RH-30: 4.4;THP-1: 9.9
LY6E	RIG-E, SCA-2, TSA-1	ENSG00000160932	Lymphocyte antigen 6 family member E	8	143017982-143023832	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level						Renal cancer:6.74e-8 (unfavourable)	Expressed in all	Expressed in all			lung: 109.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 564.1;MCF7: 492.5
LY6G6D	C6orf23, G6D, Ly6-D, MEGT1, NG25	ENSG00000244355	Lymphocyte antigen 6 family member G6D	6	31715356-31717804	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054412	Uncertain					Tissue enriched	Tissue enhanced		seminal vesicle: 2.0	prostate: 0.8	Cell line enhanced		HEL: 1.6
LY6K	CT97, FLJ35226, HSJ001348	ENSG00000160886	Lymphocyte antigen 6 family member K	8	142700111-142705127	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017770, CAB075742, CAB075743	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Lung cancer:9.17e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 29.0	adipose tissue: 5.9	Cell line enhanced		A-431: 108.7;BJ: 111.4;HeLa: 95.9;SiHa: 218.6;U-2197: 254.2
LYNX1	SLURP2	ENSG00000180155	Ly6/neurotoxin 1	8	142771197-142777810	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level						Renal cancer:2.82e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 94.6	parathyroid gland: 58.6	Cell line enhanced		BJ: 6.9;fHDF/TERT166: 7.9;HHSteC: 6.9;T-47d: 6.7
M6PR	CD-M6PR, CD-MPR	ENSG00000003056	Mannose-6-phosphate receptor, cation dependent	12	8940363-8949955	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB034464, HPA040445	Approved				Liver cancer:3.89e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 175.3	Expressed in all		
MAG	GMA, S-MAG, SIGLEC-4A, SIGLEC4A	ENSG00000105695	Myelin associated glycoprotein	19	35292125-35313804	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009345, HPA012499	Enhanced					Tissue enriched	Tissue enriched	6	cerebral cortex: 163.6	ovary: 27.5	Cell line enriched	31	WM-115: 35.4
MAGT1	DKFZp564K142, IAP, MRX95, OST3B	ENSG00000102158	Magnesium transporter 1	X	77826364-77895593	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA049851	Approved				Breast cancer:1.30e-4 (unfavourable), Pancreatic cancer:3.55e-4 (unfavourable), Melanoma:8.98e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 137.3	Expressed in all		
MANSC1	FLJ10298, LOH12CR3	ENSG00000111261	MANSC domain containing 1	12	12326056-12350541	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007955, HPA007956	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:3.30e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 24.7	Cell line enhanced		HUVEC TERT2: 42.6
MDFIC	HIC	ENSG00000135272	MyoD family inhibitor domain containing	7	114922154-115019202	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030716	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:3.65e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 48.0	Cell line enhanced		U-2197: 101.4
MEGF10	KIAA1780	ENSG00000145794	Multiple EGF like domains 10	5	127290831-127465737	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	7	cerebral cortex: 15.8	adrenal gland: 2.2	Cell line enhanced		AF22: 31.3;RH-30: 37.5
MET	DFNB97, HGFR, RCCP2	ENSG00000105976	MET proto-oncogene, receptor tyrosine kinase	7	116672390-116798386	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005282, CAB018577, HPA055607	Uncertain		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 39.0	Mixed		
MFAP3		ENSG00000037749	Microfibrillar associated protein 3	5	154038906-154220478	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015883, HPA049198	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Cervical cancer:4.28e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 74.8	Expressed in all		
MFAP3L	KIAA0626, NYD-sp9	ENSG00000198948	Microfibrillar associated protein 3 like	4	169986597-170033031	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017986	Approved				Renal cancer:1.42e-8 (favourable)	Expressed in all	Tissue enhanced		testis: 74.1	epididymis: 47.4	Cell line enhanced		HMC-1: 19.9;RT4: 30.4;SK-BR-3: 25.8
MGST2	MGST-II	ENSG00000085871	Microsomal glutathione S-transferase 2	4	139665768-139740745	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010707	Approved		Approved	Nucleoplasm	Renal cancer:3.22e-9 (favourable), Endometrial cancer:5.26e-5 (favourable)	Expressed in all	Expressed in all			liver: 178.3	Mixed		
MIA3	FLJ39207, KIAA0268, TANGO, TANGO1, UNQ6077	ENSG00000154305	MIA family member 3, ER export factor	1	222618086-222668012	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055922, HPA056816	Enhanced		Enhanced	Vesicles	Renal cancer:3.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 81.5	Expressed in all		
MLEC	KIAA0152	ENSG00000110917	Malectin	12	120686869-120701864	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:9.60e-6 (favourable), Stomach cancer:8.77e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 162.3	Expressed in all		
MMP14	MT1-MMP	ENSG00000157227	Matrix metallopeptidase 14	14	22836557-22849027	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009918, HPA051432	Approved		Approved	Intermediate filaments<br>Cytosol	Renal cancer:1.34e-4 (unfavourable), Ovarian cancer:9.48e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 236.6	Cell line enhanced		HHSteC: 664.7
MOXD1	dJ248E1.1, DKFZP564G202, MOX	ENSG00000079931	Monooxygenase DBH like 1	6	132296055-132401545	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035740	Approved		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:7.09e-5 (favourable), Stomach cancer:3.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 106.1;smooth muscle: 114.5	seminal vesicle: 53.7	Cell line enhanced		ASC diff: 111.5;fHDF/TERT166: 149.9;HBF TERT88: 116.1;U-2197: 280.6
MPIG6B	C6orf25, G6b, G6b-B, NG31	ENSG00000204420	Megakaryocyte and platelet inhibitory receptor G6b	6	31718594-31726714	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA073017			Uncertain	Golgi apparatus		Mixed	Not detected			skin: 0.8	Cell line enriched	16	HEL: 5.4
MPZL1	FLJ21047, PZR	ENSG00000197965	Myelin protein zero like 1	1	167721192-167791919	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026966, HPA063538	Approved		Supported	Vesicles<br>Plasma membrane	Renal cancer:3.99e-7 (unfavourable), Liver cancer:4.27e-6 (unfavourable), Lung cancer:3.98e-4 (unfavourable), Thyroid cancer:8.08e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 111.6	Expressed in all		
MR1	HLALS	ENSG00000153029	Major histocompatibility complex, class I-related	1	181033425-181061938	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048304			Supported	Plasma membrane		Expressed in all	Mixed			thyroid gland: 28.2	Mixed		
MS4A14	DKFZp434H092, FLJ32856, MS4A16, NYD-SP21	ENSG00000166928	Membrane spanning 4-domains A14	11	60378530-60417756	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at transcript level							Mixed	Tissue enriched	12	testis: 91.8	spleen: 7.6	Cell line enriched	23	THP-1: 6.3
MS4A3	CD20L, HTM4	ENSG00000149516	Membrane spanning 4-domains A3	11	60056587-60071128	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019210	Supported					Not detected	Tissue enriched	256	bone marrow: 305.3	skin,spleen: 1.1	Cell line enhanced		HEL: 172.0;K-562: 132.6;NB-4: 69.9;THP-1: 214.5;U-937: 98.3
MSLN	CAK1, MPF	ENSG00000102854	Mesothelin	16	760762-768865	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002216, HPA017172	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:5.91e-4 (favourable), Pancreatic cancer:6.66e-4 (unfavourable)	Tissue enhanced	Group enriched	9	fallopian tube: 445.8;lung: 105.4	epididymis: 29.1	Cell line enhanced		CAPAN-2: 448.3;EFO-21: 72.6;HeLa: 104.4;hTCEpi: 80.2
MUC1	ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM	ENSG00000185499	Mucin 1, cell surface associated	1	155185824-155192916	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000036, CAB001986, HPA004179, HPA007235, HPA008855	Enhanced				Pancreatic cancer:4.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 448.0;stomach: 654.1	cervix, uterine: 288.9	Group enriched	7	CAPAN-2: 1005.2;RPTEC TERT1: 654.7;T-47d: 360.0
MUC13	DRCC1	ENSG00000173702	Mucin 13, cell surface associated	3	124905442-124953819	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045163	Enhanced				Renal cancer:9.73e-5 (unfavourable)	Tissue enhanced	Group enriched	6	colon: 301.8;duodenum: 614.7;rectum: 330.1;small intestine: 555.7	appendix: 79.5	Cell line enhanced		A549: 6.6;CACO-2: 5.3;CAPAN-2: 11.9;Karpas-707: 5.6
MUC3A	MUC3	ENSG00000169894	Mucin 3A, cell surface associated	7	100949555-100968346	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010871	Uncertain					Tissue enhanced	Tissue enhanced		duodenum: 41.6;gallbladder: 21.8;small intestine: 37.1	rectum: 13.1	Cell line enhanced		CACO-2: 6.0;CAPAN-2: 2.1;U-2 OS: 1.4
MYRFL	bcm1377, C12orf15, C12orf28, FLJ25056	ENSG00000166268	Myelin regulatory factor-like	12	69825304-69959097	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA049340	Approved		Approved	Nucleoli		Mixed	Group enriched	5	duodenum: 23.7;small intestine: 24.0	testis: 4.3	Cell line enhanced		NTERA-2: 5.2;T-47d: 11.1
N4BP2L2	CG005, PFAAP5	ENSG00000244754	NEDD4 binding protein 2 like 2	13	32432417-32538885	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039338, HPA039434, HPA059327	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 57.6	Expressed in all		
NCAM1	CD56, NCAM	ENSG00000149294	Neural cell adhesion molecule 1	11	112961247-113278436	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000142, CAB018071, HPA039835	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Pancreatic cancer:9.11e-6 (favourable), Renal cancer:8.20e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 334.9	heart muscle: 87.5	Cell line enhanced		RH-30: 128.0;SCLC-21H: 126.2;U-138 MG: 71.8;WM-115: 77.9
NCSTN	APH2, KIAA0253	ENSG00000162736	Nicastrin	1	160343272-160358952	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB021982, HPA054846, HPA070642	Approved		Approved	Cytosol	Renal cancer:7.75e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 143.2	Expressed in all		
NDUFB5	CI-SGDH, MGC12314, SGDH	ENSG00000136521	NADH:ubiquinone oxidoreductase subunit B5	3	179604690-179627647	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005640	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:3.32e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 136.7	Expressed in all		
NECTIN1	CD111, CLPED1, ED4, HIgR, HVEC, OFC7, PRR, PRR1, PVRL1, PVRR1, SK-12	ENSG00000110400	Nectin cell adhesion molecule 1	11	119623408-119729084	CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016135, HPA026846	Approved					Expressed in all	Tissue enhanced		esophagus: 108.6;skin: 161.7	cerebral cortex: 50.3	Cell line enhanced		HaCaT: 203.5
NELL2	NRP2	ENSG00000184613	Neural EGFL like 2	12	44508275-44921848	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035714, HPA035715	Uncertain		Approved	Vesicles	Pancreatic cancer:5.56e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 204.1;fallopian tube: 96.7	prostate: 46.5	Cell line enhanced		AF22: 102.5;NTERA-2: 41.0;SCLC-21H: 88.2
NETO1	BCTL1, BTCL1	ENSG00000166342	Neuropilin and tolloid like 1	18	72742314-72868146	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA064630			Approved	Golgi apparatus		Tissue enhanced	Tissue enriched	16	cerebral cortex: 64.0	spleen: 4.1	Cell line enhanced		MOLT-4: 22.4;REH: 24.8;RPMI-8226: 30.0;RT4: 22.5;SCLC-21H: 43.0
NFASC	FLJ46866, KIAA0756, NF, NRCAML	ENSG00000163531	Neurofascin	1	204828651-205022822	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008832	Enhanced				Renal cancer:2.93e-5 (unfavourable), Pancreatic cancer:3.21e-5 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 55.7	seminal vesicle: 22.4	Cell line enhanced		BJ: 23.3;fHDF/TERT166: 39.1;SCLC-21H: 26.9;U-138 MG: 62.0;U-87 MG: 30.5
NGLY1	FLJ11005, PNG1	ENSG00000151092	N-glycanase 1	3	25718944-25790039	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036825	Approved				Liver cancer:1.96e-6 (unfavourable), Colorectal cancer:1.17e-5 (favourable)	Expressed in all	Expressed in all			testis: 116.0	Expressed in all		
NKG7	GIG1, GMP-17	ENSG00000105374	Natural killer cell granule protein 7	19	51371606-51372715	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071454			Approved	Vesicles	Renal cancer:3.32e-6 (unfavourable), Endometrial cancer:7.42e-6 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 351.3;spleen: 151.2	lymph node: 122.0	Cell line enhanced		NB-4: 109.5;THP-1: 34.5;U-937: 34.9
NLGN3	ASPGX1, AUTSX1, HNL3, KIAA1480	ENSG00000196338	Neuroligin 3	X	71144831-71171201	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003183, HPA004066	Enhanced		Supported	Golgi apparatus<br>Cell Junctions		Tissue enriched	Tissue enhanced		cerebral cortex: 62.2	seminal vesicle: 17.3	Cell line enhanced		AF22: 6.8;NTERA-2: 5.0;SH-SY5Y: 2.9
NLGN4Y	KIAA0951	ENSG00000165246	Neuroligin 4, Y-linked	Y	14522638-14845650	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA001651	Approved					Mixed	Tissue enhanced		prostate: 11.4;seminal vesicle: 12.5	cerebral cortex: 7.5	Cell line enhanced		BJ hTERT+: 28.5;fHDF/TERT166: 21.5;HDLM-2: 30.2;hTCEpi: 16.2;U-138 MG: 23.0
NOMO3		ENSG00000103226	NODAL modulator 3	16	16232495-16294814	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046697, HPA061174	Approved					Mixed	Mixed			skin: 1.9	Mixed		
NOTCH3	CADASIL, CASIL	ENSG00000074181	Notch 3	19	15159038-15200981	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005393, HPA044392	Approved		Supported	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:2.53e-7 (unfavourable), Endometrial cancer:5.92e-4 (unfavourable)	Expressed in all	Mixed			skin: 93.6	Cell line enhanced		AF22: 65.5;MCF7: 51.9
NPFFR2	GPR74, NPFF2, NPGPR	ENSG00000056291	Neuropeptide FF receptor 2	4	72031804-72148067	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026825			Approved	Plasma membrane<br>Actin filaments		Mixed	Tissue enhanced		placenta: 2.3;seminal vesicle: 4.6	epididymis: 1.1	Group enriched	11	NTERA-2: 9.2;RPTEC TERT1: 9.0;SH-SY5Y: 14.9;U-2 OS: 14.5
NPHS1	CNF, NPHN	ENSG00000161270	NPHS1, nephrin	19	35825964-35869287	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB035555	Enhanced					Mixed	Tissue enhanced		kidney: 17.7;lymph node: 5.4;pancreas: 5.5	tonsil: 2.3	Cell line enhanced		HMC-1: 1.1
NRCAM	Bravo, KIAA0343	ENSG00000091129	Neuronal cell adhesion molecule	7	108147623-108456717	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012606	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 180.4	adrenal gland: 49.5	Cell line enhanced		A549: 90.2;AF22: 93.7;EFO-21: 165.3;HMC-1: 165.2;SH-SY5Y: 122.8
NRG1	GGF, HGL, HRG, NDF, NRG1-IT2	ENSG00000157168	Neuregulin 1	8	31639386-32767959	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010964	Uncertain		Approved	Nucleoplasm		Tissue enhanced	Mixed			thyroid gland: 20.0	Cell line enhanced		A549: 130.4;hTEC/SVTERT24-B: 101.2
NRP1	CD304, NRP, VEGF165R	ENSG00000099250	Neuropilin 1	10	33177492-33336262	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004511, HPA030278	Approved		Uncertain	Mitochondria	Stomach cancer:1.22e-5 (unfavourable), Cervical cancer:7.10e-5 (unfavourable), Renal cancer:3.87e-4 (unfavourable), Glioma:7.78e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 194.1	Cell line enhanced		U-87 MG: 437.4
NRP2	VEGF165R2	ENSG00000118257	Neuropilin 2	2	205681990-205798133	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039980, HPA054974	Enhanced		Supported	Vesicles<br>Plasma membrane	Renal cancer:7.68e-7 (unfavourable), Urothelial cancer:7.80e-5 (unfavourable)	Expressed in all	Mixed			smooth muscle: 84.4	Cell line enhanced		CAPAN-2: 119.6;U-251 MG: 195.9
NRXN1	Hs.22998, KIAA0578	ENSG00000179915	Neurexin 1	2	49918505-51225575	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA071400			Approved	Nucleoli<br>Plasma membrane		Tissue enriched	Tissue enriched	12	cerebral cortex: 154.0	seminal vesicle: 12.9	Cell line enriched	9	SCLC-21H: 42.8
NRXN2		ENSG00000110076	Neurexin 2	11	64606174-64723188	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	8	cerebral cortex: 142.6	testis: 17.0	Cell line enhanced		REH: 43.5;SCLC-21H: 27.0;U-2 OS: 27.6;U-87 MG: 18.3
NT5E	CALJA, CD73, eN, eNT, NT5	ENSG00000135318	5'-nucleotidase ecto	6	85449584-85495791	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017357	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.32e-5 (unfavourable), Stomach cancer:1.02e-4 (unfavourable), Lung cancer:6.66e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 172.7	smooth muscle: 106.3	Cell line enhanced		LHCN-M2: 772.3;U-87 MG: 800.0
NTM	HNT, IGLON2, NTRI	ENSG00000182667	Neurotrimin	11	131370478-132336822	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB024875	Enhanced				Renal cancer:1.10e-8 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 116.0	lung: 39.1	Cell line enhanced		LHCN-M2: 102.1;U-2 OS: 86.6;WM-115: 164.5
OCLN	PPP1R115	ENSG00000197822	Occludin	5	69492292-69558104	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA005933, CAB013075, CAB068212, CAB068213, CAB068214	Enhanced		Supported	Plasma membrane<br>Cell Junctions	Renal cancer:6.59e-11 (favourable)	Mixed	Tissue enhanced		thyroid gland: 78.7	lung: 39.8	Cell line enhanced		CAPAN-2: 60.2;HaCaT: 48.8
ORAI1	CRACM1, FLJ14466, TMEM142A	ENSG00000276045	ORAI calcium release-activated calcium modulator 1	12	121626550-121642677	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016583, HPA061823	Approved		Supported	Cytosol	Ovarian cancer:4.30e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 47.9	Expressed in all		
ORMDL2	adoplin-2, HSPC160, MST095, MSTP095	ENSG00000123353	ORMDL sphingolipid biosynthesis regulator 2	12	55817919-55821879	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA065643			Supported	Endoplasmic reticulum	Endometrial cancer:3.30e-5 (favourable), Liver cancer:9.75e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 62.6	Expressed in all		
OSCAR		ENSG00000170909	Osteoclast associated, immunoglobulin-like receptor	19	54094668-54102692	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.71e-5 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 9.0;lung: 14.1	appendix: 3.3	Cell line enhanced		EFO-21: 13.1;HHSteC: 7.9;U-937: 14.0
OSMR	OSMRB	ENSG00000145623	Oncostatin M receptor	5	38845858-38945596	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017278	Approved		Approved	Nucleoli	Renal cancer:3.96e-6 (unfavourable), Cervical cancer:4.87e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 55.1	Mixed		
PAM	PAL, PHM	ENSG00000145730	Peptidylglycine alpha-amidating monooxygenase	5	102753981-103031105	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026119, HPA042260	Enhanced		Approved	Golgi apparatus<br>Cytosol	Endometrial cancer:1.63e-4 (favourable), Liver cancer:6.20e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 947.8	Cell line enhanced		fHDF/TERT166: 553.5
PAPPA2	PAPP-A2, PAPPE, PLAC3	ENSG00000116183	Pappalysin 2	1	176463171-176845605	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018412, HPA018430	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles		Mixed	Tissue enriched	8	placenta: 82.7	cervix, uterine: 10.8	Cell line enriched	6	U-87 MG: 19.4
PARVB	CGI-56	ENSG00000188677	Parvin beta	22	43999211-44172949	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062601			Approved	Cytosol		Expressed in all	Expressed in all			skeletal muscle: 68.6	Mixed		
PCDH1	pc42	ENSG00000156453	Protocadherin 1	5	141853111-141879246	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047720, HPA050538	Enhanced		Approved	Nucleus<br>Nucleoli<br>Cell Junctions	Liver cancer:4.96e-5 (unfavourable), Renal cancer:7.55e-5 (favourable), Pancreatic cancer:3.61e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 40.3	Cell line enhanced		CAPAN-2: 75.4;HaCaT: 95.1;RT4: 59.1;TIME: 60.2;WM-115: 51.1
PCDH12	VE-cadherin-2	ENSG00000113555	Protocadherin 12	5	141943585-141969741	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051242	Uncertain				Renal cancer:2.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 38.5	spleen: 22.5	Cell line enhanced		HUVEC TERT2: 19.4;Karpas-707: 41.2;U-937: 7.5
PCDH15	CDHR15, DFNB23, USH1F	ENSG00000150275	Protocadherin related 15	10	53802771-55627942	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074437		Supported				Tissue enriched	Tissue enhanced		adrenal gland: 25.0;cerebral cortex: 12.2	kidney: 8.1	Cell line enhanced		U-2 OS: 1.1;U-266/70: 2.5
PCDHA1		ENSG00000204970	Protocadherin alpha 1	5	140786136-141012347	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035969	Enhanced		Approved	Plasma membrane		Not detected	Tissue enhanced		cerebral cortex: 2.8;testis: 1.4	adrenal gland: 0.4	Cell line enriched	6	T-47d: 8.6
PCDHA10	CNR8, CNRN8, CNRS8, CRNR8, PCDH-ALPHA10	ENSG00000250120	Protocadherin alpha 10	5	140855883-141012344	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		cerebral cortex: 17.5	thyroid gland: 4.3	Cell line enriched	10	EFO-21: 16.6
PCDHA11	CNR7, CNRN7, CNRS7, CRNR7, PCDH-ALPHA11	ENSG00000249158	Protocadherin alpha 11	5	140868183-141012344	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA077160			Approved	Vesicles<br>Cell Junctions<br>Cytoplasmic bodies		Not detected	Tissue enhanced		cerebral cortex: 7.6;parathyroid gland: 3.8	testis: 1.8	Cell line enhanced		AN3-CA: 14.0;EFO-21: 7.3;T-47d: 5.0
PCDHA6	CNR2, CNRS2, CRNR2, PCDH-ALPHA6	ENSG00000081842	Protocadherin alpha 6	5	140827958-141012344	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059326, HPA078110	Enhanced		Approved	Vesicles		Not detected	Tissue enhanced		cerebral cortex: 4.8	parathyroid gland: 1.9	Cell line enhanced		AF22: 2.0;EFO-21: 8.1;U-2 OS: 3.7;WM-115: 5.1
PCDHB12	PCDH-BETA12	ENSG00000120328	Protocadherin beta 12	5	141208697-141212571	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA045042	Uncertain		Approved	Plasma membrane		Mixed	Mixed			endometrium: 3.6	Cell line enhanced		EFO-21: 2.8;RH-30: 3.1
PCDHGA11	PCDH-GAMMA-A11	ENSG00000253873	Protocadherin gamma subfamily A, 11	5	141421047-141512979	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			cerebral cortex,placenta: 3.2	Cell line enhanced		ASC diff: 16.8;ASC TERT1: 18.5;SK-MEL-30: 16.7;WM-115: 43.4
PCSK4	DKFZp434B217, MGC34749, PC4, SPC5	ENSG00000115257	Proprotein convertase subtilisin/kexin type 4	19	1481428-1490752	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005572	Uncertain				Endometrial cancer:9.45e-5 (favourable)	Expressed in all	Tissue enriched	9	testis: 41.3	fallopian tube: 4.8	Cell line enhanced		AN3-CA: 6.5;HMC-1: 3.2;U-266/70: 5.8
PCSK5	PC5, PC6, SPC6	ENSG00000099139	Proprotein convertase subtilisin/kexin type 5	9	75890644-76362339	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031072	Enhanced		Supported	Golgi apparatus	Renal cancer:9.61e-5 (unfavourable)	Mixed	Mixed			small intestine: 28.1	Cell line enhanced		BEWO: 31.5;HaCaT: 41.2;RPTEC TERT1: 32.1;U-2 OS: 68.5
PDGFRA	CD140a, GAS9, PDGFR2	ENSG00000134853	Platelet derived growth factor receptor alpha	4	54229097-54298247	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA004947, CAB018143	Supported		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable)	Expressed in all	Expressed in all			ovary: 222.6	Cell line enhanced		ASC diff: 306.3;ASC TERT1: 145.3;BJ hTERT+: 217.9;fHDF/TERT166: 147.1;HHSteC: 126.5;HSkMC: 276.0
PDGFRB	CD140b, JTK12, PDGFR, PDGFR1	ENSG00000113721	Platelet derived growth factor receptor beta	5	150113837-150155872	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB003842, CAB018144, HPA028499	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:5.87e-8 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 193.8	Cell line enhanced		ASC diff: 923.6;ASC TERT1: 324.4
PDIA6	ERp5, P5, TXNDC7	ENSG00000143870	Protein disulfide isomerase family A member 6	2	10783391-10837977	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB034347, HPA034652, HPA034653	Enhanced		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.51e-6 (unfavourable), Liver cancer:3.63e-5 (unfavourable), Head and neck cancer:1.20e-4 (unfavourable), Cervical cancer:1.80e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 591.9	Expressed in all		
PEAR1	FLJ00193, JEDI, MEGF12	ENSG00000187800	Platelet endothelial aggregation receptor 1	1	156893698-156916434	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035217	Approved		Approved	Nucleoplasm<br>Cell Junctions<br>Centrosome	Renal cancer:4.31e-4 (unfavourable)	Expressed in all	Mixed			placenta: 16.9	Cell line enhanced		HBEC3-KT: 21.4;HUVEC TERT2: 43.6;TIME: 69.3
PECAM1	CD31	ENSG00000261371	Platelet and endothelial cell adhesion molecule 1	17	64319415-64413776	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004690	Supported				Renal cancer:8.98e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 659.7	Cell line enhanced		HUVEC TERT2: 644.6;TIME: 437.4
PGAP3	CAB2, MGC9753, PER1, PERLD1, PP1498	ENSG00000161395	Post-GPI attachment to proteins 3	17	39671122-39696797	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016591	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:3.89e-4 (favourable), Liver cancer:3.94e-4 (favourable), Ovarian cancer:6.82e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 35.6	Cell line enhanced		SK-BR-3: 99.2
PGLYRP2	PGLYRPL, PGRP-L, PGRPL, tagL, tagL-alpha, tagl-beta, TAGL-like	ENSG00000161031	Peptidoglycan recognition protein 2	19	15468645-15498956	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB033468, HPA043568, HPA046311, HPA075237	Approved		Approved	Cell Junctions		Tissue enriched	Tissue enriched	17	liver: 133.2	testis: 7.8	Group enriched	8	MCF7: 5.7;T-47d: 6.8
PIANP	C12orf53, DKFZp547D2210, PANP	ENSG00000139200	PILR alpha associated neural protein	12	6693792-6700800	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010631	Enhanced		Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		cerebral cortex: 64.3	endometrium: 13.4	Cell line enhanced		NTERA-2: 20.8;SH-SY5Y: 20.6;U-2 OS: 11.2
PIGK	GPI8, hGPI8	ENSG00000142892	Phosphatidylinositol glycan anchor biosynthesis class K	1	77088990-77219430	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056383, HPA057040	Uncertain				Liver cancer:4.68e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.4	Expressed in all		
PIGT		ENSG00000124155	Phosphatidylinositol glycan anchor biosynthesis class T	20	45416067-45456934	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 123.1	Expressed in all		
PIGZ	FLJ12768, MGC52163, SMP3	ENSG00000119227	Phosphatidylinositol glycan anchor biosynthesis class Z	3	196946343-196969060	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA058599, HPA059920	Approved		Uncertain	Vesicles	Renal cancer:5.60e-5 (unfavourable)	Expressed in all	Tissue enhanced		colon: 18.5;rectum: 18.1	cerebral cortex: 10.9	Mixed		
PIK3IP1	HGFL, MGC17330	ENSG00000100100	Phosphoinositide-3-kinase interacting protein 1	22	31281593-31292534	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Urothelial cancer:3.80e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 121.1	Cell line enhanced		U-698: 23.5
PILRA	FDF03	ENSG00000085514	Paired immunoglobin like type 2 receptor alpha	7	100367530-100400099	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056132	Approved				Renal cancer:1.61e-4 (unfavourable), Cervical cancer:2.99e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 52.4	lung: 43.8	Cell line enhanced		ASC diff: 18.7;HMC-1: 21.9;NB-4: 12.4
PILRB	FDFACT1, FDFACT2	ENSG00000121716	Paired immunoglobin-like type 2 receptor beta	7	100352176-100367733	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026750	Approved		Approved	Mitochondria	Renal cancer:1.42e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 166.9	Expressed in all		
PKHD1	ARPKD, FCYT, TIGM1	ENSG00000170927	Polycystic kidney and hepatic disease 1 (autosomal recessive)	6	51615300-52087625	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031227	Approved				Renal cancer:9.74e-8 (favourable)	Group enriched	Group enriched	5	epididymis: 5.7;kidney: 15.3	pancreas: 1.9	Cell line enriched	7	RPTEC TERT1: 8.1
PLA2G15	GXVPLA2, LLPL, LYPLA3	ENSG00000103066	Phospholipase A2 group XV	16	68245304-68261062	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041702, HPA041727	Enhanced		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			placenta: 37.5	Expressed in all		
PLA2R1	CLEC13C, PLA2-R, PLA2G1R, PLA2IR	ENSG00000153246	Phospholipase A2 receptor 1	2	159932006-160062610	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB068217, CAB068218	Approved		Approved	Cytosol	Stomach cancer:3.08e-4 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 70.6	parathyroid gland: 34.5	Cell line enhanced		ASC TERT1: 13.7;BJ hTERT+: 13.1;SiHa: 12.5;TIME: 38.6
PLAUR	CD87, UPAR, URKR	ENSG00000011422	Plasminogen activator, urokinase receptor	19	43646095-43670547	Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050843, CAB073533	Uncertain		Supported	Plasma membrane	Renal cancer:7.83e-9 (unfavourable), Lung cancer:2.33e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 428.5	Cell line enhanced		U-251 MG: 341.1;U-87 MG: 336.6;WM-115: 338.6
PLOD2	LH2	ENSG00000152952	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2	3	146069440-146163653	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025898, HPA069126	Approved		Uncertain	Nucleoli<br>Cytosol	Renal cancer:4.99e-11 (unfavourable), Liver cancer:7.64e-10 (unfavourable), Lung cancer:1.42e-4 (unfavourable), Cervical cancer:1.97e-4 (unfavourable), Stomach cancer:2.83e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 150.8	Cell line enhanced		HBF TERT88: 615.2;U-87 MG: 554.9
PLXNA4	DKFZp434G0625PRO34003, FAYV2820, KIAA1550, PLXNA4A, PLXNA4B	ENSG00000221866	Plexin A4	7	132123332-132648688	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029919, HPA052141, HPA075592	Approved		Approved	Plasma membrane	Endometrial cancer:1.61e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 15.2;cervix, uterine: 12.5	cerebral cortex: 10.4	Cell line enhanced		ASC diff: 17.3;HMC-1: 15.0;RH-30: 17.9;TIME: 46.9
PLXNB2	KIAA0315, MM1, PLEXB2	ENSG00000196576	Plexin B2	22	50274979-50307627	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003100	Uncertain				Stomach cancer:4.75e-4 (favourable), Ovarian cancer:7.37e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 120.9	Mixed		
PMEL	D12S53E, gp100, Pmel17, SI, SIL, SILV	ENSG00000185664	Premelanosome protein	12	55954105-55973317	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031649	Enhanced				Renal cancer:3.70e-4 (favourable)	Tissue enriched	Tissue enriched	12	skin: 133.4	breast: 10.6	Cell line enriched	55	SK-MEL-30: 6730.3
PMEPA1	STAG1, TMEPAI	ENSG00000124225	Prostate transmembrane protein, androgen induced 1	20	57648392-57711536	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA072291			Supported	Vesicles	Renal cancer:2.87e-7 (unfavourable), Lung cancer:4.73e-5 (unfavourable), Cervical cancer:2.45e-4 (unfavourable), Urothelial cancer:7.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 146.1;prostate: 179.6	endometrium: 60.3	Cell line enhanced		SiHa: 218.5;U-251 MG: 397.1;WM-115: 233.9
PRAC2	C17orf93, HOXB-AS5, HOXB13-AS1, NCRNA00253	ENSG00000229637	Prostate cancer susceptibility candidate 2	17	48723168-48724758	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		prostate: 16.8;rectum: 10.1	colon: 4.5	Group enriched	5	PC-3: 44.6;REH: 17.6
PRLR		ENSG00000113494	Prolactin receptor	5	35048756-35230589	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		placenta: 70.9	kidney: 33.1	Cell line enriched	22	T-47d: 356.8
PRNP	AltPrP, CD230, CJD, GSS, PRIP, PRP	ENSG00000171867	Prion protein	20	4686236-4701590	CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA042754, HPA043398	Enhanced		Approved	Nuclear membrane<br>Vesicles<br>Cytosol	Liver cancer:7.41e-5 (unfavourable), Glioma:1.99e-4 (unfavourable), Colorectal cancer:2.96e-4 (unfavourable), Endometrial cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 619.4	Cell line enhanced		WM-115: 985.1
PROM1	AC133, CD133, CORD12, MCDR2, PROML1, RP41, STGD4	ENSG00000007062	Prominin 1	4	15963076-16084378	CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004922, CAB011525, HPA031053	Enhanced				Renal cancer:2.56e-5 (favourable)	Expressed in all	Tissue enhanced		cervix, uterine: 67.2	gallbladder: 47.5	Cell line enhanced		AF22: 36.7;CACO-2: 58.5;EFO-21: 62.9;NTERA-2: 99.9;RPTEC TERT1: 69.7
PROS1	PROS	ENSG00000184500	Protein S (alpha)	3	93873033-93974066	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007724, HPA023974	Enhanced				Urothelial cancer:4.42e-5 (unfavourable), Stomach cancer:8.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 177.6	heart muscle: 78.3	Cell line enhanced		ASC diff: 98.8;SK-MEL-30: 127.4
PRRG2	PRGP2	ENSG00000126460	Proline rich and Gla domain 2	19	49580646-49591015	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010702	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.82e-9 (favourable)	Expressed in all	Mixed			parathyroid gland: 29.5	Cell line enhanced		CAPAN-2: 13.1;T-47d: 13.6;U-266/84: 12.9
PRRT3	FLJ33674	ENSG00000163704	Proline rich transmembrane protein 3	3	9945542-9952394	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035127, HPA035128	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 19.4;parathyroid gland: 27.8	fallopian tube: 12.2	Cell line enhanced		MCF7: 17.7;SK-BR-3: 25.1
PRRT4		ENSG00000224940	Proline rich transmembrane protein 4	7	128350325-128361685	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046373, HPA052681	Uncertain		Approved	Nucleoplasm<br>Peroxisomes<br>Plasma membrane		Mixed	Group enriched	12	adipose tissue: 15.7;bone marrow: 41.2	cerebral cortex: 2.2	Cell line enriched	8	SH-SY5Y: 239.1
PRSS48	ESSPL	ENSG00000189099	Protease, serine 48	4	151277171-151291453	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA053801	Uncertain					Not detected	Tissue enhanced		testis: 1.4	skin: 0.4	Not detected		
PRSS8		ENSG00000052344	Protease, serine 8	16	31131433-31135762	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030436, HPA063533	Uncertain		Uncertain	Cytosol	Renal cancer:2.05e-10 (favourable)	Mixed	Mixed			small intestine: 164.8	Cell line enhanced		BEWO: 230.2;CACO-2: 133.7;CAPAN-2: 96.1;hTCEpi: 111.3;SK-BR-3: 136.6
PRTG	FLJ25756, IGDCC5	ENSG00000166450	Protogenin	15	55611546-55743090	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA032138	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		thyroid gland: 18.2	testis: 6.7	Cell line enriched	6	AF22: 148.8
PSG9	PSG11, PSGII	ENSG00000183668	Pregnancy specific beta-1-glycoprotein 9	19	43211791-43269530	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Not detected	Tissue enriched	118	placenta: 147.0	smooth muscle: 1.2	Cell line enhanced		BJ: 4.4;BJ hTERT+ SV40 Large T+: 4.2;HBF TERT88: 9.0;T-47d: 4.0;U-2197: 9.0
PSMD1	P112, Rpn2, S1	ENSG00000173692	Proteasome 26S subunit, non-ATPase 1	2	231056864-231172827	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB021092, HPA036736, HPA036737	Enhanced		Approved	Nucleoplasm<br>Actin filaments	Liver cancer:8.63e-12 (unfavourable), Lung cancer:2.34e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 204.0	Expressed in all		
PTGIR	IP	ENSG00000160013	Prostaglandin I2 (prostacyclin) receptor (IP)	19	46620468-46625118	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.09e-8 (unfavourable), Testis cancer:1.74e-4 (unfavourable)	Mixed	Tissue enhanced		lung: 13.9	appendix: 8.2	Cell line enhanced		BJ: 9.0;BJ hTERT+: 9.8;fHDF/TERT166: 11.8;HEL: 25.3
PTK7	CCK4	ENSG00000112655	Protein tyrosine kinase 7 (inactive)	6	43076268-43161719	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003222	Approved					Expressed in all	Mixed			endometrium: 117.3	Mixed		
PTPRA	HLPR, HPTPA, LRP, PTPA, PTPRL2, RPTPA	ENSG00000132670	Protein tyrosine phosphatase, receptor type A	20	2864184-3039076	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029412, CAB034366, HPA069480	Approved		Approved	Nucleus<br>Vesicles	Renal cancer:3.29e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 167.4	Expressed in all		
PTPRB	PTPB	ENSG00000127329	Protein tyrosine phosphatase, receptor type B	12	70515866-70637440	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004782, HPA067868	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cell Junctions	Renal cancer:1.02e-4 (favourable), Liver cancer:6.05e-4 (favourable)	Expressed in all	Mixed			lung: 54.0	Cell line enhanced		EFO-21: 22.9;HUVEC TERT2: 51.3;TIME: 74.1
PTPRC	CD45, GP180, LCA, T200	ENSG00000081237	Protein tyrosine phosphatase, receptor type C	1	198638671-198757283	Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000052, HPA000440, CAB002800, CAB056154, CAB068221	Enhanced				Renal cancer:2.42e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 372.4	Cell line enhanced		Daudi: 151.8;HEL: 73.7;HL-60: 73.8;MOLT-4: 105.0;U-698: 84.9;U-937: 62.5
PTPRD	HPTP, PTPD	ENSG00000153707	Protein tyrosine phosphatase, receptor type D	9	8314246-10612723	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054829	Uncertain		Approved	Vesicles	Renal cancer:7.45e-6 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 32.7;parathyroid gland: 47.0	ovary: 11.7	Cell line enhanced		AF22: 27.3;RH-30: 9.9
PTPRE	PTPE	ENSG00000132334	Protein tyrosine phosphatase, receptor type E	10	127907061-128085855	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015870, HPA021872	Supported		Approved	Intermediate filaments	Renal cancer:4.08e-5 (unfavourable)	Expressed in all	Mixed			appendix: 34.8	Cell line enhanced		HUVEC TERT2: 34.9;TIME: 64.9
PTPRF	LAR	ENSG00000142949	Protein tyrosine phosphatase, receptor type F	1	43525187-43623666	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012710	Uncertain		Approved	Golgi apparatus	Liver cancer:3.47e-4 (unfavourable), Stomach cancer:7.03e-4 (favourable)	Expressed in all	Mixed			skin: 128.2	Mixed		
PTPRJ	CD148, DEP1, HPTPeta	ENSG00000149177	Protein tyrosine phosphatase, receptor type J	11	47980558-48170841	CD markers, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006026	Approved				Renal cancer:1.13e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 38.6	Mixed		
PTPRO	GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2	ENSG00000151490	Protein tyrosine phosphatase, receptor type O	12	15322397-15597399	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA034525	Enhanced					Tissue enhanced	Tissue enhanced		rectum: 33.0	cerebral cortex: 21.7	Cell line enhanced		NTERA-2: 6.6;SCLC-21H: 4.7;SH-SY5Y: 8.4
PTPRS		ENSG00000105426	Protein tyrosine phosphatase, receptor type S	19	5158495-5340803	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054747			Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:1.07e-4 (favourable), Renal cancer:1.70e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 70.7	Cell line enhanced		AN3-CA: 112.7;HaCaT: 110.4
PTTG1IP	C21orf1, C21orf3, PBF	ENSG00000183255	Pituitary tumor-transforming 1 interacting protein	21	44849585-44873903	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB034146, HPA061827	Uncertain		Supported	Nucleoplasm	Pancreatic cancer:2.28e-4 (unfavourable), Stomach cancer:5.40e-4 (unfavourable), Cervical cancer:8.61e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 243.5	Expressed in all		
PVR	CD155, HVED, Necl-5, NECL5, PVS, Tage4	ENSG00000073008	Poliovirus receptor	19	44643798-44663583	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012568	Approved		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane	Cervical cancer:1.29e-4 (unfavourable), Urothelial cancer:2.75e-4 (unfavourable), Lung cancer:9.30e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 17.0	Cell line enhanced		TIME: 147.4
QSOX1	QSCN6	ENSG00000116260	Quiescin sulfhydryl oxidase 1	1	180154834-180204030	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042127, HPA056243	Uncertain		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.86e-5 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 233.0	Expressed in all		
RAET1E	bA350J20.7, LETAL, ULBP4	ENSG00000164520	Retinoic acid early transcript 1E	6	149883375-149898102	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054022			Approved	Focal adhesion sites<br>Cytosol		Tissue enhanced	Tissue enhanced		esophagus: 70.8;skin: 29.0	tonsil: 10.3	Cell line enhanced		HBEC3-KT: 15.9;HeLa: 20.3;hTCEpi: 15.6;SiHa: 11.2;U-87 MG: 9.0
RAET1G	ULBP5	ENSG00000203722	Retinoic acid early transcript 1G	6	149916878-149923121	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062673			Approved	Vesicles	Lung cancer:5.35e-4 (unfavourable)	Mixed	Tissue enhanced		adrenal gland: 8.2;esophagus: 9.5	skin: 3.4	Cell line enhanced		HeLa: 21.4;hTCEpi: 18.1;SiHa: 13.3;U-87 MG: 9.8
RAMP2		ENSG00000131477	Receptor activity modifying protein 2	17	42758447-42763041	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA052020			Approved	Vesicles		Expressed in all	Mixed			lung: 178.6	Cell line enhanced		ASC diff: 78.4;EFO-21: 72.9;HUVEC TERT2: 29.7
RASGEF1B	FLJ31695, GPIG4	ENSG00000138670	RasGEF domain family member 1B	4	81426393-82044244	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044574	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:4.21e-6 (favourable), Head and neck cancer:1.49e-5 (favourable), Cervical cancer:6.40e-4 (favourable)	Expressed in all	Mixed			skin: 31.6	Cell line enhanced		CACO-2: 12.9;Daudi: 13.1;Karpas-707: 9.0;NTERA-2: 11.1;SCLC-21H: 10.7
RCN3	RLP49	ENSG00000142552	Reticulocalbin 3	19	49527618-49546962	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043134, HPA050402	Uncertain		Approved	Endoplasmic reticulum<br>Vesicles	Renal cancer:5.80e-12 (unfavourable)	Expressed in all	Expressed in all			small intestine: 45.0	Cell line enhanced		ASC diff: 170.1;BJ: 238.6;fHDF/TERT166: 192.6
RELT	FLJ14993, TNFRSF19L	ENSG00000054967	RELT tumor necrosis factor receptor	11	73376264-73397474	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062824, HPA071518			Supported	Nucleus	Renal cancer:4.07e-11 (unfavourable)	Mixed	Tissue enriched	6	bone marrow: 95.8	spleen: 17.2	Mixed		
RET	CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51	ENSG00000165731	Ret proto-oncogene	10	43077027-43130351	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002581, HPA008356, HPA008495, CAB018342	Approved	Supported	Supported	Vesicles<br>Plasma membrane<br>Cytosol	Endometrial cancer:5.02e-4 (unfavourable)	Tissue enhanced	Tissue enriched	5	parathyroid gland: 154.5	adrenal gland: 29.8	Cell line enriched	5	SH-SY5Y: 404.3
RETSAT	FLJ20296	ENSG00000042445	Retinol saturase	2	85342088-85354620	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007961, HPA046513	Uncertain		Approved	Nucleoli	Renal cancer:1.95e-10 (favourable), Liver cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 265.4	Expressed in all		
RGMB	DRAGON, FLJ90406	ENSG00000174136	Repulsive guidance molecule family member b	5	98768650-98798643	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016993			Approved	Nucleoplasm		Expressed in all	Mixed			cerebral cortex: 43.6	Cell line enhanced		BJ: 267.0;HBF TERT88: 210.1
RIC3	AYST720, FLJ11608, PRO1385	ENSG00000166405	RIC3 acetylcholine receptor chaperone	11	8106093-8169055	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA065016	Approved					Mixed	Mixed			parathyroid gland: 28.2	Cell line enhanced		NTERA-2: 5.0;SCLC-21H: 9.9;SH-SY5Y: 6.2
RNF148	MGC35222	ENSG00000235631	Ring finger protein 148	7	122701664-122702967	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	228	testis: 73.5	lung: 0.3	Cell line enhanced		Karpas-707: 1.9
RNF150	KIAA1214	ENSG00000170153	Ring finger protein 150	4	140859807-141212877	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA037987	Uncertain				Breast cancer:1.41e-4 (favourable)	Mixed	Mixed			endometrium,fallopian tube: 21.3	Cell line enhanced		fHDF/TERT166: 21.9;SH-SY5Y: 42.3
RNF167	DKFZP566H073	ENSG00000108523	Ring finger protein 167	17	4940008-4945222	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049810	Approved		Approved	Cytosol	Pancreatic cancer:2.03e-6 (favourable), Renal cancer:4.47e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 116.9	Expressed in all		
ROR1	NTRKR1	ENSG00000185483	Receptor tyrosine kinase like orphan receptor 1	1	63774022-64181498	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057016			Uncertain	Microtubules<br>Cytokinetic bridge		Mixed	Tissue enhanced		parathyroid gland: 52.0	endometrium: 12.1	Cell line enhanced		ASC TERT1: 35.2;NTERA-2: 43.3
RPN2	RIBIIR, RPN-II, RPNII, SWP1	ENSG00000118705	Ribophorin II	20	37178410-37241623	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008297, CAB019277, HPA025922	Enhanced		Supported	Endoplasmic reticulum	Renal cancer:1.44e-10 (unfavourable), Liver cancer:1.38e-4 (unfavourable), Urothelial cancer:2.44e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 364.2	Expressed in all		
RTBDN	FLJ36353	ENSG00000132026	Retbindin	19	12825478-12835428	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA052511			Approved	Endoplasmic reticulum		Mixed	Group enriched	6	adrenal gland: 4.6;cerebral cortex: 14.6;testis: 3.5	stomach: 1.2	Cell line enhanced		SCLC-21H: 9.8;SH-SY5Y: 5.8;U-266/84: 16.0
SARAF	MGC8721, TMEM66	ENSG00000133872	Store-operated calcium entry associated regulatory factor	8	30063012-30083208	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040400			Supported	Endoplasmic reticulum<br>Rods & Rings	Lung cancer:5.28e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 287.0	Expressed in all		
SCN1B		ENSG00000105711	Sodium voltage-gated channel beta subunit 1	19	35030466-35040449	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.38e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 145.1	cerebral cortex: 52.4	Cell line enhanced		A549: 15.7;TIME: 21.3
SCN3B	HSA243396	ENSG00000166257	Sodium voltage-gated channel beta subunit 3	11	123629187-123655244	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041707			Approved	Intermediate filaments<br>Cytosol		Tissue enhanced	Tissue enriched	11	cerebral cortex: 132.1	adrenal gland: 11.5	Cell line enhanced		hTCEpi: 4.6;RH-30: 2.8;SCLC-21H: 7.5;SH-SY5Y: 5.0
SDC1	CD138, SDC, SYND1, syndecan	ENSG00000115884	Syndecan 1	2	20200797-20225433	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB002424, HPA006185	Approved		Supported	Focal adhesion sites	Breast cancer:2.22e-4 (unfavourable), Glioma:8.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 250.7;skin: 287.9	liver: 144.7	Cell line enhanced		U-266/84: 739.8
SDHD	cybS, PGL, PGL1	ENSG00000204370	Succinate dehydrogenase complex subunit D	11	112086773-112120013	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045727	Approved				Renal cancer:1.99e-10 (favourable)	Expressed in all	Expressed in all			kidney: 305.5	Expressed in all		
SEC22C	MGC13261, MGC5373, SEC22L3	ENSG00000093183	SEC22 homolog C, vesicle trafficking protein	3	42547969-42601080	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055594			Approved	Golgi apparatus	Renal cancer:1.35e-7 (favourable), Liver cancer:3.04e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 63.7	Expressed in all		
SECTM1	K12	ENSG00000141574	Secreted and transmembrane 1	17	82321024-82334074	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051214	Approved					Expressed in all	Tissue enhanced		small intestine: 96.6	duodenum: 64.4	Cell line enhanced		SiHa: 125.5;U-2197: 82.3
SEL1L	IBD2, SEL1L1	ENSG00000071537	SEL1L ERAD E3 ligase adaptor subunit	14	81471549-81533861	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA024267	Approved					Expressed in all	Expressed in all			thyroid gland: 90.5	Expressed in all		
SELENOP	SELP, SeP, SEPP, SEPP1	ENSG00000250722	Selenoprotein P	5	42799880-42887392	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036287	Approved		Approved	Nucleus<br>Golgi apparatus	Renal cancer:6.97e-6 (favourable)	Expressed in all	Expressed in all			liver: 2947.1	Cell line enhanced		Hep G2: 350.2;HSkMC: 307.3;T-47d: 109.6
SEMA4A	CORD10, FLJ12287, SEMAB, SemB	ENSG00000196189	Semaphorin 4A	1	156147366-156177752	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053726, HPA066006, HPA069136	Supported		Enhanced	Nucleus	Head and neck cancer:1.09e-4 (favourable), Renal cancer:8.20e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 62.3	Cell line enhanced		Karpas-707: 108.3;U-698: 46.5
SEMA4B	KIAA1745, MGC131831, SEMAC, SemC	ENSG00000185033	Semaphorin 4B	15	90160604-90229679	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013372	Approved				Renal cancer:3.33e-8 (unfavourable), Lung cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 49.3	Expressed in all		
SEMA4C	Semacl1, Semaf, SEMAI	ENSG00000168758	Semaphorin 4C	2	96859716-96870757	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011090	Approved				Renal cancer:9.50e-7 (unfavourable), Colorectal cancer:3.53e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 62.9	Cell line enriched	6	BEWO: 298.1
SEMA4D	C9orf164, CD100, coll-4, FLJ39737, SEMAJ	ENSG00000187764	Semaphorin 4D	9	89360787-89498130	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015662, HPA023277	Approved		Supported	Endoplasmic reticulum<br>Vesicles	Urothelial cancer:4.06e-5 (favourable), Cervical cancer:4.17e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 72.4	Cell line enhanced		HDLM-2: 124.4;HMC-1: 86.7;MOLT-4: 98.7
SEMA4F	SEMAM, SEMAW	ENSG00000135622	Ssemaphorin 4F	2	74654228-74683853	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064095, HPA065969	Approved		Approved	Nucleus<br>Plasma membrane<br>Centrosome	Renal cancer:9.74e-6 (unfavourable), Endometrial cancer:5.94e-5 (unfavourable), Glioma:3.18e-4 (unfavourable), Thyroid cancer:6.94e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 14.1	Mixed		
SEMA4G	FLJ20590, KIAA1619	ENSG00000095539	Semaphorin 4G	10	100969518-100985871	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038362, HPA077752	Uncertain		Uncertain	Vesicles<br>Lipid droplets		Mixed	Tissue enhanced		rectum: 92.7	duodenum: 53.8	Cell line enhanced		A549: 28.9;CACO-2: 25.3;Hep G2: 76.9
SEMA5A	SEMAF, semF	ENSG00000112902	Semaphorin 5A	5	9035026-9546075	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004632	Approved				Renal cancer:3.66e-8 (favourable), Head and neck cancer:2.45e-4 (favourable)	Expressed in all	Mixed			cervix, uterine: 19.3	Cell line enhanced		BJ hTERT+: 52.1;fHDF/TERT166: 29.1;RT4: 54.3
SEMA6A	HT018, KIAA1368, SEMA, SEMA6A1, SEMAQ	ENSG00000092421	Semaphorin 6A	5	116443616-116574934	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031265, HPA031267	Approved		Supported	Nucleus<br>Intermediate filaments	Liver cancer:4.39e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 49.1	Cell line enhanced		AF22: 36.5;AN3-CA: 41.0;BEWO: 36.9;HAP1: 53.6;NTERA-2: 115.0
SEMA6C	KIAA1869	ENSG00000143434	Semaphorin 6C	1	151131685-151146664	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA076150, HPA077625			Approved	Nucleoplasm<br>Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Pancreatic cancer:3.06e-5 (favourable), Endometrial cancer:3.27e-4 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 111.3	testis: 33.8	Cell line enhanced		AF22: 13.8;HUVEC TERT2: 20.6
SEMA6D	FLJ11598, KIAA1479	ENSG00000137872	Semaphorin 6D	15	47184101-47774223	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043109			Approved	Golgi apparatus<br>Plasma membrane	Renal cancer:5.96e-5 (favourable)	Tissue enhanced	Tissue enhanced		placenta: 63.6	small intestine: 44.3	Cell line enhanced		BJ hTERT+: 12.7;SCLC-21H: 16.1;SH-SY5Y: 13.4
SERPINA10	PZI, ZPI	ENSG00000140093	Serpin family A member 10	14	94280455-94293271	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048739			Approved	Nucleoplasm<br>Cytosol	Liver cancer:9.00e-4 (favourable)	Tissue enriched	Tissue enriched	89	liver: 193.7	bone marrow: 2.1	Cell line enriched	6	Hep G2: 13.4
SEZ6L2	FLJ90517, PSK-1	ENSG00000174938	Seizure related 6 homolog like 2	16	29871159-29899547	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064471	Enhanced				Colorectal cancer:1.31e-4 (unfavourable), Glioma:7.27e-4 (unfavourable), Cervical cancer:7.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 82.4;parathyroid gland: 58.4	adrenal gland: 30.6	Cell line enhanced		EFO-21: 72.2
SFXN5	BBG-TCC	ENSG00000144040	Sideroflexin 5	2	72942036-73075619	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015473, HPA056866	Approved		Approved	Nucleoplasm<br>Mitochondria	Pancreatic cancer:2.26e-6 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 39.4	epididymis: 18.6	Mixed		
SGCA	A2, adhalin, ADL, DMDA2, LGMD2D, SCARMD1	ENSG00000108823	Sarcoglycan alpha	17	50164214-50175931	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007537	Uncertain					Mixed	Tissue enhanced		heart muscle: 79.5;skeletal muscle: 181.4	seminal vesicle: 38.3	Cell line enriched	13	LHCN-M2: 65.0
SIDT2	CGI-40	ENSG00000149577	SID1 transmembrane family member 2	11	117178733-117197445	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052352	Approved				Renal cancer:4.18e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 60.8	Expressed in all		
SIGLEC10	MGC126774, PRO940, SIGLEC-10, SLG2	ENSG00000142512	Sialic acid binding Ig like lectin 10	19	51410021-51417803	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025807, HPA027093	Enhanced		Supported	Plasma membrane<br>Actin filaments<br>Cytosol	Renal cancer:4.74e-5 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 48.4;spleen: 36.9	lymph node: 22.1	Cell line enhanced		Daudi: 21.0;HEL: 13.5;HMC-1: 10.2;U-698: 14.8;U-937: 9.7
SIGLEC6	CD327, CD33L, CD33L1, OB-BP1, SIGLEC-6	ENSG00000105492	Sialic acid binding Ig like lectin 6	19	51519525-51531856	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009084, HPA018198	Enhanced					Tissue enhanced	Tissue enriched	25	placenta: 147.9	lung: 6.0	Cell line enriched	7	HMC-1: 401.5
SIGLEC7	CD328, p75/AIRM1, QA79, SIGLEC-7, SIGLEC19P, SIGLECP2	ENSG00000168995	Sialic acid binding Ig like lectin 7	19	51142299-51153526	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 21.0	appendix: 14.4	Group enriched	10	Karpas-707: 39.7;RPMI-8226: 23.1;U-937: 27.4
SIGLECL1	C19orf75, FLJ40235, SIGLEC23P, SIGLECP7	ENSG00000179213	SIGLEC family like 1	19	51246348-51269330	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	86	testis: 40.1	cervix, uterine: 0.4	Not detected		
SIGMAR1	OPRS1, SR-BP1	ENSG00000147955	Sigma non-opioid intracellular receptor 1	9	34634722-34637809	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB013470, HPA018002, HPA024071	Approved				Urothelial cancer:3.42e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 67.8	Expressed in all		
SIRPB1	CD172b, SIRP-BETA-1	ENSG00000101307	Signal regulatory protein beta 1	20	1563521-1620061	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047463	Uncertain		Uncertain	Vesicles		Mixed	Tissue enhanced		appendix: 38.7;bone marrow: 33.7	lung: 28.0	Cell line enhanced		HMC-1: 46.6;NB-4: 46.7;THP-1: 38.2
SLAMF1	CD150, SLAM	ENSG00000117090	Signaling lymphocytic activation molecule family member 1	1	160608100-160647295	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002438, HPA069319	Enhanced					Mixed	Tissue enhanced		appendix: 15.4;lymph node: 21.1;tonsil: 14.3	spleen: 7.9	Cell line enriched	134	HDLM-2: 142.1
SLAMF7	19A, CD319, CRACC, CS1	ENSG00000026751	SLAM family member 7	1	160739057-160754821	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB015445, HPA055945, HPA061654	Enhanced		Approved	Vesicles	Renal cancer:8.57e-5 (unfavourable), Ovarian cancer:3.93e-4 (favourable)	Mixed	Mixed			spleen: 58.3	Group enriched	7	SK-MEL-30: 45.6;U-266/70: 216.2
SLC10A3	DXS253E, P3	ENSG00000126903	Solute carrier family 10 member 3	X	154487306-154490690	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA021656	Approved		Approved	Intermediate filaments	Colorectal cancer:4.15e-5 (unfavourable), Cervical cancer:4.53e-4 (favourable), Pancreatic cancer:7.22e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 33.0	Expressed in all		
SLC15A3	hPTR3, PHT2	ENSG00000110446	Solute carrier family 15 member 3	11	60937084-60952530	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA047880, HPA057642	Approved		Supported	Vesicles	Cervical cancer:4.07e-5 (favourable)	Expressed in all	Expressed in all			lung: 102.2	Cell line enhanced		BJ hTERT+ SV40 Large T+: 91.0;BJ hTERT+ SV40 Large T+ RasG12V: 114.5;HHSteC: 47.3
SLC25A14	BMCP1, UCP5	ENSG00000102078	Solute carrier family 25 member 14	X	130339888-130373361	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA060316			Approved	Mitochondria	Renal cancer:5.52e-6 (unfavourable), Urothelial cancer:1.39e-5 (favourable), Cervical cancer:1.72e-5 (favourable), Pancreatic cancer:1.78e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 20.4	Expressed in all		
SLC2A5	GLUT5	ENSG00000142583	Solute carrier family 2 member 5	1	9035107-9088478	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005449	Enhanced				Renal cancer:5.44e-5 (unfavourable)	Group enriched	Tissue enhanced		duodenum: 109.0;small intestine: 92.6;testis: 139.9	bone marrow: 64.4	Cell line enhanced		Daudi: 134.4;U-266/70: 111.0;U-698: 121.2;U-937: 52.9
SLC35E3	BLOV1	ENSG00000175782	Solute carrier family 35 member E3	12	68746106-68793964	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at transcript level	HPA049403	Uncertain				Endometrial cancer:1.78e-4 (favourable)	Expressed in all	Mixed			skin: 6.1	Mixed		
SLC39A10	DKFZp564L2123, FLJ90515, KIAA1265	ENSG00000196950	Solute carrier family 39 member 10	2	195575977-195737702	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA036512, HPA036513, HPA066087	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Glioma:2.05e-5 (favourable), Liver cancer:4.39e-5 (unfavourable), Pancreatic cancer:3.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 77.7;thyroid gland: 79.2	prostate: 30.8	Expressed in all		
SLC39A14	KIAA0062, NET34, ZIP14	ENSG00000104635	Solute carrier family 39 member 14	8	22367249-22434129	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016508	Approved		Approved	Endoplasmic reticulum<br>Golgi apparatus<br>Plasma membrane	Renal cancer:3.79e-7 (unfavourable), Colorectal cancer:5.00e-5 (favourable)	Expressed in all	Mixed			liver: 203.0	Expressed in all		
SLC39A4	AEZ, AWMS2, ZIP4	ENSG00000147804	Solute carrier family 39 member 4	8	144409742-144416895	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:9.04e-4 (favourable)	Expressed in all	Group enriched	8	duodenum: 134.2;small intestine: 95.7	kidney: 14.3	Group enriched	9	CAPAN-2: 50.5;Hep G2: 102.1
SLC39A5		ENSG00000139540	Solute carrier family 39 member 5	12	56230049-56237846	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018423			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:5.05e-4 (favourable)	Tissue enhanced	Group enriched	12	colon: 73.2;duodenum: 240.2;kidney: 115.0;liver: 86.0;pancreas: 53.1;rectum: 48.9;small intestine: 240.4	gallbladder: 10.0	Group enriched	62	CACO-2: 33.1;Hep G2: 39.7
SLC3A1	ATR1, CSNU1, D2H, NBAT, RBAT	ENSG00000138079	Solute carrier family 3 member 1	2	44275458-44321494	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA038360, HPA071102	Enhanced		Approved	Nuclear bodies<br>Mitochondria	Renal cancer:3.67e-7 (favourable)	Tissue enriched	Tissue enhanced		kidney: 688.2	small intestine: 148.9	Cell line enriched	14	RPTEC TERT1: 80.7
SLC4A5	NBC4	ENSG00000188687	Solute carrier family 4 member 5	2	74216242-74343414	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036621	Approved					Tissue enriched	Group enriched	6	testis: 30.9;thyroid gland: 44.9	skin: 6.3	Cell line enhanced		U-266/70: 7.2
SLC51A	OSTalpha	ENSG00000163959	Solute carrier family 51 alpha subunit	3	196211487-196243178	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA039123	Enhanced				Liver cancer:7.54e-4 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 29.3;liver: 35.1;small intestine: 71.3	colon: 9.9	Cell line enhanced		REH: 3.4
SLC52A2	D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2	ENSG00000185803	Solute carrier family 52 member 2	8	144354135-144361272	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA063036	Approved				Liver cancer:2.04e-6 (unfavourable), Renal cancer:1.23e-4 (unfavourable), Cervical cancer:7.55e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 20.8	Expressed in all		
SLC5A6	SMVT	ENSG00000138074	Solute carrier family 5 member 6	2	27199587-27212958	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA036958	Approved		Approved	Cell Junctions	Renal cancer:3.60e-7 (unfavourable)	Expressed in all	Expressed in all			epididymis: 81.3	Expressed in all		
SLC6A9	GLYT1	ENSG00000196517	Solute carrier family 6 member 9	1	43991500-44031467	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA013977	Uncertain		Approved	Nucleus<br>Golgi apparatus	Renal cancer:5.93e-4 (unfavourable), Endometrial cancer:9.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 49.7	adrenal gland: 30.8	Cell line enhanced		hTCEpi: 77.6
SLC8A1	NCX1	ENSG00000183023	Solute carrier family 8 member A1	2	40097270-40611053	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB022694, HPA070007	Uncertain		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		heart muscle: 78.0	seminal vesicle: 37.6	Cell line enhanced		BJ: 24.4;fHDF/TERT166: 54.5
SLC8B1	FLJ22233, NCKX6, NCLX, SLC24A6	ENSG00000089060	Solute carrier family 8 member B1	12	113298759-113359493	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA040668	Approved				Urothelial cancer:5.02e-4 (favourable), Breast cancer:9.52e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 48.4	Mixed		
SLC9A6	KIAA0267, NHE6	ENSG00000198689	Solute carrier family 9 member A6	X	135973841-136047269	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA059445, HPA059590	Enhanced		Supported	Vesicles		Expressed in all	Tissue enhanced		cerebral cortex: 67.9	parathyroid gland: 16.6	Mixed		
SLCO1A2	OATP, OATP-A, OATP1A2, SLC21A3	ENSG00000084453	Solute carrier organic anion transporter family member 1A2	12	21264600-21419594	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA071152			Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 28.7	salivary gland: 6.6	Cell line enhanced		NTERA-2: 16.5;RPMI-8226: 8.3;U-266/70: 18.6
SLIT2	SLIL3, Slit-2	ENSG00000145147	Slit guidance ligand 2	4	20253260-20620561	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB007590, HPA019511, HPA023088	Uncertain				Renal cancer:6.51e-4 (favourable)	Mixed	Mixed			lung: 49.5	Cell line enhanced		BJ hTERT+: 175.8;BJ hTERT+ SV40 Large T+: 96.6;fHDF/TERT166: 96.4;HBF TERT88: 115.2
SLITRK3	KIAA0848	ENSG00000121871	SLIT and NTRK like family member 3	3	165186720-165197109	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017636, HPA048042	Enhanced		Approved	Mitochondria		Tissue enriched	Tissue enhanced		cerebral cortex: 17.3;endometrium: 12.3	fallopian tube: 9.8	Cell line enhanced		AF22: 2.6;HAP1: 2.3;SCLC-21H: 1.7
SMIM7	C19orf42, MGC2747	ENSG00000214046	Small integral membrane protein 7	19	16630751-16660442	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043127	Uncertain		Approved	Golgi apparatus		Expressed in all	Expressed in all			epididymis: 55.4	Expressed in all		
SMOC2	SMAP2	ENSG00000112562	SPARC related modular calcium binding 2	6	168441151-168673445	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB033979	Uncertain				Renal cancer:1.16e-6 (unfavourable)	Expressed in all	Mixed			endometrium: 183.6	Cell line enhanced		AF22: 8.0;EFO-21: 2.6;RPMI-8226: 7.7;RPTEC TERT1: 2.8
SNX14	RGS-PX2	ENSG00000135317	Sorting nexin 14	6	85505496-85594156	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017639	Approved		Supported	Cytosol	Head and neck cancer:2.78e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 156.6	Expressed in all		
SPACA3	ALLP17, CT54, LYC3, LYZL3, SLLP1	ENSG00000141316	Sperm acrosome associated 3	17	32970376-32997877	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA023633	Enhanced					Tissue enhanced	Tissue enriched	17	testis: 77.5	pancreas: 4.5	Cell line enriched	17	U-266/70: 72.1
SPINT1	HAI, MANSC2	ENSG00000166145	Serine peptidase inhibitor, Kunitz type 1	15	40844018-40858207	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006903, HPA031178	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.37e-7 (favourable), Breast cancer:6.97e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 217.3	Cell line enhanced		BEWO: 311.8;HaCaT: 333.0;RT4: 245.6;SK-BR-3: 418.2;T-47d: 251.3
SPINT2	HAI-2, Kop	ENSG00000167642	Serine peptidase inhibitor, Kunitz type 2	19	38244035-38292614	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011101, CAB018969	Approved		Uncertain	Plasma membrane<br>Intermediate filaments<br>Cytosol	Renal cancer:3.41e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 539.2	Cell line enhanced		A-431: 736.5;CAPAN-2: 1060.7
SPTY2D1-AS1		ENSG00000247595	SPTY2D1 antisense RNA 1	11	18588781-18610255	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	21	testis: 366.7	skin: 17.2	Mixed		
SSR2	TLAP, TRAPB	ENSG00000163479	Signal sequence receptor subunit 2	1	156009048-156020959	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.00e-7 (unfavourable), Liver cancer:2.86e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 551.1	Expressed in all		
ST3GAL4	CGS23, FLJ11867, NANTA3, SAT3, SIAT4, SIAT4C, STZ	ENSG00000110080	ST3 beta-galactoside alpha-2,3-sialyltransferase 4	11	126355640-126440344	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049827	Approved					Expressed in all	Mixed			epididymis: 106.8	Expressed in all		
ST6GALNAC6	SIAT7F, ST6GALNACVI	ENSG00000160408	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 6	9	127885321-127905408	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018890	Approved		Approved	Nucleus		Expressed in all	Expressed in all			rectum: 154.1	Expressed in all		
SUSD1	DKFZP761E1824	ENSG00000106868	Sushi domain containing 1	9	112040785-112175408	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048554	Approved		Approved	Nucleoplasm	Renal cancer:3.63e-6 (favourable)	Expressed in all	Mixed			placenta: 21.5	Cell line enhanced		HEL: 50.2
SUSD5	KIAA0527	ENSG00000173705	Sushi domain containing 5	3	33150042-33219215	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA052788	Uncertain		Uncertain	Golgi apparatus<br>Vesicles		Tissue enhanced	Mixed			cerebral cortex: 11.0	Cell line enhanced		BJ hTERT+ SV40 Large T+: 26.7;HUVEC TERT2: 60.2;LHCN-M2: 23.3;TIME: 23.4
TAPBP	TAPA	ENSG00000231925	TAP binding protein	6	33299694-33314387	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007066	Approved				Breast cancer:2.76e-4 (favourable), Melanoma:6.29e-4 (favourable)	Expressed in all	Expressed in all			spleen: 30.7	Cell line enhanced		CAPAN-2: 67.6
TAPBPL	FLJ10143, TAPBP-R, TAPBPR	ENSG00000139192	TAP binding protein like	12	6451690-6466517	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039545	Uncertain				Renal cancer:6.04e-5 (favourable), Breast cancer:1.98e-4 (favourable), Urothelial cancer:7.86e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.2	Cell line enhanced		CAPAN-2: 58.5
TCTN3	C10orf61, DKFZP564D116, JBTS18, TECT3	ENSG00000119977	Tectonic family member 3	10	95663396-95694143	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026987	Approved		Approved	Microtubules	Endometrial cancer:5.77e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 138.1	Expressed in all		
TEK	CD202b, TIE-2, TIE2, VMCM, VMCM1	ENSG00000120156	TEK receptor tyrosine kinase	9	27109141-27230175	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010359, HPA073265	Approved		Supported	Plasma membrane<br>Microtubule organizing center	Liver cancer:2.31e-5 (favourable), Renal cancer:7.81e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 65.9	lung: 42.6	Group enriched	8	HUVEC TERT2: 74.6;NTERA-2: 44.2;TIME: 80.0
TEX101	CT131, MGC4766, SGRG, SPATA44	ENSG00000131126	Testis expressed 101	19	43401496-43418597	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041915, HPA042513	Enhanced					Mixed	Tissue enriched	108	testis: 173.9	skin: 1.6	Not detected		
TEX264	FLJ13935, ZSIG11	ENSG00000164081	Testis expressed 264	3	51662693-51704323	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005002, HPA017739	Enhanced		Supported	Nucleoli<br>Cytosol	Renal cancer:7.95e-9 (favourable), Pancreatic cancer:5.67e-4 (favourable)	Expressed in all	Expressed in all			testis: 113.1	Expressed in all		
TGFBR1	ACVRLK4, ALK-5, ALK5, ESS1, MSSE	ENSG00000106799	Transforming growth factor beta receptor 1	9	99104038-99154192	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002441, CAB031481, HPA056473	Uncertain		Supported	Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			placenta: 69.8	Expressed in all		
TGFBR3	betaglycan, BGCAN	ENSG00000069702	Transforming growth factor beta receptor 3	1	91680343-91906335	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008257, CAB018971	Supported		Uncertain	Cytosol	Thyroid cancer:3.14e-4 (unfavourable), Endometrial cancer:3.36e-4 (unfavourable), Head and neck cancer:4.84e-4 (favourable), Renal cancer:4.99e-4 (favourable)	Expressed in all	Expressed in all			ovary: 99.9	Cell line enhanced		ASC diff: 152.4;ASC TERT1: 75.3;U-2197: 71.9
THSD4	ADAMTSL6, FLJ13710, FVSY9334, PRO34005	ENSG00000187720	Thrombospondin type 1 domain containing 4	15	71096952-71783383	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026845			Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		cervix, uterine: 160.5	fallopian tube: 59.6	Cell line enhanced		BJ hTERT+: 43.1;TIME: 54.2
THY1	CD90	ENSG00000154096	Thy-1 cell surface antigen	11	119417378-119424985	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003733, CAB068243, CAB068244	Enhanced		Approved	Nucleus<br>Plasma membrane	Renal cancer:2.40e-6 (unfavourable), Glioma:9.64e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 421.8;smooth muscle: 434.2	gallbladder: 161.0	Cell line enhanced		BJ: 643.3;BJ hTERT+: 686.4;fHDF/TERT166: 1040.5
TIE1	JTK14, TIE	ENSG00000066056	Tyrosine kinase with immunoglobulin like and EGF like domains 1	1	43300993-43323108	Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		placenta: 70.6	lung: 40.1	Cell line enhanced		EFO-21: 100.1;HUVEC TERT2: 199.8;TIME: 171.4
TIMMDC1	C3orf1, FLJ22597	ENSG00000113845	Translocase of inner mitochondrial membrane domain containing 1	3	119498532-119525090	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053214, HPA055846	Uncertain		Enhanced	Nucleus<br>Mitochondria	Liver cancer:1.12e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 31.5	Expressed in all		
TLR1	CD281, KIAA0012, rsc786	ENSG00000174125	Toll like receptor 1	4	38790677-38856817	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Mixed			appendix: 37.2	Cell line enhanced		Daudi: 8.0;HUVEC TERT2: 10.5;RPMI-8226: 9.8;U-698: 14.4
TLR3	CD283	ENSG00000164342	Toll like receptor 3	4	186069152-186088069	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025658	Enhanced				Pancreatic cancer:3.09e-4 (unfavourable)	Mixed	Mixed			placenta: 24.5	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 29.4;CAPAN-2: 42.4
TM2D2	BLP1	ENSG00000169490	TM2 domain containing 2	8	38988808-38996824	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047152, HPA050547	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane	Colorectal cancer:1.71e-4 (favourable), Breast cancer:7.49e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 51.3	Expressed in all		
TM2D3	BLP2, FLJ22604	ENSG00000184277	TM2 domain containing 3	15	101621444-101652391	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054064	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 97.2	Expressed in all		
TM7SF3		ENSG00000064115	Transmembrane 7 superfamily member 3	12	26973195-27014434	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057640			Supported	Nucleus<br>Cytosol	Renal cancer:1.32e-4 (favourable)	Expressed in all	Expressed in all			kidney: 190.9	Expressed in all		
TM9SF1	HMP70, MP70	ENSG00000100926	Transmembrane 9 superfamily member 1	14	24189143-24195687	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059249	Supported		Approved	Golgi apparatus	Lung cancer:2.04e-4 (unfavourable), Cervical cancer:8.94e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 73.0	Expressed in all		
TMED1	Il1rl1l, IL1RL1LG, MGC1270, p24g1, p24gamma1, ST2L	ENSG00000099203	Transmembrane p24 trafficking protein 1	19	10832438-10836318	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018507	Uncertain				Renal cancer:8.66e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.6	Expressed in all		
TMED2	P24A, p24b1, p24beta1, RNP24	ENSG00000086598	Transmembrane p24 trafficking protein 2	12	123584531-123598577	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA014060	Approved		Supported	Vesicles	Renal cancer:2.35e-7 (unfavourable), Head and neck cancer:3.36e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 328.1	Expressed in all		
TMED3	C15orf22, p24B, p24g4, p24gamma4	ENSG00000166557	Transmembrane p24 trafficking protein 3	15	79311062-79427432	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA049314, HPA076949	Approved		Supported	Golgi apparatus	Renal cancer:3.73e-4 (unfavourable), Breast cancer:7.71e-4 (unfavourable)	Expressed in all	Mixed			salivary gland: 163.2	Mixed		
TMED4	HNLF, p24a3, p24alpha3	ENSG00000158604	Transmembrane p24 trafficking protein 4	7	44577894-44582287	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014650	Approved				Renal cancer:1.37e-4 (favourable), Endometrial cancer:7.37e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 190.7	Expressed in all		
TMED5	CGI-100, p24g2, p24gamma2	ENSG00000117500	Transmembrane p24 trafficking protein 5	1	93149742-93180728	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050289	Approved					Expressed in all	Expressed in all			kidney: 28.2	Expressed in all		
TMED7	CGI-109, FLJ90481, p24g3, p24gamma3	ENSG00000134970	Transmembrane p24 trafficking protein 7	5	115613508-115632992	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008960, CAB025883	Supported					Expressed in all	Expressed in all			thyroid gland: 138.8	Expressed in all		
TMEM108	CT124, MGC3040	ENSG00000144868	Transmembrane protein 108	3	133038391-133397792	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA063350	Uncertain		Approved	Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 21.9;testis: 25.8	adrenal gland: 15.0	Cell line enhanced		HMC-1: 21.3;SCLC-21H: 24.8;SH-SY5Y: 98.2
TMEM116	FLJ90167	ENSG00000198270	Transmembrane protein 116	12	111931282-112013185	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA040720	Approved		Approved	Nucleoplasm<br>Microtubules	Renal cancer:1.08e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 57.3	testis: 48.2	Mixed		
TMEM119		ENSG00000183160	Transmembrane protein 119	12	108589846-108598320	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051870, HPA052650	Enhanced				Renal cancer:2.06e-6 (unfavourable), Ovarian cancer:8.37e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 93.0	gallbladder: 55.2	Cell line enhanced		ASC diff: 378.8;ASC TERT1: 106.4;BJ hTERT+: 134.8;HSkMC: 171.1
TMEM168	DKFZp564C012, FLJ13576	ENSG00000146802	Transmembrane protein 168	7	112762382-112790592	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA020389	Approved				Lung cancer:4.07e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 44.3	Expressed in all		
TMEM178A	MGC33926, TMEM178	ENSG00000152154	Transmembrane protein 178A	2	39664982-39717963	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at transcript level	HPA052128	Uncertain		Approved	Nucleus<br>Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 55.4	kidney: 19.3	Cell line enhanced		AF22: 137.1;NTERA-2: 17.7;SCLC-21H: 30.2
TMEM179	C14orf90, FLJ42486, TMEM179A	ENSG00000258986	Transmembrane protein 179	14	104474678-104605647	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at transcript level	HPA002942			Uncertain	Mitochondria		Mixed	Group enriched	8	adrenal gland: 14.6;cerebral cortex: 27.9	testis: 2.5	Cell line enhanced		NTERA-2: 8.5;SCLC-21H: 42.8;SH-SY5Y: 12.2
TMEM191C		ENSG00000206140	Transmembrane protein 191C	22	21466423-21471269	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	9	testis: 1.5	endometrium,lung,ovary: 0.1	Not detected		
TMEM196	MGC42090	ENSG00000173452	Transmembrane protein 196	7	19719310-19773598	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA043163	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 9.2	endometrium: 2.2	Group enriched	7	ASC diff: 3.1;ASC TERT1: 3.1
TMEM199	C17orf32, MGC45714, VMA12, VPH2	ENSG00000244045	Transmembrane protein 199	17	28357581-28363683	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA027051	Uncertain				Liver cancer:1.54e-4 (unfavourable), Endometrial cancer:5.55e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 19.3	Expressed in all		
TMEM205	MBC3205, UNQ501	ENSG00000105518	Transmembrane protein 205	19	11342776-11346518	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA041504	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 258.0	Expressed in all		
TMEM213		ENSG00000214128	Transmembrane protein 213	7	138797952-138838101	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054059	Enhanced				Renal cancer:5.54e-7 (favourable)	Tissue enriched	Group enriched	9	kidney: 80.7;salivary gland: 22.6	breast: 5.7	Not detected		
TMEM25	FLJ14399	ENSG00000149582	Transmembrane protein 25	11	118531041-118547280	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012163, HPA051562	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			duodenum: 47.0	Cell line enhanced		T-47d: 41.7
TMEM38B	bA219P18.1, C9orf87, D4Ertd89e, FLJ10493, TRIC-B	ENSG00000095209	Transmembrane protein 38B	9	105694544-105776612	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018465	Uncertain				Renal cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			testis: 51.9	Expressed in all		
TMEM44	DKFZp686O18124	ENSG00000145014	Transmembrane protein 44	3	194587673-194633689	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043718	Uncertain		Approved	Cytosol	Renal cancer:6.55e-13 (unfavourable)	Expressed in all	Mixed			epididymis: 16.7	Mixed		
TMEM52		ENSG00000178821	Transmembrane protein 52	1	1917590-1919273	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		pancreas: 38.8;skeletal muscle: 105.7	adrenal gland: 24.4	Cell line enhanced		Hep G2: 13.9;RPMI-8226: 25.7
TMEM59	C1orf8, HSPC001	ENSG00000116209	Transmembrane protein 59	1	54026681-54053504	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Expressed in all			fallopian tube: 650.0	Expressed in all		
TMEM67	JBTS6, MGC26979, MKS3, NPHP11	ENSG00000164953	Transmembrane protein 67	8	93754844-93819234	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level						Renal cancer:7.62e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 21.5	testis: 12.5	Mixed		
TMEM70	FLJ20533	ENSG00000175606	Transmembrane protein 70	8	73972437-73982783	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA023187, CAB034226	Uncertain		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 30.2	Expressed in all		
TMEM87A	DKFZP564G2022	ENSG00000103978	Transmembrane protein 87A	15	42210452-42273663	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018104, HPA018189	Enhanced		Supported	Golgi apparatus		Expressed in all	Expressed in all			prostate: 124.3	Expressed in all		
TMEM94	KIAA0195	ENSG00000177728	Transmembrane protein 94	17	75441159-75500090	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008423, HPA050660	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 54.2	Expressed in all		
TMEM95	MGC129793, UNQ9390	ENSG00000182896	Transmembrane protein 95	17	7355123-7357219	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	48	testis: 9.9	gallbladder: 0.2	Not detected		
TMIGD1	TMIGD, UNQ9372	ENSG00000182271	Transmembrane and immunoglobulin domain containing 1	17	30316333-30334059	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA021946			Approved	Mitochondria		Tissue enhanced	Group enriched	23	colon: 81.8;rectum: 109.8;small intestine: 162.9	kidney: 5.1	Not detected		
TMPRSS12	CT151, MGC57341	ENSG00000186452	Transmembrane protease, serine 12	12	50842920-50887884	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	75	testis: 39.5	epididymis: 0.5	Not detected		
TMPRSS5	MGC141886, MGC148044	ENSG00000166682	Transmembrane protease, serine 5	11	113687550-113706373	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010992			Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		cerebral cortex: 10.1	salivary gland: 3.0	Cell line enhanced		CAPAN-2: 2.9;WM-115: 2.6
TMUB1	C7orf21, SB144	ENSG00000164897	Transmembrane and ubiquitin like domain containing 1	7	151081080-151083546	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA029429	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			small intestine: 52.2	Expressed in all		
TMX2	PDIA12, TXNDC14	ENSG00000213593	Thioredoxin related transmembrane protein 2	11	57712600-57740973	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040282, HPA063763	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.55e-5 (favourable), Urothelial cancer:3.37e-4 (unfavourable), Head and neck cancer:3.64e-4 (unfavourable), Liver cancer:4.11e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 129.2	Expressed in all		
TMX3	FLJ20793, KIAA1830, PDIA13, TXNDC10	ENSG00000166479	Thioredoxin related transmembrane protein 3	18	68673688-68715298	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014157	Uncertain				Renal cancer:2.87e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 31.4	Expressed in all		
TNFRSF11A	CD265, FEO, LOH18CR1, PDB2, RANK	ENSG00000141655	TNF receptor superfamily member 11a	18	62325287-62391292	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010391, HPA027728, HPA047976	Uncertain		Supported	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		duodenum: 30.6	small intestine: 20.5	Cell line enhanced		HDLM-2: 116.8;PC-3: 18.0;SCLC-21H: 24.0
TNFRSF12A	CD266, FN14, TweakR	ENSG00000006327	TNF receptor superfamily member 12A	16	3018445-3022383	Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007853	Approved		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:5.50e-4 (unfavourable), Renal cancer:8.78e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 199.0	Mixed		
TNFRSF14	ATAR, CD270, HVEA, HVEM, LIGHTR, TR2	ENSG00000157873	TNF receptor superfamily member 14	1	2555639-2565382	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006404, CAB026150, CAB030007	Approved		Approved	Cytosol<br>Rods & Rings	Urothelial cancer:7.79e-6 (favourable), Endometrial cancer:8.01e-6 (favourable), Breast cancer:4.39e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 45.5	Cell line enhanced		CAPAN-2: 23.4;HDLM-2: 25.7;HHSteC: 25.4;SK-MEL-30: 41.0
TNFRSF18	AITR, CD357, GITR	ENSG00000186891	TNF receptor superfamily member 18	1	1203508-1206691	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008025	Approved				Renal cancer:4.40e-11 (unfavourable), Endometrial cancer:7.72e-6 (favourable), Head and neck cancer:4.12e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 43.3	parathyroid gland: 18.0	Group enriched	11	RPMI-8226: 148.8;SCLC-21H: 173.4
TNFRSF1A	CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60	ENSG00000067182	TNF receptor superfamily member 1A	12	6328757-6342114	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004102, CAB010309	Approved				Renal cancer:2.70e-7 (unfavourable), Head and neck cancer:3.68e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 141.2	Mixed		
TNFRSF1B	CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80	ENSG00000028137	TNF receptor superfamily member 1B	1	12167003-12209228	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004796	Approved				Renal cancer:8.35e-5 (unfavourable), Testis cancer:8.68e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 100.4	spleen: 77.8	Cell line enhanced		CAPAN-2: 31.7;K-562: 41.3;THP-1: 35.7;U-87 MG: 34.0
TNFRSF25	APO-3, DDR3, DR3, LARD, TNFRSF12, TR3, TRAMP, WSL-1, WSL-LR	ENSG00000215788	TNF receptor superfamily member 25	1	6461151-6466195	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069834			Approved	Nucleus<br>Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Renal cancer:1.65e-7 (unfavourable), Head and neck cancer:3.09e-4 (favourable), Colorectal cancer:4.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 29.6	spleen: 12.1	Cell line enhanced		HDLM-2: 24.6;RPMI-8226: 17.9
TNFSF11	CD254, ODF, OPGL, RANKL, TRANCE	ENSG00000120659	Tumor necrosis factor superfamily member 11	13	42562736-42608013	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009193, HPA045142	Enhanced					Mixed	Tissue enhanced		lymph node: 17.3	appendix: 6.3	Cell line enhanced		HSkMC: 1.5;NTERA-2: 3.0
TOMM7	Tom7	ENSG00000196683	Translocase of outer mitochondrial membrane 7	7	22812628-22822852	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Head and neck cancer:6.30e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 677.6	Expressed in all		
TPO	TPX	ENSG00000115705	Thyroid peroxidase	2	1374223-1543711	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007987, CAB009587	Enhanced					Tissue enriched	Tissue enriched	103	thyroid gland: 1817.4	spleen: 17.6	Cell line enhanced		Karpas-707: 6.9;RPMI-8226: 2.9
TRABD2A	C2orf89, TIKI1	ENSG00000186854	TraB domain containing 2A	2	84821650-84907008	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA045817	Approved					Group enriched	Tissue enhanced		colon: 35.4;ovary: 30.7;rectum: 43.1	lymph node: 11.7	Cell line enhanced		BEWO: 38.1;HDLM-2: 29.0;hTEC/SVTERT24-B: 17.5;SiHa: 18.3
TREM1	CD354, TREM-1	ENSG00000124731	Triggering receptor expressed on myeloid cells 1	6	41267926-41286719	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005563	Uncertain					Tissue enhanced	Tissue enhanced		appendix: 67.7;bone marrow: 63.0;lung: 103.1	adipose tissue: 26.9	Cell line enriched	11	U-87 MG: 24.5
TREM2	TREM-2, Trem2a, Trem2b, Trem2c	ENSG00000095970	Triggering receptor expressed on myeloid cells 2	6	41158506-41163186	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010917, HPA012571	Approved				Liver cancer:4.24e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 37.0;lung: 40.5	adrenal gland: 16.1	Cell line enhanced		HBEC3-KT: 9.0;hTCEpi: 49.6;THP-1: 26.6
TSHR	LGR3	ENSG00000165409	Thyroid stimulating hormone receptor	14	80954989-81146302	Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000473	Approved					Tissue enriched	Tissue enriched	282	thyroid gland: 445.5	lymph node: 1.5	Cell line enhanced		MOLT-4: 18.4;SCLC-21H: 25.2;U-266/70: 7.9
TSPAN3	TM4-A, TM4SF8, TSPAN-3	ENSG00000140391	Tetraspanin 3	15	77041404-77083984	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA015996	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			epididymis: 527.2	Expressed in all		
TSPAN31	SAS	ENSG00000135452	Tetraspanin 31	12	57738013-57750211	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057489	Approved				Renal cancer:9.91e-5 (favourable), Head and neck cancer:1.09e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 74.5	Expressed in all		
TTC13	FLJ22584	ENSG00000143643	Tetratricopeptide repeat domain 13	1	230906243-230978875	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018022, HPA051558	Uncertain		Approved	Nucleoplasm	Renal cancer:1.60e-11 (unfavourable), Pancreatic cancer:4.59e-5 (favourable), Head and neck cancer:7.66e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 23.0	Expressed in all		
TXNDC15	2310047H23Rik, C5orf14, FLJ22625	ENSG00000113621	Thioredoxin domain containing 15	5	134873803-134901525	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015483	Approved		Approved	Golgi apparatus	Renal cancer:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 85.3	Expressed in all		
TYRP1	b-PROTEIN, CAS2, CATB, GP75, OCA3, TRP, TYRP	ENSG00000107165	Tyrosinase related protein 1	9	12685439-12710290	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA000937, CAB002520	Enhanced		Supported	Vesicles		Tissue enriched	Group enriched	6	heart muscle: 40.2;skin: 169.1	kidney: 17.0	Cell line enriched	51	SK-MEL-30: 1084.9
UBAC2	FLJ30548, PHGDHL1, RP11-178C10.1	ENSG00000134882	UBA domain containing 2	13	99200774-99386434	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013448	Approved		Approved	Cytosol	Pancreatic cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 35.8	Expressed in all		
UBR3	DKFZp434P117, FLJ37422, KIAA2024, ZNF650	ENSG00000144357	Ubiquitin protein ligase E3 component n-recognin 3 (putative)	2	169827458-170084131	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035390	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 39.6	Expressed in all		
UBXN8	D8S2298E, REP8, UBXD6	ENSG00000104691	UBX domain protein 8	8	30732247-30767006	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017725, HPA077538	Approved		Supported	Nucleoplasm<br>Nucleoli<br>Endoplasmic reticulum	Renal cancer:5.25e-5 (unfavourable), Colorectal cancer:6.13e-4 (favourable)	Expressed in all	Expressed in all			ovary: 109.4	Expressed in all		
UGT1A10	UGT1J	ENSG00000242515	UDP glucuronosyltransferase family 1 member A10	2	233636454-233773305	Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:4.55e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 49.7;duodenum: 80.9;small intestine: 59.1	rectum: 39.6	Cell line enriched	108	RT4: 416.9
UGT2A1		ENSG00000173610	UDP glucuronosyltransferase family 2 member A1 complex locus	4	69588417-69653249	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017261, HPA045108	Uncertain					Tissue enhanced	Group enriched	7	kidney: 8.1;liver: 5.5	skin: 0.9	Not detected		
UGT2B28		ENSG00000135226	UDP glucuronosyltransferase family 2 member B28	4	69280499-69295050	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045108	Uncertain					Tissue enriched	Tissue enriched	12	breast: 267.2	gallbladder: 21.5	Group enriched	9	Daudi: 2.1;NB-4: 1.7
UGT2B4	UGT2B11	ENSG00000156096	UDP glucuronosyltransferase family 2 member B4	4	69480165-69526014	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB033260, HPA045108	Enhanced					Tissue enriched	Tissue enriched	78	liver: 655.5	heart muscle: 8.3	Cell line enriched	11	RH-30: 4.5
UGT2B7	UGT2B9	ENSG00000171234	UDP glucuronosyltransferase family 2 member B7	4	69051363-69112987	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045108	Uncertain				Colorectal cancer:7.65e-5 (favourable), Renal cancer:3.79e-4 (favourable), Urothelial cancer:5.38e-4 (favourable)	Group enriched	Group enriched	13	kidney: 1326.3;liver: 825.7	fallopian tube: 79.7	Cell line enhanced		EFO-21: 73.2;RPTEC TERT1: 235.7;U-2197: 40.2
UGT3A1	FLJ34658	ENSG00000145626	UDP glycosyltransferase family 3 member A1	5	35951010-36001028	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047697, HPA056290	Uncertain		Approved	Vesicles<br>Cytosol		Group enriched	Tissue enhanced		kidney: 53.4;liver: 29.2	duodenum: 9.5	Cell line enriched	51	RH-30: 26.5
UGT3A2		ENSG00000168671	UDP glycosyltransferase family 3 member A2	5	36035017-36071358	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059475	Uncertain		Approved	Nucleus<br>Cytosol		Tissue enriched	Tissue enhanced		skin: 11.9;testis: 4.6	bone marrow: 3.2	Cell line enhanced		HDLM-2: 6.3;MOLT-4: 9.8;REH: 25.8;T-47d: 6.7;THP-1: 11.2
UGT8	CGT	ENSG00000174607	UDP glycosyltransferase 8	4	114598455-114678224	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014405, HPA065785	Approved		Approved	Mitochondria	Renal cancer:8.55e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 101.0	kidney: 29.8	Cell line enhanced		CAPAN-2: 44.4;RPTEC TERT1: 37.0;SCLC-21H: 32.8
UMOD		ENSG00000169344	Uromodulin	16	20333052-20356301	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009446, HPA043420, HPA054721	Enhanced					Tissue enriched	Tissue enriched	726	kidney: 2392.4	cerebral cortex: 3.2	Not detected		
UNC5C		ENSG00000182168	Unc-5 netrin receptor C	4	95162504-95549206	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		thyroid gland: 20.0	adrenal gland: 11.6	Group enriched	6	AF22: 17.6;SH-SY5Y: 82.9
UPK3B	FLJ32198, MGC10902, p35, UPIIIb	ENSG00000243566	Uroplakin 3B	7	76510428-76516521	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA010506	Approved		Approved	Nucleus<br>Vesicles<br>Cytosol		Group enriched	Group enriched	11	esophagus: 12.4;lung: 29.8;urinary bladder: 11.0	tonsil: 1.6	Group enriched	8	A549: 12.0;CAPAN-2: 41.9;HaCaT: 8.6;RT4: 26.3;T-47d: 25.4
VIPR2	VPAC2, VPAC2R	ENSG00000106018	Vasoactive intestinal peptide receptor 2	7	159028175-159144957	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062707	Approved					Tissue enhanced	Tissue enhanced		seminal vesicle: 28.3	epididymis: 14.9	Cell line enhanced		HMC-1: 7.8;MOLT-4: 10.2;U-266/70: 30.8
VKORC1	VKCFD2	ENSG00000167397	Vitamin K epoxide reductase complex subunit 1	16	31090842-31095980	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042720	Approved		Supported	Endoplasmic reticulum	Renal cancer:2.09e-10 (unfavourable)	Expressed in all	Expressed in all			liver: 141.4	Expressed in all		
VLDLR	CARMQ1, CHRMQ1, VLDLRCH	ENSG00000147852	Very low density lipoprotein receptor	9	2621834-2660053	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB032462, HPA051312	Uncertain		Approved	Vesicles<br>Cytokinetic bridge<br>Microtubule organizing center	Endometrial cancer:5.95e-4 (favourable)	Expressed in all	Tissue enhanced		ovary: 110.0;parathyroid gland: 124.0	fallopian tube: 43.7	Cell line enhanced		BEWO: 60.5
VNN2	FOAP-4, GPI-80	ENSG00000112303	Vanin 2	6	132743870-132763459	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.72e-7 (unfavourable)	Mixed	Tissue enhanced		spleen: 76.9	lymph node: 45.0	Cell line enriched	6	Daudi: 40.8
VOPP1	DKFZp564K0822, ECop, FLJ20532, GASP	ENSG00000154978	Vesicular, overexpressed in cancer, prosurvival protein 1	7	55436056-55572988	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level						Renal cancer:6.99e-8 (unfavourable), Liver cancer:4.35e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 110.2	Mixed		
VSIG1	MGC44287	ENSG00000101842	V-set and immunoglobulin domain containing 1	X	108044970-108079184	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001445, HPA036310, HPA036311	Enhanced		Approved	Vesicles<br>Cytosol		Group enriched	Group enriched	10	stomach: 185.7;testis: 91.1	gallbladder: 14.3	Cell line enhanced		HBEC3-KT: 2.5;HUVEC TERT2: 5.9;PC-3: 2.2
VSIG10		ENSG00000176834	V-set and immunoglobulin domain containing 10	12	118063593-118136026	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062022			Approved	Microtubule organizing center<br>Cytosol	Liver cancer:1.76e-4 (unfavourable), Melanoma:7.53e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 27.7	Cell line enhanced		HAP1: 35.3
VSTM1	UNQ3033	ENSG00000189068	V-set and transmembrane domain containing 1	19	54040825-54063953	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059365			Approved	Vesicles		Mixed	Tissue enriched	38	bone marrow: 35.4	urinary bladder: 0.9	Not detected		
VSTM4	C10orf72, FLJ31737	ENSG00000165633	V-set and transmembrane domain containing 4	10	49014245-49115509	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA017279	Uncertain		Approved	Nucleus<br>Vesicles	Urothelial cancer:4.25e-4 (unfavourable)	Tissue enriched	Mixed			adrenal gland: 54.8	Cell line enhanced		RH-30: 9.1;U-138 MG: 10.5;U-2197: 22.4;U-87 MG: 11.4
WHRN	CIP98, DFNB31, PDZD7B, USH2D	ENSG00000095397	Whirlin	9	114402080-114505450	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002480, CAB033194	Uncertain				Pancreatic cancer:2.28e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 73.0	testis: 44.4	Cell line enhanced		Karpas-707: 96.9;U-266/70: 64.0;U-266/84: 64.8
ZNF511	MGC30006	ENSG00000198546	Zinc finger protein 511	10	133308475-133313162	Predicted membrane proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA035360	Uncertain				Renal cancer:1.13e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 12.2	Expressed in all		
